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ABSTRACT 
Diseases affecting the cartilage and/or bone, including osteoarthritis (OA), are the 
most prevalent musculoskeletal tissue pathologies. OA is the result of cartilage 
degradation, altered sub-chondral bone, impaired joint mobility and severe pain - making 
it one of the leading causes of disability worldwide. While OA is stereotypically 
described as a physical wear and tear disease, mounting evidence suggests that synovial 
inflammation significantly contributes to its pathogenesis. In OA, macrophages infiltrate 
the synovium and secrete supra-physiological levels of pro-inflammatory cytokines, 
which create a caustic joint environment promoting articular cartilage degradation. Due 
to the pro-inflammatory characteristics of OA, the immunomodulatory potential of stem 
cells likely represents an under investigated therapeutic alternative.  
The purpose of this research was to investigate if stem cells from the amniotic 
membrane (a tissue routinely discarded after the birth of term pregnancies) represent an 
efficacious alternative cell source for future OA therapies. This was achieved by directly 
comparing the abilities of human amniotic membrane derived stem cells and a commonly 
employed stem cell, human adipose derived stem cells, with regards to osteogenic and 
chondrogenic differentiation potential as well as the ability to mitigate OA disease 
progression both ex vivo and in vivo. 
Our results demonstrate stem cells from the amniotic membrane exhibit 
heightened differentiation potential, higher yields, enhanced immunomodulatory 
properties, and the ability to induce pro-regenerative (M2) phenotypes within 
macrophages, in OA experimental models. Additionally, amnion stem cells appeared to 
iii 
offer accelerated treatment time lines compared to adipose derived stem cells. For these 
reasons, we believe amnion membrane derived stem cells are an efficacious stem cell 
source for OA therapeutic approaches. 
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CHAPTER ONE 
 
Background & Significance 
 
 
1.1 Stem Cells & Orthopedic Regenerative Medicine 
Musculoskeletal disorders represent the largest disease subset in the U.S. 
population, as recent reports estimate that 50% of the U.S. population (approximately 110 
million individuals) suffers from at least one musculoskeletal tissue pathology.1 Due to 
increases in life expectancy these estimates are expected to rise.1,2 Direct costs associated 
with musculoskeletal disease management have been estimated upwards of $510 billion.1 
Additionally indirect costs, including lost wages, are estimated near $350 billion.1 
Moreover, the societal costs covering the care of such conditions (hospitals, physicians, 
therapists, caregivers, etc.) near $1 trillion.1 Though physical therapy and non-invasive 
treatment options are often initially pursued, many patients require further intervention.  
Orthopedic surgical intervention typically occurs when the conservative 
management of musculoskeletal tissue pathologies has failed. Such surgeries usually 
involve the replacement of native tissue(s) with biological or metal implants.3,4 
Musculoskeletal tissue grafts have demonstrated only limited success.3 Metal-based 
orthopedic replacements fail prematurely with the potential for biological incompatibility 
due to the generation of metal wear debris particles.3,4 In light of these shortcomings, 
recent research in the field of orthopaedic regenerative medicine has turned to the use of 
biologic therapies, including stem cell-based therapies.3–7 Clinically, these cells could be 
used alone or in combination with either synthetic or natural scaffolds in order to mitigate 
progression of disease or to promote the repair or regeneration of damaged 
musculoskeletal tissues. Numerous stem cell sources have been evaluated, yet currently 
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no single stem cell source has been identified as being ideal for any specific orthopaedic 
application (i.e. regeneration of bone, cartilage, muscle, tendon, etc.…).  
However, evidence is starting to emerge which may suggest preferential tissue-
specific lineage differentiation of adult and perinatal stem cells.6,8,9 While it may stand to 
reason that adult stem cells derived from the target tissue (i.e. the tissue to be repaired / 
regenerated) may be optimal; the possibility that these stem cells have 1) also succumb to 
damage or disease and 2) are only available in limited quantities make them less than 
ideal for clinical use.5,10–12 It has been widely accepted that stem cells must be 
administered in large quantities to demonstrate clinical efficacy. However, only recently 
has clinical evidence emerged from the orthopedic community suggesting therapeutic 
benefit is only achieved when stem cell are administered in high doses.13 In light of this 
need for large quantities of cells, it has been suggested that the ex vivo expansion of 
mesenchymal stem cells (MSCs) makes them suited for orthopedic applications.4,5,14 
However, ex vivo expansion exposes cells to increased possibilities of contamination, 
alterations to their phenotype and differentiation potentials, and a potentially delayed 
administration.15–17 Thus, a stem cell source requiring limited (or no) ex vivo expansion 
in order to achieve clinically significant numbers would be preferred. Accordingly, stem 
cells with both demonstrated orthopedic applications and high yield isolations, both 
discussed herein, would be most clinically relevant.   
1.1.1 The Need For Orthopedic Regenerative Medicine 
According to the American Academy of Orthopedic Surgeons, over 2 million 
musculoskeletal tissue repairs are performed in the US, annually.18 Many of these repairs 
rely on tissue grafts or metal implants in order to reduce pain and restore tissue function. 
3 
Tissue grafts have been shown to fail due to incomplete filling of the defect, failed 
resorption (bone), or lack of host tissue integration.3,19 Tendon grafts, specifically, do not 
adequately reproduce the tendon-bone interface, limiting the strength and functionality of 
the graft.4 Additionally, there have been reports of allogeneic musculoskeletal tissue graft 
rejection.3,4 Implanted biomaterials have finite lifespans, increasing patient morbidity 
through the resulting necessary re-operation.4 Metal implants in particular, have the 
potential to elicit an immune response through metal debris particles and metal implant 
infection typically necessitates a re-operation to remove the implant.3,4  
Alternative methods address not only the restoration of musculoskeletal tissue 
function but also aim towards host tissue integration and regeneration. For example, in 
osteochondral defect repair, the micro-fracture technique punctures the sub-chondral 
bone allowing bone marrow to leak into the repaired area, accelerating healing.4,5 
Autologous cartilage transplantation has also been utilized for enhanced cartilage defect 
repair.4 Additionally, tissue-engineered materials (ex. calcium sulfate pellets, methyl 
methacrylate, collagen and hydroxyapatite (HA) have been utilized as bone fillers in bone 
defect repair.19 A developing area of research over the past twenty years has been 
platelet-rich plasma (PRP). PRP therapies involve the autologous administration of the 
patient’s own concentrated plasma.20,21 As platelets play a significance role in natural 
wound healing (via cell recruitment and growth factor secretion), the administration of 
PRP has the potential to enhance healing of various orthopedic injuries.21 Growing 
evidence supports accelerated healing and/or enhanced tissue regeneration in bone, 
muscle and tendon injuries after PRP injection therapy.20,21      
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1.1.2 Stem Cells: The Future for Orthopedic Regenerative Medicine? 
Stem cells have been proposed as an intriguing alternative for orthopedic 
regenerative medicine due to their musculoskeletal tissue differentiation and 
immunomodulatory capacities. Most musculoskeletal tissues have limited capacity for 
self-renewal.6 Therefore, stem cells could be considered as alternative healthy cells 
within target tissues, potentially leading to replenished host cell populations and tissue 
regeneration. Additionally, as some musculoskeletal tissue disorders, such as arthritis, 
have an identified immune component; paracrine or juxtacrine stem cell effects could 
assist in disease modulation.4,7,11  
In addition to the hypothesized benefits of stem cell therapies, experimental 
evidence supports their beneficial use in orthopedics. As previously mentioned, the 
micro-fracture technique in osteochondral defect repair introduces bone marrow to the 
defect repair area, promoting tissue healing by exposing the area to bone marrow stem 
cells.4,5 MSCs have also been used successfully as a therapy for delayed fracture union, 
non-unions, arthrodesis, and bone defects.6 The autologous chondrocyte transplantation 
technique has been employed with not only autologous chondrocytes, but chondrocyte 
precursor cells, periosteum and stem cells, as well.4 Preliminary cohort studies have 
demonstrated that MSC administration is at least as effective as autologous chondrocyte 
transplantation.22 High dose stem cell therapies have also been employed in the treatment 
of rheumatoid arthritis and other rheumatic diseases, with positive outcomes.4 Though 
beyond the scope of our review, there are also numerous animal studies employing stem 
cells that show mitigation of musculoskeletal disease progression and/or tissue 
regeneration.3–6 Interestingly, animal studies comparing the efficacy of current orthopedic 
5 
regenerative medicine techniques (periosteal graft, mosaicplasty, and autologous 
chondrocyte transplantation) to stem cell therapy, show stem cell therapy is superior to 
periosteal grafts and mosaicplasty.23 
 
1.2 Basic Stem Cell Characteristics 
Stem cells, by definition, must demonstrate potency (the ability to differentiate 
into target tissue cell types) and self-renewal (the ability to both proliferate and generate 
progeny stem cells).9,24 The minimal criteria defining MSCs was determined by the 
International Society for Cellular Therapy in 2006. MSCs must: 1) demonstrate plastic 
adherence, 2) test positively (>95%) for CD105, CD73, and CD90 and negatively (<2% 
positive) for CD45, CD34, CD14 or CD11b, and CD79 or CD19, and 3) be capable of 
differentiating into adipogenic, chondrogenic and osteogenic lineages.25 To ensure 
isolated cells meet such requirements, experiments are conducted demonstrating 1) 
plastic adherence through serial passaging on plastic tissue culture flasks, 2) appropriate 
cell phenotype through flow cytometric analysis (cell marker identification via antibody 
tagging) with serial passaging, and 3) in vitro (and in some cases in vivo) differentiation 
experiments where cells are exposed to signals (ex. exogenous growth factors or other 
chemicals, mechanical stimulation) and evaluated for morphologic and gene/protein 
phenotypic likeness to target cells.  
Large variability in MSC isolation, propagation and characterization techniques 
exist.7,9,14,24–26 Some authors have attributed such variability to the noted discrepancy 
between in vitro experiment success and in vivo experiment (or clinical trial) failure.7,14 
As such, there has been a push to employ more than “minimal” criteria when proposing 
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to use MSCs.14,24 Additional suggested criteria include in vivo (as opposed to the 
common practice, in vitro) differentiation potential, the ability to form colonies in vitro 
and evaluation of teratoma formation in vivo. It has also been suggested that the 
definitions of potency and self-renewal should reflect the overarching goal of use in 
human; thus restricting MSC criteria to in vivo (not in vitro) demonstrations.24,27    
Bone marrow derived stem cells (BMSCs), adipose derived stem cells (ADSCs), 
amniotic fluid stem cells (AFSCs), amniotic mesenchymal stem cells (AMSCs), and 
chorionic mesenchymal stem cells (CMSCs), have been previously evaluated and meet 
the minimal MSC criteria defined by the International Society for Cellular Therapy.28–42 
Table 1 reports the verified stem cell criteria for each cell type, including reports of cell 
surface marker expression (phenotype). Cell phenotype is passage dependent and can also 
vary depending on the isolation method employed.9 Though ≥95% and ≤2% are the 
threshold values assigned to positive and negative surface marker expression, variable 
expression has been reported with positive values as low as 80%.9 
 
1.3 Review of Common MSC Isolation Techniques 
1.3.1 BMSC Isolation Techniques Bone%marrow%(BM)%aspiration% is% typically%required% for%BMSC% isolation.%For%several%decades,% the%most% common% site% of% aspiration% has% been% the% iliac% crest,% though% the% femoral%shaft% has% also% been% utilized.43,44% As% illustrated% in% figure% 1,% BM% is% collected% through% an%aspiration%needle%system%at%varying%depths%of%insertion%into%the%iliac%crest.%Typically,%the%BM%aspirate% is% separated% into% its% constituent% components% using%Ficoll% gradient% centrifugation.%This%technique%employs%centrifugation%to%separate%BM%components%by%density,%resulting%in% 
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Table 1: Verified Stem Cell Criteria for human BMSCs, ADSCs, AFSCs, AECs, AMSCs, CVSCs and CMSCs. 
Criteria selections have corresponding references supporting the stem cells’ ability to meets each specific criterion. The 
far right column represents additional phenotypic analysis for each stem cell type.     
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the separation of solid components. 
The BMSCs are located within the 
resulting cell pellet, which is known 
as the mononuclear cell (MNC) 
fraction. The MNC contains not only 
BMSCs but populations of cells with 
phenotypic expression profiles 
dissimilar to those of a defined stem 
cell.33,43,59 The BMSCs can be 
isolated from the other cells of the 
MNC by re-suspending (i.e. adding 
media and gently mixing to re-
distribute the cells throughout the 
suspension) the MNC pellet and 
culturing on plastic (at least 
overnight), with BMSCs found 
amongst the adherent cells. Flow 
cytometric analysis and 
multipotency assays, like those 
previously described, to confirm the 
 
 
Figure 1: Left, Pictorial Representation of 
BMSC Isolation beginning at the top with bone 
marrow aspiration from the iliac crest, followed 
by centrifugation to separate the MNC, 
supernatant aspiration, re-suspension in media 
and plating, where the adherent cells are termed 
BMSCs. 
10 
presence of mesenchymal stem cells 
are also suggested.59  
1.3.2 ADSC Isolation Techniques 
Adipose tissue is relatively 
abundant, and it is typically removed 
in large quantities through gross 
resection, conventional liposuction 
and ultra-sound assisted liposuction 
procedures.60 Laser-assisted 
liposuction is less commonly 
employed.61 Adipose tissue is most 
commonly removed from the 
abdomen, and there does not appear 
to be a relationship between body 
mass index or gender and ADSC 
yield.62 To obtain the ADSCs, the 
adipose tissue is usually washed, 
minced, and enzymatically digested 
(typically in collagenase) to obtain 
what is commonly referred to as the  
 
 
Figure 2: Left, Pictorial Representation of 
ADSC Isolation beginning at the top, human 
lipoaspirate is washed and minced prior to 
centrifugation to separate the SVF, supernatant 
aspiration, re-suspension in media and plating, 
where the adherent cells are termed ADSCs. 
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stromal vascular fraction (SVF).7,9,60,63 The SVF is comprised of stromal and stem cells 
(<0.1%), endothelial cells (10-20%), lymphocytes (10-15%), monocytes and 
macrophages (5-15%), pericytes (3-5%), among other cell types.9 ADSCs can be 
separated from the SVF via Ficoll gradient centrifugation.7,9 As with BMSCs, in vitro 
culture (at least overnight) and flow cytometric analyses for the previously mentioned 
surface markers are commonly employed to ensure stemness of the isolated cells.  
1.3.3 AFSC Isolation Techniques 
Amniotic fluid (AF) is typically obtained during the second trimester by 
ultrasound-guided needle puncture (trans-abdominal or trans-cervical) during an 
amniocentesis procedure, though it can be obtained with minimal risk from week 14 
through the duration of the pregancy.34,57 In’t Anker et al collected AF via trans-
abdominal and trans-cervical amniocentesis from second and third trimester pregnancies. 
AFSCs free of maternal contamination were successfully isolated in n=10/10 trans-
abdominal and in n=4/10 trans-cervical second trimester amniocentesis samples (mean 
AF volume: 8.7±1.7mL trans-abdominal; 32.3±13.9mL trans-cervical). AFSCs free of 
maternal contamination were successfully isolated in only n=2/10 third trimester samples 
(mean AF volume: 10.7±4.8mL).57 This highlights the utility of trans-abdominal 
amniocentesis and the known change (decrease in AFSC) in the AF cellular profile 
throughout pregnancy. Higher volumes of AF can be obtained via trans-cervical 
amniocentesis, but these samples do not reliably yield pure AFSC populations. Trans-
abdominal amniocentesis seems to routinely yield pure AFSC populations throughout the 
second trimester, but lower volumes of AF are typically taken using this procedure.  
Though groups such as Kaviani et al describe taking as much as 22mL of AF during 
12 
amniocentesis, it has been reported 
that as little as 1-2mL of AF is 
required to successfully isolate 
AFSCs.39,51 As illustrated in figure 
3, the AF is centrifuged, the resultant 
cell pellet is re-suspended and 
cultured on plastic (at least 
overnight), with the adherent cells 
termed AFSCs.38,40,52,64 The danger 
of plastic adherence-based isolation 
of AFSCs is the known plastic 
adherence exhibited by three distinct 
AF cells types: E-type, F-type, and 
AFSCs.65 Thus stem cell yields 
calculated from plastic adherence-
based isolation are likely inflated 
values. Plastic adherence-based 
isolation followed by flow 
cytometric analysis for CD117, a 
Figure 3: Left, Pictorial Representation of 
AFSC Isolation beginning at the top, human AF 
is typically obtained via amniocentesis prior to 
centrifugation (to obtain the cell pellet), 
supernatant aspiration, re-suspension in media 
and plating, where the adherent cells are either 
AFSCs, E-Type or F-type cells. Flow cytometric 
analyses are typically required to further separate 
AFSCs.  
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tyrosine kinase receptor of stem cell 
factors, is preferred.34,40,50,66 
However, more meticulous isolation 
methods such as that described by 
Phermthai et al would also remove 
this bias in yield reporting.67 
1.3.4 AMSC Isolation Techniques 
Amniotic membrane (AM) is 
typically obtained after term 
cesarean section.54 The AM contains 
two distinct populations of cells that 
exhibit stem cell markers: 1) 
amniotic epithelial cells (AECs) and 
2) amniotic mesenchymal stem cells 
(AMSCs). The isolation, 
characterization, and potential 
application of amniotic cells have 
been previously reviewed by our 
group.68 In’t Anker et al successfully 
Figure 4: Left, Pictorial Representation of 
AMSC Isolation beginning at the top, human 
AM is mechanically peeled from the CM and 
digested in trypsin/EDTA (to selectively remove 
AECs) followed by digestion in collagenase (to 
remove AMSCs). Similar processing steps are 
utilized as previously described. Adherent cells 
from the trypsin digest are termed AECs while 
adherent cells from the collagenase digest are 
termed AMSCs.   
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isolated AMSCs from n=8/10 second trimester and n=7/10 term AMs.57 The most 
traditional method to isolate out each amniotic cell population is via serial digestion with 
trypsin/EDTA (to selectively remove the AECs from the epithelial layer) followed by 
collagenase or dispase digestion (to liberate the AMSCs from the stromal tissue 
layer).41,54 To obtain AMSCs, the collagenase-digested sample is centrifuged; the 
resultant cell pellet is re-suspended and cultured on plastic (at least overnight), with the 
adherent cells termed AMSCs. It should be noted that initial collagenase digestion of the 
amniotic membrane (without a trypsin digestion step) results in a mixed (AEC+AMSC) 
population of cells. In our experience, similar results can be obtained by using diluted 
volumes of trypsin during the initial digestion step, resulting in only the partial removal 
of AECs and consequent removal of the remaining AECs and AMSCs during collagenase 
digestion. Yields reported using such methods are thus inflated, as they do not depict a 
pure AMSC population. Flow cytometry for epithelial markers (to ensure no AEC 
contamination) and mesenchymal stem cell markers are suggested employed to further 
distinguish AMSCs. In fact, Marongiu warns that standard trypsin isolation 
concentrations (0.05% weight/volume) do not reproducibly yield pure AMSC populations 
and recommends purification through a density separation method.47  
1.3.5 CMSC Isolation Techniques 
The chorionic membrane contains two primary stem cell populations that retain 
mesenchymal stem cell characteristics: 1) chorionic mesenchymal stem cells (CMSCs) 
harvested from the stromal chorionic layer and 2) chorionic villous stem cells (CVSCs) 
isolated from the trophoblastic chorionic villi (As such, CVSCs are also referred to as 
chorionic trophoblastic cells). Placentas for CMSC isolation are typically obtained after 
15 
term cesarean section. Nazarov et al 
reported the ability to isolate plastic-
adherent CMSCs in all n=10/10 and 
Ba"enková et al reported success in 
all n=6/6 isolation attempts under 
such conditions.46,69 Jones et al 
compared first and third trimester 
CMSCs, finding similar phenotypes 
and differentiation potentials despite 
the developmental discrepancy. 
Additionally, first trimester CMSCs 
exhibited heightened kinetics, 
smaller sizes and unique surface 
expression profiles more 
characteristic of embryonic stem 
cells.70 However, as the author 
acknowledged, therapeutic use of 
first trimester CMSCs would require 
pregnancy termination.  
 
 
 
 
Figure 5: Left, Pictorial Representation of 
CMSC Isolation beginning at the top, human 
CM is removed form the maternal decidua and 
digested in trypsin/EDTA (to selectively remove 
CVSCs) followed by digestion in collagenase (to 
remove CMSCs). Similar processing steps are 
utilized as previously described. Adherent cells 
from the trypsin digest are termed CVSCs while 
adherent cells from the collagenase digest are 
termed CMSCs.   
16 
 
These authors could find no report of CVSC use in orthopedic regenerative 
medicine, though there are reports of using general chorionic (CMSCs+CVSCs) stem 
cells in musculoskeletal tissue engineering and regenerative medicine investigations. 
Additionally, as previously indicated their removal is necessary to ensure pure CMSC 
populations and we have thus briefly included them in our review. CVSCs can be 
obtained throughout pregnancy through trans-cervical chorionic villous samplings.34 The 
primary concern in CVSC isolation is maternal contamination, which is frequently 
reported.54,71 The most traditional methods by which to isolate out each chorionic cell 
population is via serial digestion with trypsin (to selectively remove the trophoblastic 
cells) followed by collagenase and or dispase digestion (to liberate the CMSCs from the 
stromal tissue layer), and subsequent in vitro culture to confirm plastic adherence.31,70–72 
There are also reports of CVSC isolation by the explant culture method.35,73 Briefly, 
chorionic villi are attached to plastic culture dishes maintained in culture medium for 
approximately 14-20 days, at which time the migrated cells (CVSCs) are harvested.  
 
1.4 Review of MSC Yields 
 Beyond orthopedics, the importance of high dose stem cell administration has 
been established in therapeutic strategies combating wound healing, fistula and heart 
failure.74–76 Moreover, in recent proof of concept clinical trials examining the potential 
therapeutic efficacy of using stem cells to mitigate musculoskeletal tissue pathologies (in 
this instance osteoarthritis), it has been demonstrated that only study groups receiving 
high doses (10x107 autologous ADSCs) show statistically significant improvement 
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compared to low dose stem cell administration and non-stem cell treated controls.13 Such 
reports further the relevance of stem cell yields in musculoskeletal regenerative medicine 
approaches, as sources exhibiting the highest yields represent the most practical (readily 
useable) stem cell.  
1.4.1 BMSC Yields 
Pittenger suggests that only 0.001 – 0.01% of isolated MNCs are stem cells.59 
This was corroborated by Pasquinelli et al who reported 0.001 – 0.1% of MNC 
suspensions were BMSCs as indicated by stem cell surface marker profiles.33 Recently, 
Li et al evaluated the number of colony forming unit fibroblasts (CFU-F; i.e. BMSCs) 
from repeated BM aspirations in healthy patients and those with leukemia.77 On average 
after the first aspiration, the mean number of CFU-F’s per 1 x 106 MNC’s was 84; this 
indicates roughly a 0.008% yield, which is within the range established by Pittenger’s 
findings. Furthermore, Li found the average number of MNC’s isolated during the first 
aspiration was 12 x 106/ mL BM, resulting in an average normalized stem cell yield of 
approximately 1 x 103 BMSC/mL of BM aspirate.77 Wexler et al had previously assessed 
the frequency of stem cells in the CFU-F population to be one BMSC in every 3.4 x 104 
cells.44 Baer et al cites that “a bone marrow transplant contains approximately 6 x 106 
nucleated cells per mL.”78 Taken together with the percentage range (0.01-0.001%) of 
BMSCs per nucleated cell established by Pittenger et al; 60 - 600 BMSCs can be 
theoretically obtained per milliliter of BM aspirate, which is in accordance with the 
values determined by Li et al. Lannert et al found no significant difference in BMSC 
yield when varying bone marrow aspiration methods, resulting in an average of 0.11 - 
0.34 x 108 total nucleated cells per liter of BM.43 Considering that only a small portion of 
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these cells are actually BMSCs; the theoretical stem cell yield per mL aspirate would be 
11 - 340 BMSC/mL, which represent slightly lower values than those determined by 
other authors. 
1.4.2 ADSC Yields 
Chung et al determined that traditional suction assisted liposuction yields a mean 
stem cell count of 5.4 x 105 cells per mL with roughly 81% cell viability (i.e. 4.4 x 105 
viable ADSCs/mL processed lipoaspirate).61 Baer et al cite that the SVF of adipose tissue 
contains approximately 0.5 – 2 x 106 cells per gram.78 Jurgens et al suggest that 
approximately 5% of the total cell count found in the SVF from liposuction of the 
abdomen is ADSCs, though Bourin suggests it can be as low as 0.1%.9,79 In line with this 
finding, Baer cites others who indicate that 1-10% of the cells in the SVF are stem cells.78 
Using a conservative estimate of 5% and provided the total number of cells estimated per 
gram of SVF by Baer, the calculated theoretical ADSC yield is 2.5 x 104 – 1 x 105 
ADSCs/g adipose tissue (or 5 x 103 – 2 x 105 ADSCs/g, if you assume 10% of the SVF 
are stem cells). Oedayrajsingh-Varma et al compared whole tissue resection, tumescent 
liposuction, and ultrasound-guided liposuction to determine if there was a difference in 
cell yields between these methods. These methods yielded 7 x 105, 5 x 105, and 6 x 105 
SVF cells (+/- 1 x 105)/g of harvested tissue, respectively.60 Using the 5% estimate, the 
total ADSC yield by these methods was approximately 3.5 x 104, 2.5 x 104, and 3 x 104 
(+/- 1 x 105) ADSC/g. This suggests similar effectiveness between isolation methods, and 
is in accordance with previously calculated ADSC yield values. Christodoulou et al 
isolated a mean SVF yield of 312 x 106 cells from 173.8g of adipose tissue.80 Applying 
the 5% estimate, approximately 8.9 x 104 ADSC/g were obtained, again in accordance 
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with previously predicted values. However, it is noteworthy that all of these calculated 
values are larger than the 5 x 103 ADSCs/g cited by Hass et al.32 Zuk et al suggests that 2 
– 6 x 108 nucleated cells can be found in the SVF obtained from 300 mL of raw 
lipoaspirate, which would yield 6.7 x 105 – 2 x 106 cells per mL.63 Again, assuming 5% 
of these cells are stem cells (in accordance with Jurgen et al79) this would result in 
approximately 3.4 x 104 – 1 x 105 ADSCs/ mL of lipoaspirate, which is in agreement with 
Baer’s citations (which includes Zuk et al and others).   
1.4.3 AFSC Yield 
Though the cellular profile of AF has been shown to change with fetal age, the 
majority of cells isolated from AF are terminally differentiated and do not have the 
proliferative capacities characteristic of mesenchymal stem cells.48,52 It is estimated that 
only 1% of the cells obtained during amniocentesis are AFSCs.34,40 It has been reported 
that the mean AF volume is relatively constant (207±92mL at 16 weeks, 258±97mL at 18 
weeks and 365±88mL at 20 weeks), but during the second trimester the number of cells 
within the AF varies from 10-1,000 cells/µL.65 Based on these reports, the theoretical 
number of cells in the total volume of AF at 20 weeks is between 3.65 x 106 – 3.65 x 108 
cells. Following reports that AFSCs constitute only 1% of the overall AF cell population; 
the theoretical number of AFSCs in the entire AF at 20 weeks is 3.65 x 104 – 3.65 x 106 
AFSCs (or 100-10,000 AFSCs/mL AF). However, it must be noted that the entire AF 
volume could never be utilized without compromising pregnancy. Pappa et al reported an 
average of 0.9-1.5% AFSCs isolated from 10-15mL of AF taken at 15-18 gestational 
weeks, which resulted in 2.7 x 105 total AFSCs (or 1.8 x 104 – 2.7 x 104 AFSCs/mL AF), 
within the previously calculated theoretical range.29 Unpublished observations by Ekblad 
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also fall within this theoretical range, as 1,500±3,250 AFSCs/mL were obtained by 
pooling 2-3 AF samples (mean sample volume: 6.7mL) and combining n=7 pooled 
samples together.   
1.4.4 AMSC Yields 
Expected yields using the previously described serial enzymatic digestion 
technique are 4-5 x 106 AMSCs/AM.55 Soncini et al reports a typical isolation of 24 ± 10 
x 106 AMSCs/AM.71 Using a similar method, Casey et al isolated 1 x 106 AMSCs/g of 
AM (mass of amnion tissues: 5-15 grams).53 Published data by Bilic et al states that a 
mean of 1.7 x 106 AMSCs/g could be harvested.49 Unpublished results by Bilic et al 
(reviewed by Parolini et al54) state that “typically 4 x 106 AMSCs per 100 cm2 of starting 
material” can be isolated from the term amnion. While Alviano et al noted 1.3-1.5 x 106 
AMSC/4cm2 AM (3.2-3.75 x 105 AMSC/cm2). They extrapolated that with an average 
amnion area of 1300cm2, 4 x 108 AMSCs can be isolated/AM.37 Unpublished data by our 
group seems to align with previous reports, as we routinely isolate an average of 1.6 x 106 
AMSCs/mL and as many as 3 x 108 AMSC/AM. 
1.4.5 CMSC Yields 
We are not the only authors to remark at the extremely limited information 
available regarding CMSCs.34,46,81 Witkowska-Zimny et al cite Soncini et al who report 
that 21 x 106 CMSCs can be isolated from the enzymatic digestion of a single chorionic 
membrane.34,71 While Bačenková reported 11 x 106 CMSCs were isolated from 6-pooled 
10x10cm chorion segments (11 x 104 CMSC/cm2).31 Abumaree successfully isolated 
11.55 ± 1.23 x 103 CVSCs/40mg chorion (wet weight) when employing the standard 
explant culture technique (2.89 x 102/mg) and 24.66 ± 2.67 x 103 CVSCs/40mg chorion 
21 
(wet weight) when employing trypsin (6.17 x 102/mg), with confirmation that the CVSCs 
were free of maternal contamination.73 Both Zhang and Igura et al reported 1 x 104 
CVSCs/5mm3 chorion using the explant culture method (2 x 103/cm2).35,81 All of the 
previously reviewed stem cell yields are succinctly reviewed below in table 2.  
 
Table 2: Calculated and Reported MSC Yields 
Stem 
Cell [Stem Cells/ mL tissue] 
[Stem Cells/ 
g tissue] 
% Stem Cells 
in Cellular 
Fraction 
Other Reference(s) 
BMSC 
1x103, 
60-600, 
11-340 
NA 
0.001-0.01%, 
0.001-0.1%, 
0.008% 
NA 33,43,59,78,79 
ADSC 4.4x10
5, 
3.4x104-1x105 
2.5x104-1x105, 
3.5x104, 
2.5x104, 
3x104, 
8.9x104, 
5x103 
5%, 
1-10% NA 
48,56,59,60, 
62,78,79 
AFSC 
1x102-1x104, 
1.8x104-2.7x104, 
1.5x102-3.25x102 
NA 1% NA 29,34,40 
AMSC 1.7x106 NA NA 
4-5x106/AM, 
24±106/AM, 
4x108/AM, 
4x104/cm2, 
3.2-3.75x105/cm2 
37,53,54,72,81 
CVSC NA 6.17x105 NA 2x103/cm2 77 
CMSC NA NA NA 21x10
6/CM, 
11x104/cm2 
31,34,72 
Table 2: Reported and Extrapolated MSC Yields reviewing the previously described yields obtained or calculated 
(underlined values) based on the current literature. This table highlights the numerous ways stem cell yields are 
reported, limiting immediate cross-comparisons between MSC types. Underlined data points indicate calculated values 
based on the 0.001-0.01% (BMSC), 5% (ADSC) and 1% (AFSC) ranges 
 
 
1.5 Obtaining “Clinically Relevant” Stem Cell Populations 
It has been widely accepted that stem cells must be administered in large 
quantities to demonstrate clinical efficacy.4,5,14 Commonly, this is expressed as needing to 
obtain “clinically relevant” stem cell populations, presumably through ex vivo 
expansion.82,83 With limited past precedence within orthopedics, we define clinically 
relevant populations as those commonly employed in orthopedic clinical trials. Upon  
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Figure 6: Calculated AFSC, AMSC and CMSC Yields with the dashed lined indicating the mean reported dose of 
current orthopedic clinical trials employing MSCs. 
 
 
review of the United States National Institutes of Health clinicaltrials.gov website, 
between 1 x 106 -1 x 109 stem cells are commonly employed in various clinical trials for 
orthopedic applications, seeming to imply that 1 x 106 is the minimum number of stem 
cells required for clinical relevance in stem cell-based orthopedic therapies. Of note, no 
orthopedic trials were discovered utilizing AFSCs, AMSCs, CMSCs or CVSCs. (Note: 
The reported range excludes studies with dosages reported as mL BM aspirate. The 
lowest BM aspirate reported is 6mL, which based on our calculations would yield 3.6 x 
102 - 3.6 x 103). However, this claim can only be verified upon study conclusion and 
evaluation of ongoing trials.  
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Based on our summation of the literature and extrapolation of stem cell yields, 
AMSCs yields are the highest of all stem cell types examined. An averaged size AM can 
yield up to 4 x 108 AMSCs, whereas the largest yield reported from the chorionic 
membrane is only 21 x 106 CMSCs, approximately 20x less than the amniotic membrane.  
AFSC isolation using the entire AF volume at 20 gestational weeks yields 3.65 x 104 – 
3.65 x 106, approximately 100x less mesenchymal stem cells than the amniotic 
membrane. These relative yields are represented in figure 6. Additionally, it cannot be 
ignored that being able to utilize the entire AF volume represents an unrealistic 
therapeutic scenario. We were unable to determine average lipoaspirate or BM aspirate 
volumes removed during standard procedures from the literature, but calculated yields 
Figure 7: Largest Reported BMSC, ADSC, AFSC and AMSC Yields highlighting the exponentially greater yields 
of AMSCs compared to more standard stem cell sources. 
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indicate 3.4 x 104 – 1 x 105 ADSCs/mL lipoaspirate, nearly 500x greater than the 
calculated BMSC yield of 60-600BMSC/mL BM aspirate, can be obtained. Still, 
hAMSCs can be isolated in as much as 40x greater quantities than ADSCs (1.6 x 106 
AMSC/mL AM vs. 3.4 x 104 – 1 x 105 ADSCs/mL lipoaspirate).  These relative yields 
are represented in figure 7. 
In order to obtain the previously identified (minimal) number of stem cells 
required for clinical relevance (1 x 106 stem cells) without ex vivo expansion of cells, at 
least 1.6L BM, 10mL lipoaspirate, 55mL AF, 0.625mL AM, or 500cm2 CM would be 
required (illustrated in figure 8). This highlights the utility of stem cell sources such as 
the amnion, as one amnion would be substantial to obtain multiple therapeutic doses.  
The highest reported clinical trial dosage of 1 x 109 is not possible without ex 
vivo expansion of any of the listed cell types. However, the mean reported dosage (2 x 
108 stem cells, also the dosage termed “clinically relevant” by Schallmoser et. al.83) could 
only be accomplished without ex vivo expansion through using AM. As previously 
indicated, ex vivo expansion exposes cells to increased possibilities of contamination as 
well as alterations to their phenotype and differentiation potentials.15–17 Thus, AMSCs 
may be an under-used stem cells source in orthopedic regenerative medicine.  
It should be noted that reported values for stem cell yields vary within each tissue 
due to the differing isolation techniques employed. Furthermore, it is difficult to make 
direct comparisons between stem cell yields within the same tissue as different 
investigators utilize varying techniques for quantification. The dosage range of current 
orthopaedic clinical trials employing stem cell therapies seems to indicate that at least 1 x 
106 stem cells are required for clinical significance. Based on our summation of the 
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literature and extrapolation of stem cell yields, AMSCs yields are the highest of all stem 
cell types examined. AMSCs are also the only cell type examined that can be isolated in 
quantities equal to the mean dosage of stem cells currently employed in orthopedic 
clinical trials.  
 
Figure 8: Tissue Required To Obtain 1x106 Stem Cells, the minimum number of stem cells required for clinical 
significance, without ex vivo expansion.   
 
1.6 FDA Regulation of Stem Cells 
 MSCs currently fall under the jurisdiction of the U.S. FDA’s Center for Biologics, 
Evaluation and Research’s (CBER) Office of Cellular, Tissue and Gene Therapies 
(OCTGT).  Stem cells are considered as human cells, tissues or cellular and tissue-based 
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products. As such, their use must meet current FDA regulatory codes and good 
manufacturing practices, specifically Title 21, Part 1271.7,68 The FDA has two clinical 
regulatory pathways governing the use of MSCs and MSC-based products. It is possible, 
but not likely, for an MSC-based product to be regulated under Section 361 of the Public 
Health System’s Act if the product meets the following criteria: 1) the product has been 
minimally manipulated, 2) the product is intended for homologous use only, 3) the 
product was not combined with any other biologic or synthetic article, 4) the product 
does not have a systemic effect or depend on the activity of living cells for its primary 
function and 5) the product is for autologous use.7,68 Regulation by Public Health system 
Act Section 361 grants products sanctioned use for investigational trials without formal 
FDA approval. While MSCs are HCT/Ps, to the best of the authors knowledge they do 
not meet the criteria listed above an accordingly are regulated the PHS act under Section 
351 as a biologic drug which must follow current good manufacturing and tissue 
practices (cGMP and CGTP, respectively) and require investigational device exemptions 
and clinical trial data to provide evidence of safety and efficacy to gain approval prior to 
marketing. To date are no FDA approved MSC-based products for orthopaedic 
applications. For more information on FDA regulations, please see our previous review.68   
1.7 Stem Cell Differentiation 
Stem cells, especially stem cells combined with biomaterial scaffolds, have the 
potential to differentiate into target cells, establishing new populations of healthy, tissue-
forming, cells in diseased areas.11,84,85 In some instances it has been demonstrated that 
stem cell differentiation can occur “spontaneously.” That is, differentiation can occur 
without the addition of exogenous growth factors. In such instances the stem cells are 
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typically seeded onto a scaffold. It is hypothesized that the physical and/or chemical 
properties of the scaffold provides the stimulatory cues necessary to promote stem cell 
differentiation, though the exact mechanisms behind such differentiation are not yet fully 
understood.86–88  
However the primary means to achieve stem cell differentiation involves 
manipulation not currently allowed by FDA regulation, the addition of exogenous growth 
factors to culture media (see figure 9).32,86,89–97 As different cell types require different  
 
Figure 9: Growth Factor-Induced Stem Cell Differentiation is the most common technique to achieve stem cell 
differentiation into desired tissue types. This involves the supplementation of cell culture media with growth factors. 
Individual growth factors are best suited to specific lineages of differentiation.   
growth factors to sustain their phenotype and functionality, a variety of chemical 
cocktails are employed to achieve stem cell differentiation into multiple cell lineages. As 
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previously indicated, osteogenic, adipogenic and chondrogenic differentiation are 
necessary characteristics to be defined as a stem cell.25 Therefore, these lineages are the 
most widely investigated. For the purposes of this review, only those with 
musculoskeletal tissue relevance (osteogenic and chondrogenic) will be explained in 
further detail.  
Osteogenic differentiation has been achieved through the addition of 
dexamethasone, #-glycerophosphate, ascorbic acid or bone morphogenic proteins (BMPs) 
to culture media.32,49,89,90,92–95,98 Differentiation is typically evaluated through enhanced  
 
Figure 10: Osteogenic Differentiation is typically accomplished via media supplementation with dexamethasone, #-
glycerophosphate, ascorbic acid or bone morphogenic proteins (BMPs). Differentiation is confirmed through gene 
expression of key osteogenic markers and through protein deposition of bone matrix elements, notably, calcium. 1Photo 
credit: OrthoX colleague, Sandra Siatkowski 
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gene expression of master osteogenic transcription factor, runx-2, and other osteogenic 
markers: osteocalcin, osteonectin, osteopontin and osteoprotegrin.32,89,94,98 At the protein 
level, differentiation is also evaluated through alkaline phosphatase expression and 
calcium deposition (visualized through von Kossa or Alizarin Red 
staining).32,49,89,90,92,93,95,98,99 
Chondrogenic differentiation has been achieved through the addition of 
transforming growth factor #1, ascorbate-2-phosphate and dexamethasone.32,93–97 Growth  
 
Figure 11: Chondrogenic Differentiation is typically accomplished via media supplementation with transforming 
growth factor #1, ascorbate-2-phosphate and/or dexamethasone. Differentiation is confirmed through gene expression 
of key chondrogenic markers and through protein deposition of cartilage matrix elements, notably, glycosaminoglycans 
(GAGs). 1Photo credit: OrthoX colleague, Sandra Siatkowski 
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and differentiation factor-5, fibroblastic growth factor-2 and BMP-6 have also been 
described.32 Studies requiring the use of serum-free media (typically those aiming to 
achieve clinical relevance of results through the use of human cells without animal serum 
effects), typically employ insulin transferrin selenium (ITS).86,94,97 Differentiation is 
typically evaluated through enhanced gene expression of master chondrogenic 
transcription factor, sox-9, and other chondrogenic markers: aggrecan and collagen-
2.32,93,95–97 At the protein level, differentiation is also evaluated through matrix staining of 
glycosaminoglycans (GAGs; visualized through Alcian Blue staining).32,95   
 In addition to plated culture, chondrogenic differentiation of MSCs is 
accomplished through pellet culture. In this approach, stem cells remain in a pellet after 
centrifugation (as opposed to being re-suspended in culture media and plated). This 
provides the cells a 3D environment, allowing cell-to-cell interactions that more 
accurately mimic the natural condensation of MSCs during chondrogenesis to 
occur.100,101  
1.8 Bone and Cartilage Formation: Endochondral Ossification 
 Bone formation (osteogenesis) can occur through mesenchymal condensation 
differentiation into osteoblasts; this process forms the membranous elements of the 
vertebral skeleton during development.102 However, most of the vertebral skeleton forms 
through endochondral ossification100,102, the central biochemical pathway responsible for 
both chondrogenesis and osteogenesis. In endochondral ossification, cells differentiate 
into chondrocytes, proliferate and undergo hypertrophy until they reach terminal 
differentiation (ossification).87,100,102–104 Simultaneously some cells differentiate into 
osteoblasts and osteoclasts.102,103 Together these cells degrade the cartilage matrix 
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(osteoclasts) and replace it with newly formed bone matrix (osteoblasts) through a 
process known as remodeling.   
 
Figure 12: Endochondral Ossification is the primary pathway through which osteogenesis and chondrogenesis 
occurs; it is also the pathway of MSC differentiation into cells of chondral and osteo lineages. Initially, MSCs 
condense, forming either osteoblasts/clasts or chondrocytes. These chondrocytes proliferate, ultimately undergo 
hypertrophy and terminally differentiate through ossification. 
 Master chondrogenic transcription factor, sox-9, is required for mesenchymal cell 
condensation formation.102,103 All chondroprogenitor cells but not all chondrocytes 
express sox-9.102 Hypertrophic chondrocytes, in particular, and osteoblasts do not express 
sox-9, further implicating sox-9 in the proliferative as opposed to the later phases of 
endochondral ossification.102,103 
 Sox-5 and sox-6 are regulators of key chondrocyte matrix components, collagen 2 
and aggrecan.102,103 Sox-5 and sox-6 are not required for mesenchymal cell condensation 
but are required immediately following chondrocyte maturation where high levels of 
surrounding matrix are produced.102 There does seem to be a redundancy in this pathway 
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whereby mice deficient in either sox-5 or sox-6 mature with limited skeletal 
abnormalities.102 However, mice deficient in both sox-5 and sox-6 die in utero.102    
 As previously indicated, runx-2 is a transcription factor controlling the rate of 
expression of osteocalcin and other osteogenic matrix components. Runx-2 is required for 
osteogenic differentiation. Through chemical induction, mesenchymal stem cells can up-
regulate runx-2 in order to promote osteogenic differentiation.102 Natively, runx-2 is 
expressed by hypertrophic chondrocytes and osteoblasts.102   
 
Figure 13: Sox-9 & Runx-2 Involvement in Endochondral Ossification is extensive. Sox-9 is primarily responsible 
for condensation and chondrocyte proliferation. Runx-2 is primarily implicated in condensation of terminally 
differentiated osteoblasts/clasts and the transition from proliferative to hypertrophic chondrocytes.  
The TGF superfamily is another group of regulators influencing cell growth, 
differentiation and apoptosis in many cell types, including chondrocytes and 
osteoblasts.103 The TGF superfamily includes the BMPs 2-8 as well as the TGF-"s.103,105 
TGF binding has been shown to influence chondrogenesis through two primary 
molecular interactions, MAPK and SMAD pathways.103 
 As previously indicated, many members of the TGF superfamily are used as 
exogenous growth factors to induce differentiation in stem cells. Previously it has been 
demonstrated that TGF-" supplemented medium induces chondrogenesis more 
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effectively in adult but not fetal BMSCs; conversely, medium supplemented with BMP-2 
induces chondrogenesis more effectively in fetal but not adult BMSCs.95 TGF-β receptor 
binding leads to the phosphorylation of SMAD2 and SMAD3.95,105–107 Whereas, BMP-2 
receptor binding leads to the phosphorylation of SMAD1 and SMAD5.95,105–107 Each of 
these SMADs serve specific (though not currently completely defined) functions. BMP-
pathway deficient mice have underdeveloped growth plates due to inhibition of 
chondrocyte proliferation.106 Whereas, TGF-β-pathway deficient mice tend to develop 
elongated growth plates due to maintenance of chondrocytes in the proliferative phase.106 
TGF-β-related SMAD signaling has also been correlated with increased likelihoods of 
osteoarthritis and osteophyte formation throughout cartilage.106 While it has been 
established that both signaling pathways are necessary for proper development106, there 
appear to be chondrogenic advantages (less potential for bone formation and maintenance 
of chondrocytes in the proliferative phase) in BMP-induced chondrogenesis. The 
biochemical process of endochondral ossification describes the formation of cartilage and 
bone cells. These cells, together with specified matrix components, create the distinctive 
tissue structures known as cartilage and bone.   
 
1.9 Articular Cartilage: Structure & Function 
 Cartilage is a roughly 2-4 mm thick connective tissue composed of a unique host 
cell type, chondrocytes, and the extracellular matrix (primarily composed of water, 
collagen and proteoglycan) surrounding the chondrocytes.108–110 Despite having minimal 
components, cartilage is a complex tissue with the cells and matrix fibers organized in 
multiple patterns (referred to as zones). This heterogeneous structure results in varying 
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cell phenotypes, gene and protein expression.108,109 Therefore each individual zone offers 
a unique function to the cartilage unit.  
 
Figure 14: Cartilage Structure is heterogeneous; the variable composition (cellular shape/phenotype and matrix) of 
each zone yields specific functions. These zones combine together to serve one primary function: the absorption and 
dissipation the mechanical loads of the joint. Cartilage lines the surface of joints, including the knee joint (pictured at 
left).   
 In the superficial zone (figure 14), flattened chondrocytes arrange with their 
lacunae oriented parallel to the cartilage surface.108 In a similar manner, type II and IX 
collagen fibers align parallel to the surface.109 Type II collagen is the most abundant 
extracellular matrix component (approximately 90-95% dry weight).109,111 Collagens I, 
IV, V, VI and XI are also present, but in much lower proportions; these collagens 
function primarily to stabilize the type II collagen network.109 Though this zone is the 
thinnest cartilage layer (roughly 15% of total cartilage thickness), this parallel orientation 
functions to protect deeper cartilage layers from mechanical stresses.109 Thus, the 
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integrity of the superficial layer is paramount to overall cartilage function.112 This zone 
also exhibits high levels of lubricin and hyaluronic acid (HA) secretion, lubricating the 
joint surface (allowing fluid, pain-free movement).108 Water is also most abundant in the 
superficial zone (approximately 80% wet weight), filling intrafibrilar spaces and 
facilitating nutrient exchange.109   
 In the intermediate zone (figure 14), a combination of more rounded chondrocytes 
can be found sparsely thought an oblique network of extracellular matrix fibers.109 These 
fibers, primarily thicker collagen segments and proteoglycans, function to resist 
compressive forces.109 Proteoglycans (up to 15% wet weight) are crucial to the 
compressive resistance exhibited by cartilage. Aggrecan, the most abundant cartilage 
proteoglycan, has unique osmotic properties, making it specially suited to resist 
compressive loading.109  
 The deep zone (figure 14) provides the primary resistance to compressive 
forces.109 In the deep zone, chondrocytes arrange in a columnar orientation perpendicular 
to the cartilage surface. Dense networks of large diameter collagen fibers and 
proteoglycans arrange parallel to chondrocyte columns (perpendicular to the surface). 
The deep zone contains the highest proteoglycan and lowest water contents.109       
 Together the superficial, intermediate and deep zones make up the non-
mineralized portion of cartilage.108 These non-calcified zones do not contain blood 
vessels. Thus the chondrocytes in these regions live under hypoxic conditions, absorbing 
nutrients from neighboring joint tissues.108,109,113 Though the exact mechanism is not 
understood, it has been suggested that the high levels of collagen-2 and aggrecan 
observed in these zones are a result of the hypoxic environment, as chondrocytes cultured 
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under normoxia do not display the appropriate biochemical profile.108 Additionally, 
hypoxia produces a more chondroprotective environment, reducing synthesis rates of 
matrix metalloproteinases one and thirteen (MMP-1 and MMP-13, respectively; both 
responsible for cartilage extracellular matrix degradation and fragmentation).108 These 
regions are separated from the deep calcified cartilage by the tide mark (a line roughly 
parallel to the cartilage surface visualized through hematoxylin staining).108    
   Calcified cartilage (figure 14) has a particularly unique composition that 
drastically changes with age. Over time, nerves and blood vessels arise from the 
subchondral bone, infiltrating the calcified cartilage.108 Additionally, the chondrocytes in 
this zone express markers of hypertrophy (ex. runx-2, MMP-13 and type X 
collagen).104,108,112    
Together, the primary functions of cartilage are to absorb and dissipate 
mechanical loads.108 In fact, mechanical stresses are required to maintain cartilage 
homeostasis, as loading produces fluid movement within the joint.108,113 This (synovial) 
fluid facilitates nutrient exchange as well as lubrication and will be addressed in more 
detail in the subsequent section entitled, “Introduction to Osteoarthritis.” Biochemically, 
mechanical loading decreases matrix metalloproteinase 3 (MMP-3; a cartilage 
extracellular matrix degrading enzyme) and increases aggrecan expression in 
chondrocytes.108 There is also evidence that mechanical loading prevents the secretion of 
inflammatory mediators, including interleukin 1 (IL-1) and tumor necrosis factor alpha 
(TNF-α).108  
In normal adults cartilage is in a quiescent state.108,109,112,113 This is largely 
possible due to the extremely long turn over rates of the primarily components: collagen 
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(400 years) and proteoglycans (25 years).109 Chondrocytes, themselves, do not routinely 
proliferate.108–110,113 Each chondrocyte is responsible for the turnover of the extracellular 
matrix in its immediate vicinity. This essentially traps the chondrocytes in place, 
preventing cell clustering and cell-to-cell signal transduction.109 Additionally, the 
extracellular matrix does not repair and replenish the previously described collagen and 
proteoglycan networks.108,109,114 Numerous pathologies, including osteoarthritis, disrupt 
this previously described homeostatic regulation through the activation of chondrocytes.  
 
1.10 Introduction to Osteoarthritis (OA)  
1.10.1 Prevalence & Pathogenesis 
 OA is the most common form of arthritis, affecting over 30% of the U.S. 
population over the age of 65.11,12,110,111,113–118 OA is the result of degraded cartilage, 
impairing joint mobility and causing severe pain - making it one of the leading causes of 
disability worldwide.12,110,111,113,119,120 Costs associated with OA have been described as 
accounting for up to 2% of gross national product in the U.S., the United Kingdom, 
Canada, France and Australia.12,120,121 Additionally, is estimated that the prevalence of 
OA will double by 2020.122  
Articular cartilage degradation is the result of multiple physical and biochemical 
processes including, general wear and tear (the result of years of joint use), inappropriate 
mechanical loading and inflammation.11,12,104,108,111,114,115,117,119,122 Both systemic (trauma, 
obesity and genetic predisposition) and local inflammation (primarily synovial 
inflammation) have been implicated in OA.11,108,110,123–126  
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Though commonly associated with the degeneration of cartilage, OA is a disease 
of the entire joint space.12,85,108,113,117,118,126–128 In OA, the subchondral bone, synovium, 
ligaments and meniscus interact with the cartilage via non-homeostatic 
mechanisms.12,85,108,113 Specifically, the subchondral bone can exhibit sclerosis, and 
osteophyte formation is noted at the junction of the synovium with the periosteum.115,127 
Synovial fluid - the fluid surrounding and lubricating the joint, becomes filled with pro-
inflammatory mediators and cartilage degradation products.11,104 Currently, the exact 
mechanisms of such processes are unknown, obscuring our understanding of OA 
etiology.   
 
Figure 15: Osteoarthritis (OA) is the result of numerous physical and biochemical processes. Though commonly 
associated with cartilage injury, OA is also affiliated with osteophyte formation within the cartilage or at the 
synovial/periosteal interface and chronic inflammation of the synovial membrane and the synovial fluid.  
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In OA, chondrocytes exist in an activated (“senescent” as opposed to quiescent) 
state, resulting in rapid cell proliferation, cluster and matrix formation and increased 
secretion of matrix degrading enzymes (ex. MMPs and A Disintegrin And 
Metalloproteinase with Thrombospondin Motifs, ADAMTS).104,108,110,113,129    
 
Figure 16: Activated Chondrocytes contribute to the microscopic changes observed in OA through increased 
proliferation, clustering and the secretion of potent cartilage matrix degrading enzymes, MMPs and ADAMTs. These 
enzymes contribute to the overall decrease in collagen and proteoglycan observed in OA cartilage.  
Primary MMPs involved in OA pathogenesis include MMP-13, MMP-3 and to a 
lesser extent MMP-2. MMP-13 is a collagenase (collagen degrading enzyme) with a 
particular affinity for type II collagen.12,104 In OA, MMP-13 expression is increased 
within both the synovium and cartilage.115 In addition to being an effective aggrecanase 
(aggrecan degrading enzyme), MMP-3 is an upstream regulator and promoter of 
downstream MMP synthesis.12,108 MMP-2 cleaves numerous types of collagen and also 
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has a regulatory role, promoting the synthesis of other MMPs.115 The ADAMTS are a 
family of potent aggrecanases. Those most often implicated in OA are ADAMTS 4 and 
ADAMTS 5.12,108 In fact, ADAMTS 5 knockout mice have been shown to be protected 
against OA progression.12,108,130 However MMP-13 knockout mice prevent collagen (but 
not aggrecan) depletion.12,108  
Activated chondrocytes also express unique surface receptors, promoting the 
binding of inflammatory cytokines and chemokines (specifically those released from the 
synovium), which activate downstream inflammatory cascades further promoting 
cartilage destruction.104,108,131    
1.10.2 Synovial Inflammation & OA 
Under normal conditions, the synovial membrane (synovium) is composed of 
fibrous extracellular matrix approximately 2-3 cell layers thick. The synovium acts as a 
semi-permeable membrane, facilitating cartilage nutrient exchange through the regulation 
of synovial fluid composition.113 The host cells of the synovium, synovial cells, are 
responsible for secreting synovial fluid components. Two primary components include 
lubricin and HA, which, as previously indicated, help protect and maintain the surface of 
articular cartilage.108,109,113 Lubricin, specifically, is responsible for reducing the 
deposition of pathologic proteins on the cartilage surface.113 These molecules are not 
permeable, allowing high concentrations to be retained within the synovium. In OA, the 
concentrations of lubricin and HA are lowered, limiting their intrinsic chondroprotective 
roles. This depletion is attributed to a change in synovial membrane permeability. 
Clinically, high serum HA concentrations and low synovial fluid HA concentrations have 
been used to confirm synovitis.113   
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Synovitis is a broad term used to describe (inflammatory) changes within the 
synovium, which are characteristic of arthritic diseases. Classically, synovitis refers to 
membrane compositional and organizational changes observed histologically.113 These 
include thickening, increased populations of leukocytes and angiogenesis (indicated by 
increased VEGF concentrations within the synovial fluid) within the synovial 
membrane.132,133 However, the synovial biopsy required for such histological 
examination is not always available. Thus, gross appearance during surgery or magnetic 
resonance imaging (MRI) have also become acceptable observations.113,132 It has been 
reported that as many as 50% of OA cases have significant synovitis that is visible 
through MRI.132,134 In comparison to other inflammatory-based arthritis diseases (ex. 
rheumatoid arthritis), OA synovitis is a low-grade chronic inflammation within the 
membrane.113,119,133,135,136 Though synovial inflammation is more frequently observed in 
end-stage OA135, the synovial lining is twice as thick (inflamed) in early stage OA 
compared to late stage OA.119 Additionally, it has been shown that the degree of synovitis 
positively correlates with patient pain.113,137 Synovitis is also directly related to cartilage 
degradation.118,132,138,139 
Numerous inflammatory pathways can promote the development and maintenance 
of synovitis.104 Recently it has been suggested that the most likely pathway begins when 
cellular stresses (as a result of injury or non-local inflammation) result in the release of 
matrix degradation products. These matrix fragments activate toll-like receptors (TLRs) 
along the cells of the synovial membrane through damage-associated molecular patterns 
(DAMPS).108,113,135 The downstream consequence of TLR activation in the synovium is 
nuclear-factor κB (NF-κB) activation, which is a transcription factor regulating pro-
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inflammatory chemokines (ex. IL-8) and cytokines (ex. IL-1, IL-6 and TNF-#).104,113,135 
Synovial cell TLR activation is also responsible for the downstream up-regulation of  
MMPs and aggrecanses.113,128,135,140 Similar NF-$B dependent pathways are also
responsible for the inhibition of transcription factors controlling chondrogenesis (ex. sox- 
9).11 
 
 
Figure 17: Toll-Like Receptor (TLR) Activation occurs through the binding of cartilage matrix fragments (i.e. 
DAMPs) to both cells within the synovium or chondrocytes. This binding results in the up-regulation of pro-
inflammatory transcription factor NF-$B. Downstream consequences of this up-regulation include increases in pro-
inflammatory cytokines and cartilage matrix degrading enzymes.   
 
Notably, in addition to synovial TLR activation, chondrocytes have exhibited 
TLR activation in response to DAMPs.12,113 Though it has been suggested that this 
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activation pathway does not lead to the production of an activated form of IL-1,108 this 
pathway still results in the up-regulation of MMPs and ADAMTS. Specifically, TLR-2 
and TLR-4 are up-regulated in regions of cartilage erosion.104,113,135 Up-regulation of 
these specific TLRs has been linked to downstream increases in master MMP regulator, 
MMP-3.113,135 Additionally, TLR-4 activation has been shown to recruit and activate 
macrophages to/within the synovium.113 Specific DAMPs have also been isolated from 
OA synovial fluid; the concentration of DAMPs present was able to predict future 
cartilage destruction.134  
This multi-focal activation of TLRs is one reason OA is beginning to be described 
as a feed-forward pathology, where the cartilage and the synovium act against one 
another, each fueling the other’s disease progression. However, it is generally assumed 
that cartilage injury initiates the propagation of OA.125,135 An alternate depiction of TLR 
activation can be found in appendix A.   
1.10.3 Synovial Macrophages & OA 
Though commonly associated with host defense, macrophages are involved in 
many other homeostatic and tissue remodeling activities.141–143 Tissue microenvironments 
promote macrophage differentiation into functional phenotypes.143,144 The two most 
prominent phenotypes are M1 (pro-inflammatory) and M2 (pro-regenerative/regulatory) 
polarized macrophages.133,142,143 M1 macrophage differentiation is commonly induced by 
interferon-γ (INFγ) or other pro-inflammatory cytokines (ex. TNF-α).141,142,144 M1 
macrophages secrete potent pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6 
and IL-12.144 Contrastingly, anti-inflammatory mediators (ex. IL-4, IL-10 and IL-13) 
secreted during times of tissue remodeling and hypoxia induce M2 differentiation.142,144 
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M2 macrophages do not express but rather down-regulate IL-1" expression.144 While M1 
macrophages exhibit increased chemokine CCR7 expression, M2 macrophages display an 
up-regulation of mannose receptors144, making both (CCR7 and mannose receptors) 
functional biomarkers for M1 and M2 phenotypic analysis, respectively. Despite their 
investigation in numerous pathologies, M1 and M2 macrophage phenotypes have not 
been thoroughly studied in OA.133  
   
 
Figure 18: Macrophage Polarization refers to the variable phenotypes of tissue macrophages, the most common 
being M1 (pro-inflammatory) and M2 (pro-regenerative) macrophages. Pro-inflammatory mediators (ex. INF% or TNF-
#) promote M1 differentiation; while anti-inflammatory mediators (IL-4, IL-10 and IL-13) promote M2 differentiation. 
M1 macrophages secrete potent pro-inflammatory mediators. The most significant downstream effect of M2 
macrophage secretions is the down-regulation of IL-1. 
 
Within the normal human joint space, the body maintains necessary populations 
of M1 and M2 macrophages according to specific host needs. Therefore, normal 
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synovium exhibits varying proportions of M1 and M2 synovial macrophages.145,146 As 
previously described, in OA the synovial membrane becomes inflamed. This involves the 
migration and accumulation of numerous macrophages within the synovial tissue.115,134 
Macrophages and T-cells have been reported as the most prominent cells types within 
OA synovial tissue.133 Though macrophage populations remain above physiologically 
normal levels through all stages of OA, evidence suggests there are more CD68+ cells 
(i.e. macrophages) present in synovium from early stage OA compared to late stage OA 
tissue samples.12,119 However, in studies comparing late stage OA synovial fluid to that of 
(healthy) controls, statistically higher levels of macrophage-related inflammatory 
mediators are observed.147  
 Clinical studies have demonstrated infiltration of macrophages into the synovium 
of patients with OA.110 The presence of synovial macrophages largely determines the 
degree of synovitis and has been shown to positively correlate with OA cartilage 
damage.127 The potent pro-inflammatory cytokines and chemokines expressed by 
macrophages (specifically M1 macrophages) feed the previously described inflammatory 
cascades, advancing the stage of the disease. Macrophages can produce an array of 
MMPs and ADAMTS.110,115 However, they are also capable of secreting factors that 
regulate and promote the synthesis of cartilage degrading enzymes.110,115,127,131,134 It is 
also thought that growth factors secreted by macrophages (ex. TGFβ and BMP) can 
directly promote osteophyte formation.127  
Macrophages have been further implicated in OA pathology through experimental 
models where synovial macrophages were systematically depleted. In such models, OA 
progression was halted in macrophage depleted cultures.127,134 Additionally, culturing OA 
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chondrocytes with macrophage-conditioned medium was shown to most accurately 
reflect the in vivo human pathology  (i.e. increased type X collagen production, increased 
MMP activity, increased ADAMST 4 activity, decreased cartilage proteoglycan content) 
compared to all other models tested.110   
 
Figure 19: M1 Macrophage Infiltration in OA contributes to the state of chronic inflammation observed in OA 
joints. Under normal conditions, the body maintains physiologically relevant levels of M1 and M2 macrophages within 
the synovium. In OA, large populations of M1 macrophages infiltrate the synovium, disrupting homeostasis and 
creating a pro-inflammatory milieu.  
 
1.10.4 Notable Pro-Inflammatory Mediators in OA  
 IL-1" is a monocyte, macrophage and chondrocyte-secreted pro-inflammatory 
cytokine suppressing aggrecan and collagen synthesis.110,113,118,135 Downstream 
consequences of IL-1" production also include the up-regulation of ADAMTS-4, MMP-
1, MMP-3 and MMP-13 as well as IL-6, IL-8m MCP-1 and CCL5 (also known as 
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RANTES).113,118,135 Clinically, blocking only IL-1 activity does not alleviate OA-induced 
pain.113,122,147 There is also evidence suggesting a crucial role of this cytokine in normal 
the regulation of cartilage homeostasis.118 Unlike other inflammatory based arthritis 
diseases, IL-1β is not consistently elevated in OA patients.113,128,136,148 Additionally, it is 
becoming more widely understood that IL-1β’s primary role is in early stage OA.147 
When reported, IL-1β concentrations in late stage OA synovial fluid are typically <4.8 
pg/mL,136,147,149 though there are isolated reports of concentrations as high as 250 
pg/mL.148   
 Contrastingly, TNF-α is readily detectable in the synovial fluid of patients with 
OA.113,118,136 However, there are varying reports on disease stage-dependent expression, 
with late stage OA concentrations synovial fluid concentrations reported between 0-20 
pg/mL.113,136,147 TNF-α, like IL-1β, is implicated in cartilage degradation via the 
stimulation of collagenases and aggrecanases as well as the suppression of aggrecan and 
type II collagen synthesis.110,118 Like IL-1β, downstream consequences of TNF-α 
production also include the up-regulation of MMP-1, MMP-3 and MMP-13 as well as IL-
6, IL-8m MCP-1 and CCL5 (also known as RANTES). Similar to IL-1, trials blocking 
only TNF-α do not uniformly result in the alleviation of patient pain.113,147  
 While the singular elimination of IL-1β or TNF-α has not shown clinical efficacy, 
it has been demonstrated that simultaneous blocking of both cytokines results in OA 
mitigation.150 This likely represents a redundancy in the OA pro-inflammatory cascade; 
whereby suppression of both pro-inflammatory mediators is required to completely 
modify (halt the progression) of the cascade. Studies utilizing bovine and porcine OA 
explants suggest both IL-1β and TNF-α lead to increased expression of ADAMTS-4; 
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however, neither cytokine affected the expression of ADAMTS-5, which is thought to be 
the primary ADAMTS involved in OA.118 
 Other cytokines with more obscure connections to OA include IL-7 and IL-15.  
IL-7, produced by chondrocytes, stimulates the production of MMPs and aggrecanases.113 
IL-7 is routinely reported in OA synovial fluid.128 IL-15 is regulated by TLR-2 and TLR-
4 stimulation. It is elevated in early stage OA, and its expression has a positive 
correlation with expression of MMP-1 and MMP-13.113,118,135  
IL-6 has a less understood role in OA.118 Though commonly (but not always) 
detected in patients with OA119,128,135,137, IL-6 has been shown to have a 
chondroprotective effect in early stage OA while promoting disease progression (via 
osteophyte formation) in late stage OA. It is routinely detected in the synovial fluid of 
OA patients.118 High levels of circulating IL-6 have been associated with increased 
likelihood of cartilage degradation.118 In an IL-1β-dependent manner, IL-6 up regulates 
the expression of MMP-1 and MMP-13 and is thus associated with reduced cartilage 
matrix component expression.118 Additionally, IL-6 concentrations have been positively 
correlated with leukocyte counts.132  
 Chemokines mediate the recruitment and regulation of inflammatory cells. 
Chemokines can also induce production of master MMP regulator, MMP-3.113 
Chemokines also induce IL-6 production.118 Specific chemokines that have been linked to 
worsening symptoms include CCL19, IL-8, MCP-1 and RANTES and CCR7.113,118 As 
previously described, CCR7 is expressed by M1, pro-inflammatory, macrophages.   
 While cytokine and chemokines play crucial roles in the development and 
maintenance of OA, it must be emphasized that individual biomarker results offer little 
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research utility and clinical value. Many variables including circadian and diurnal 
variation as well as differences between joint and circulating values influence biomarker 
concentrations.118 Combined, many biomarkers and/or data regarding cartilage structure, 
synovial inflammation and clinical data (symptom, pain levels, etc.) provide much more 
meaningful insight into OA.  
1.10.5 In Vitro Models of OA 
Investigators have studied the pathogenesis of OA and the efficacy of potential 
OA therapies via the use of in vitro co-culture models. These in vitro co-culture models 
range in complexity and actual likeness to the disease state. Unfortunately many in vitro 
studies are completed using non-human tissue samples.110 These results likely offer 
limited mechanistic insight into OA due to the known differences in inflammatory-driven 
matrix degradation, specifically the activation and regulation of ADAMTS 4 and 
ADAMTS 5, between species.108,110,151,152  
1.10.5.1 OA Chondrocyte/Cartilage Explant Culture 
 Monolayer culture of human OA chondrocytes remains the most common model 
to study OA.110,114,129,131 However, monolayer culture has been shown to alter cell 
phenotype limiting the translational applicability of such results.128,153,154 Specifically, 
hypoxia and cell-matrix interactions can be altered/absent in monolayer cultures and are 
better accomplished through 3-D culture.110 To overcome such barriers, human OA 
chondrocytes have also been seeded onto tissue engineered scaffolds.110  
 OA cartilage and synovium explants have been successfully cultured (separate 
from each other) in vitro for up to 21 days.128 Such cultures tend to show no differences 
in proteoglycan loss and cell viability over time.128 It has also been suggested that the 
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cytokine profiles obtained from individual explant co-culture media are less reflective of 
the levels described in vivo.128   
1.10.5.2 Chemical Doping of OA Explants 
As our understandings of the inflammatory nature of OA have progressed, groups 
have begun mimicking OA progression through the addition of pro-inflammatory 
mediators, such as IL-1β and TNF-α, to OA cartilage explant cultures.128 There are also 
reports of adding chemical/cytokines to chondrocyte-seeded scaffolds (or unseeded OA 
chondrocytes) in order to model OA.110 While, IL-1β and TNF-α are central to OA 
pathology, there are many other inflammatory mediators influencing OA disease 
progression. Such chemical doping models fail to represent this complexity, and are 
therefore not fully representative of OA pathology.110 Specific examples include the 
failure to replicate a loss of type II collagen within the cartilage matrix and to 
demonstrate hypertrophy within the chondrocytes.110 Additionally, chemical doping leads 
to concentrations of pro-inflammatory mediators 10-1,000x greater than physiologically 
reported concentrations, rapidly accelerating the time course of disease progression.128  
1.10.5.3 OA Explant Co-culture 
 As previously discussed, OA is a multifactorial disease involving multiple tissues 
in the joint. Therefore, greater mechanistic insight could likely be obtained from multi-
tissue culture systems (i.e. co-culture). There are few reports of OA chondrocytes in co-
culture with OA synovial cells.128,155 These systems have the benefit of more accurately 
modeling the human anatomy and involved tissues. However, they succumb to the same 
previously mentioned limitations of cells in monolayer culture. Namely, monolayer 
culture has been shown to alter cell phenotype limiting the translational applicability of 
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such results.128,153,154  
 Co-culture models involving joint tissue explants have also been 
described.128,140,156–158 The majority of such research has been completed using non-
human tissues to study rheumatoid arthritis.156–158 However, Beekhuizen was among the 
first to describe similar co-culture models for OA.128 In joint tissue explant co-culture, 
OA cartilage explants are placed in the bottom of a tissue well plate. Synovial tissue is 
added to the culture via a permeable well plate insert. Thus, the cartilage and synovium 
share the same microenvironment without physically touching (similar to the anatomy of 
a human joint). Beekhuizen was able to confirm the ability to culture OA cartilage and 
synovial explants for up to 21 days without greatly compromising viability (viability  
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Figure 20: Summary of In Vitro OA Models highlighting the advantageous and shortcoming of each approach.   
 
assessments were made using a LDH cytotoxicity assay but were not included in the 
manuscript; exact viability data is unavailable).128 They were also able to confirm the co-
culture system modeled certain aspects of OA disease, including the presence of CD68+ 
cells (i.e. macrophages) after 21 days in culture, a reduction in cartilage proteoglycan 
production and similar cytokine profiles to those reported in vivo.128   
Interestingly, there are reports of chemically doping joint tissue explant co-culture 
models in an attempt to gauge the therapeutic efficacy of different HA products as 
compared to progressing OA.159 However, as previously indicated, the un-natural 
acceleration of disease progression observed in such studies does not lend itself to 
translational applications. 
1.10.6 In Vivo (Preclinical) Models of OA 
The purpose of in vivo, preclinical, models are to reproduce the scale and 
progression of OA in a controlled manner such that the disease itself can be studied and 
new therapies can be developed.117,121,160,161 Ideal preclinical models are of low cost, 
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reproducible and display likeness to the human pathology under investigation.117,160 In the 
case of OA, one particularly important pathological consideration is the proper 
progression of the disease (too rapid progression is not representative of the slowly 
degenerative nature of OA and prevents the observation of subtle changes in disease 
characteristics with time).117,121 One specific advantage of animal models is the ability to 
establish intermediate and terminal end points of tissue collection, allowing assessment of 
the disease in various stages of development.121 Genetically engineered, experimentally 
induced and spontaneously occurring OA animal models are described in detail below.  
Though not specific to OA, cartilage defect models have been employed to study 
consequences of cartilage injury and efficacy of potential treatment options.162 Genetic 
knock-out mice have been employed to study mechanisms of OA pathogenesis and 
progression.163,164 However, genetic models are typically high cost and can produce lethal 
genetic deletions.121 Additionally, OA can be induced through the intra-articular injection 
of cartilage matrix degrading enzymes including collagenase, papain, and chondroitinase, 
among others.117,161,165 These models have the advantage of being very rapidly 
progressive, minimally invasive and easy to implement. However correlations between 
this progression and human OA have yet to be established.121  
 Experimentally, OA can also be induced through surgical procedures aimed at 
producing mechanical instability in the joint. These models have the advantages of 
reflecting the inflammatory characteristics of OA and exhibiting quick disease 
progression.117,161 However, due to the traumatic nature of OA induction these models are 
not fit for studies researching degenerative OA pathogenesis.117,121 The most commonly 
reported procedure to induce traumatic OA is anterior cruciate ligament transection.121 
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Figure 21: Summary of Common In Vivo OA Models (arranged by size) highlighting the advantages and limitations 
of each approach.  
 
This approach has been successfully utilized in murine110,117,121,160,161,166,167 (however the 
small nature of the joints limit research and applicability to humans160), 
rabbit84,117,121,160,161,168,169 (however, it should be noted that rabbits primarily load the 
lateral stifle and are therefore not reflective of human knee joint biomechanics121,160,161), 
canine117,121,160,161 (anatomically and biomechanically, canine models are considered to 
most closely mimic humans; however, public perception of canine use in research has 
limited their abailability160), capra85,117,121,160 (while capra joints are similarly sized to 
humans they are not prone to spontaneous OA, and the ability to reproducibly induce OA 
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through surgical transection is under debate160) and cow121 models, with terminal points 
varying from as little as six weeks to as long as two years. Other surgically-induced OA 
models include medial meniscectomy, medial cruciate ligament transection, and 
combinations thereof.117 Additionally, there are thirteen published studies assessing 
randomized blinded placebo trials in traumatically-induced equine models of OA.116 The 
specific advantages and disadvantages of these preclinical models have been succinctly 
reviewed elsewhere.117  
In some animals, OA occurs spontaneously during animal development. 
Spontaneous OA has been noted in the knee joints of mice, though as previously 
indicated the small nature of the joints limit the number of possible outcome measures.161 
Non-human primates also exhibit spontaneous OA; however there are stringent 
guidelines limiting their use in research.161 The most researched animal exhibiting 
spontaneous OA is the guinea pig. Similar to the human condition, spontaneous models 
have the advantage of being naturally occurring after 7 months of age, variable depending 
on genetic and environmental factors such as weight and reflective of long-term 
degenerative OA.117,121,160,170   
Anatomically, the guinea pig knee is very similar to the human knee, though it is 
much smaller.160 Additionally, guinea pigs exhibit the multi-factorial nature of bone 
growth and growth plate fashion observed in humans.160 Notably, guinea pigs primarily 
load the medial stifle, making the medial compartment most prone to OA development 
(similar to humans).160 The histopathology of the guinea pig has been extensively 
evaluated and deemed similar to human OA.160 Drawbacks of the guinea pig model 
include an extensive time course (natural disease progression takes months-years to 
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develop) incurring moderate-high costs.117,121,160 Though it has been suggested that more 
advanced OA can be achieved through communal caging.117  
The male Dunkin-Hartley 
guinea pig model has been well 
characterized and offers the following 
similarities to the pathogenesis of non-
traumatic, idiopathic human OA: 1) its 
susceptibility to common OA risk 
factors (i.e. advanced age and body 
mass index)171,172, 2) spontaneous 
development of progressive OA in the 
medial compartment of the knee161, 3) 
evidence of IL-1#, MMP-1, -3 and -13 involvement in OA173–175, 4) early-stage OA with 
synovial inflammation, chondrocyte cell death, and proteoglycan loss160,176 5) its likeness 
in histopathology.177 Both male and female DHGPs develop spontaneous OA. However, 
the accelerated weight gain and maturation of males allows them to develop more 
consistent changes consistent with OA.161 Additionally, the DHGP model illustrates 
bilateral symmetry of the disease thus allowing for patient-matched degenerative 
controls.161 Furthermore, recent studies indicate no adverse reaction of these animals 
following implantation of human stem cells in this model.178  
1.10.7 OA Treatment Options 
Currently there is no cure for OA; meaning, there is no treatment option halting 
the progression of the disease.11,116,118,128,129,140,160 Patients suffering from OA are offered 
Figure 22: Guinea Pig Model of OA relies on the spontaneous 
development of degenerative OA by guinea pigs, with age. 
Other advantages include anatomical, biomechanical and 
pathological similarities to the human condition. However, these 
models require long study periods, heightening associated costs.  
57 
palliative treatment options or surgery for symptomatic relief.11,117,120,122,128,129 These 
options, as well as those currently under pre-clinical investigation, are described in detail 
below.  
1.10.7.1 Available Treatments 
 Common treatments for OA include physical therapy/strengthening 
programs12,120,126,179, viscosupplementation12,122 and glucosamine/chondroitin sulfate 
supplementation.12,120,122 All of the previously described treatment options have 
demonstrated only minimal improvement compared to placebo treatment.12 The only 
pharmacologic treatment recommended by the American Academy of Orthopedic 
Surgeons is non-steroidal anti-inflammatory drugs (NSAIDs).11,12,118,120,126,179 Narcotics 
such as Tramadol have also been utilized to alleviate pain in patients with severe OA 
symptoms.12 Notably, the intra-articular injection of symptomatic slow acting drugs (ex. 
HA) has met scrutiny as to whether the benefits meet the minimum clinically important 
difference (MCID).126  
 Arthroscopic surgery (total joint replacement) has been employed to alleviate pain 
and to help restore joint mobility to patients suffering from OA.11,12,120 However, a recent 
comprehensive series reviewing of the success of such procedures (by the New England 
Journal of Medicine) concluded that arthroscopic surgery is only minimally 
effective.12,180–182 Another common surgical practice for the treatment of smaller chondral 
defects is autologous chondrocyte implantation.11,12,87,112,120 Though there are reports of 
increased Knee Injury and Osteoarthritis Scores, this method suffers from major draw 
backs, including, the inabilities to rapidly expand chondrocytes, to maintain chondrocyte 
phenotypes and to produce articular cartilage upon implantation.12,87,114 There is also data 
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suggesting other experimental approaches, including one-step stem cell therapies, are 
more effective than autologous chondrocyte transplantation at repairing osteochondral 
lesions.183  
 Specifically for knee OA, the AAOS utilizes a guideline rating the level of 
evidence and grade of recommendation for varying treatment modalities (patient 
education & lifestyle changes, rehabilitation, mechanical intervention, pain relievers, 
intra-articular injection, etc.).184 Those recommendations receiving “A” grades (i.e. most 
positive endorsement) include: encouraging weight loss among overweight patients, 
encouraging participation in low-grade aerobics, encouraging glucosamine or chondroitin 
sulfate not be prescribed and recommending against arthroscopic debridement/lavage.  
1.10.7.2 Clodronate (A Pre-clinically Investigated Treatment) 
Di-chloromethylene bisphosphonate [Cl2MDP] (Clodronate) is a bisphosphonate 
with known anti-bone resorption and anti-inflammatory properties.185 As a non-
nitrogenous bisphosphonate, clodronate prevents the binding of specific transcription 
factors to DNA, resulting in the production of a non-functional ATP competitor, 
ultimately resulting in cell apoptosis.185–187 Though clodronate is primarily cited for 
inducing apoptosis in macrophages, there is also evidence suggesting the induction of 
apoptosis in osteoclasts and monocytes (pre-differentiated macrophages), both in vitro 
and in vivo.185,188,189 Clodronate is water soluble, limiting its ability to freely cross the 
phospholipid bi-layer of most cellular membranes. Thus, clodronate is commonly 
delivered to the intracellular space through liposomes, taking advantage of the phagocytic 
properties of the usual target cells: the osteoclast and the macrophage. In osteoclasts, 
clodronate induces osteoclast cell apoptosis diminishing the overall number of 
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osteoclasts, slowing the resorption of bone. This is a common therapeutic technique used 
in osteoporosis.  
In macrophages, clodronate induces macrophage apoptosis resulting in overall 
macrophage depletion. Downstream consequences of this depletion include a reduction in 
IL-1 and TNF- concentrations and overall cartilage destruction (i.e. reduced proteoglycan 
and collagen loss) in experimental arthritis models.187,190,191 Macrophage depletion has 
been used to model various inflammatory-based (ex. OA) as well as various growth and 
development-based conditions. Historically, liposomes have been used to deliver a wide 
array of genes, antigens, antimicrobials, etc. to macrophages.185,192 Liposome-
encapsulation has been shown to increase clodronate efficacy by greater than 10x when 
compared to free clodronate.187,193,194 This efficacy is typically analyzed through 
immunohistochemical analysis of pan-macrophage marker CD68 and monocyte marker 
CD14, as well as assessment of cartilage destruction at the time of surgery through Visual 
Analogue Scales.185  
 Previously, clodronate has been shown to be somewhat effective as a therapeutic 
agent in both rheumatoid arthritis and adjuvant arthritis preclinical models.185,195–197 With 
mounting evidence suggesting a primary role of macrophages in OA pathogenesis, 
clodronate (among other bisphosphonates) are beginning to be investigated for their 
therapeutic efficacy of mitigating OA progression.122,198 Clodronate intra-articularly 
injected into human knee joints resulted in improved VAS pain scores.199 Additionally, 
some oral antiresorptive drugs resulted in decreased pain (assessed by WOMAC scores) 
and less subchondral bone abnormalities.200    
There is also evidence suggesting mesenchymal stem cells can be cultured with 
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clodronate-encapsulated liposomes without adverse responses.201 Therefore, future 
investigations could maximize therapeutic potential through a combined approach.   
 However, it should be noted that therapies targeting macrophage depletion suffer 
from significant drawbacks. Firstly, for a sustained effect, clodronate therapy would need 
to be administered (likely via intra-articular injection) routinely. Sustained macrophage 
depletion is not possible in vivo due to recruitment of new monocytes/macrophages 
through blood supply. In fact, it has been shown that the re-population of macrophages 
occurs after 2 weeks.185 Secondly, there is conflicting evidence suggesting that mitigating 
disease progression implies a clinical alleviation of symptoms.122 Thus, patients may 
need a palliative drug regimen in addition to clodronate therapy. Thirdly, the regulatory 
aspects surrounding bisphosphonate use in OA are strenuous and demanding. To date, no 
such treatment has been approved through the appropriate regulatory channels.122    
1.10.8 Stem Cells as an OA Therapeutic Agent  
 With the evolving view of OA as an inflammatory condition driven by 
macrophages and their pro-inflammatory secretions, immunomodulatory therapies have 
come to the forefront of investigation. Due to their trophic, anti-inflammatory and 
immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA 
therapies.11,12,84,87,134,202    
1.10.8.1 Pre-Clinical and Clinical OA Stem Cell Therapies 
 Numerous stem cell therapies have been described in animal models of OA. The 
stem cells are typically delivered via intra-articular injection into the knee joint. In 
comparison studies, stem cell therapies have been shown to yield better outcomes than 
autologous chondrocyte transplantation.12 There is also evidence that the stem cells are 
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still located within guinea pig joint tissues after 1 week120,170 and up to 8 weeks post-
implantation in rats.120 There are also reports of the stem cells exhibiting signs of 
proliferation and differentiation. 120,170  
 Twenty weeks post injection of 10x106 autologous BMSCs (within an HA carrier) 
into goat knees, less osteophyte formation and cartilage degeneration were noted.85 
Twelve weeks post injection of 9x105 BMSCs (within an HA carrier) into porcine knees, 
increased type II collagen and better healing was observed.162 After 6 months, the 
injection of 2x106 BMSCs (in an HA scaffold) into rabbit knees resulted in decreased 
MMP activity and regenerated cartilage with increased type II collagen expression.168 
 The injection of 1-2x105 allogeneic ADSCs resulted in decreased MMP-1 and 
TNF-α concentrations.169 ADSCs have also been shown to decrease synovitis and 
proteoglycan loss in mice with collagen-induced arthritis.12 Scaffold-free infrapatellar fat 
pad-derived stem cells injected into rabbit knees showed less cartilage degeneration and 
osteophyte formation after 12 weeks.203  
Table 3: Summary of Stem Cell Therapies for Osteoarthritis 
Primary 
Author Model Stem Cell  
Length of 
Study Results 
Murphy85 Capra 10x10
6 
BMSCs 20 Weeks 
• Decreased%osteophyte%formation%
• Decreased%cartilage%degeneration%
Lee162 Porcine 9x10
5 
BMSCs 12 Weeks 
• Increased%collagen%II%production%within%cartilage%
Grigolo168 Rabbit 2x10
6 
BMSCs 6 Months 
• Decreased%MMP%activity%
• Increased%collagen%II%expression%
• Evidence%of%cartilage%regeneration%
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Toghraie203 Rabbit 
1-2x105 
Infrapatellar 
fat pad-
derived SCs 
12 Weeks 
• G$2($'-$6%"-0$".>10$%
7"(&'0/"#%
• G$2($'-$6%2'(0/3'@$%
6$@('6'0/"#
Frisbie116 Equine 
Comparative 
ADSC v. 
BMSC 
70 Days 
• L"%-/@#/7/2'#0%6/77$($#2$-%
?$0)$$#%@("5.-%
Sato170 Guinea Pig 
7x106 
Human 
MSCs 
5 Weeks 
• L"%-/@#-%"7%/&&5#$%
($M$20/"#%"7%+89-%
• K</6$#2$%"7%2'(0/3'@$%
($@$#$('0/"#%N%2"33'@$#%HH%
.("6520/"#%%
 
Equine studies compared the efficacy of BMSC and ADSC intra-articular 
injections through arthroscopically inducing OA in the middle carpal joint.116 There were 
no significant differences reported between groups, though it was noted that the BMSCs 
appeared to have a more beneficial impact. 116 Additionally, one study injecting 7x106 
commercially available human stem cells into guinea pig knees reported no immune 
response after 5 weeks.178 Stem cell therapies have also been experimentally utilized in 
humans. Autologous BMSCs (8x106-4x107) have been intra-articularly injected with 
patient follow-up for up to 2 years. 120,204–206 Such methods have resulted in decreased 
patient pain as reported by WOMAC and VAS pain scales.120,204–206 Autologous ADSCs 
(1x107-10x107) were injecting in a dosing study, which reported that high doses resulted 
in improved joint function and decreased pain.13 Infrapatellar fat pad-derived stem cells 
seeded onto PRP scaffolds have resulted in improved VAS, Lysholm and OA index 
scores after 2 years.207 Injection of allogeneic BMSCs (5x107) 10 days after 
meniscectomy resulted in decreased pain.208 Similar reports in France utilize autologous 
Table 3: Summary of Stem Cell Therapies for Osteoarthritis noting the animal model employed, the type and 
dosage of stem cells as well as significant study results. Orange text indicates the stem cells were administered via an 
HA carrier. 
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ADSCs.84  
1.10.8.2 Potential Mechanisms behind OA Mitigation 
Hyaluronan facilitates granulation tissue formation, the initial phase of tissue 
regeneration, during natural wound healing.85,209 Stem cells also enable wound healing 
through facilitating and accelerating granulation tissue formation. Additionally, many 
stem cell therapies are injected in the presence of a hyaluronan (or HA) carriers.85,168,206 
Such approaches likely amplify and accelerate natural tissue repair mechanisms.  
 As previously indicated, stem cells, especially stem cells combined with 
biomaterial scaffolds, have the potential to differentiate into target cells, establishing new 
populations of healthy cells in diseased areas.11,84,85 For the purposes of OA, stem cells 
exhibiting enhanced chondrogenic differentiation potential would prove advantageous, as 
these cells would more readily differentiate into chondrocytes upon implantation into OA 
joint spaces. Though it has been demonstrated that stem cell implantation into rabbit 
femoral condyles with cartilage defects resulted in the production of new cartilage, this 
cartilage was not continuous with the host tissue.210,211 As previously indicated, integrity 
of the surface layer of cartilage is paramount to its health and function. Thus, the 
intended use of stem cells as chondrocyte progenitor cells remains questionable in 
translational regenerative medicine approaches.  
A more intriguing therapeutic mechanism of action is stem cell paracrine effects. 
Stem cells secrete mediators which attract and home host stem cells to target areas.11,84 
Focal inflammatory cells express monocyte chemoattractant protein-1 (MCP-1). Stem 
cells express the MCP-1 receptor, CCR2, resulting in their recruitment to the area.84 
Interestingly, stem cell therapies rarely lead to new chondrocyte formation (i.e. 
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differentiation of stem cells); rather the majority of stem cells home to the synovium.140  
Stem cells release a variety of growth factors and anti-inflammatory mediators 
which could help modulate diseases characterized by immune-dysregulation.11,84,119,129,207 
Such immunomodulatory regulators can inhibit the activation and recruitment of 
inflammatory cells. Those most researched include: indoleamine 2,3-dioxygenase (IDO), 
interleukin receptor antagonist (IL-1ra), prostaglandin E2 (PGE2) and IL-10.11,84,134 
These anti-inflammatory mediators have been proposed as a primary mechanism through 
which stem cells establish immune-suppressive local environments, aiding in their 
immune-privileged status.11 Notably, stem cells also have the documented ability to 
induce anti-inflammatory (M2) phenotypes in macrophages.134,212,213  
It has been demonstrated that stem cells must be “primed” in order to exhibit anti-
inflammatory and immunomodulatory characteristics.134,214 Typically this involves the 
stimulation of stem cells through potent pro-inflammatory cytokines such as INFγ.84,214 
Though the exact timeline has not been established, the need for priming does represent 
an inherent delay in the efficacy of OA stem cell therapies. This could be one explanation 
for delays in patient progress post initiation of stem cell therapy.  
 
1.10.9 Amniotic Membrane Derived Stem Cells & OA 
 
Though adult stem cells have been widely investigated as a potential OA 
therapeutic, there are drawbacks associated ADSCs and BMSCs that are less attributable 
to alternative stem cell sources (such as perinatal stem cells). Examples include the 
inability of BMSCs isolated from OA patients to proliferate and differentiate as 
effectively as BMSCs from healthy donors.10–12,85 Adult trabecular bone mesenchymal 
stem cells have exhibited similar deficiencies.12 OA BMSCs exhibit an increased 
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potential for osteogenic and a decreased potential for chondrogenic differentiation.10,11,112 
Though it has been suggested that additional exogenous growth factor supplementation 
can curb these abnormal effects.12,215,216 Human periosteal mesenchymal stem cells 
exhibit spontaneous chondrogenic differentiation in younger donors (< age 30).12 
However, the majority of OA cases occur in patients above age 65. Additionally, 
implantation of pre differentiated BMSC (into a chondrogenic phenotype) in a capra OA 
model resulted in non-maintenance of the chondrocyte phenotype (cell demonstrated an 
increased likelihood of hypertrophy an decalcification).87,217 
Additional drawbacks of using adult stem cells include low stem cell yields and 
painful harvest procedures.87 More recently perinatal stem cells have illustrated promise 
as an alternative stem cell source for regenerative medicine.68,218 Previously it has been 
shown that cord blood MSCs differentiate more readily into chondrocytes compared to 
ADSCs and BMSCs.87,219 Moreover, cord blood MSCs have the capacity to differentiate 
into chondrogenic phenotypes in pro-inflammatory environments comparable to OA; 
whereas BMSCs do not.87 Furthermore, cord blood MSCs exhibit increased expression of 
anti-inflammatory mediators (compared to BMSCs) in OA co-culture models.87    
An equally intriguing, though less researched, perinatal stem cell source are those 
stem cells derived from the amniotic membrane (a tissue routinely discarded as medical 
waste following the birth of full-term babies). Advantages of amniotic membrane derived 
stem cells (hAMSCs) include 1) their capacity for chondrogenic differentiation and 
generation of cartilage91,97,220, 2) their availability of large cell yields at harvest49,54,71, 3) 
their ontogenically youthful status limiting their exposure to detrimental age-related 
changes221, 4) their proven immunomodulatory and immunosuppressive nature.55,68,220,222–
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224 Furthermore, recent evidence suggests that perinatal stem cells exhibit superior 
chondro-protective effects in an inflammatory environment, exhibiting the ability to 
induce a pro-regenerative (M2) phenotype within synovial macrophages.73,87 There is 
also evidence suggesting hAMSCs do not require inflammatory priming prior to initiating 
therapeutic benefit.225 Notably, such characteristics do not appear to be affected by 
freeing or heating cycles, a necessary property owing to the likely need for tissue banking 
of such a stem cell source.225   
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CHAPTER TWO 
 
PROJECT APPROACH 
 
2.1 Significance 
  Stem cells are being investigated as alternative therapeutics for numerous 
orthopedic regenerative medicine approaches, largely due to their musculoskeletal 
differentiation, anti-inflammatory and immunomodulatory capacities.4,6,7,11 In order for 
stem cell therapies to be effective, high numbers of stem cells must be utilized. 
Therefore, stem cells exhibiting musculoskeletal differentiation, anti-inflammatory and 
immunomodulatory capacities as well as high yields would be an ideal stem cell source 
for orthopedic regenerative medicine approaches.  
  The largest subset of musculoskeletal tissue pathologies involves bone and/or 
cartilage. Currently, no side-by-side comparative analyses have been conducted in order 
to determine which stem cell source(s) most robustly differentiates into osteogenic and 
chondrogenic lineages. Such information would allow clinicians to utilize the best-suited 
stem cells source in future therapeutic approaches.   
  While stem cells have shown promise in prevalent musculoskeletal tissue 
pathologies, including osteoarthritis, few stem cell sources have been evaluated in such 
therapeutic approaches.85,116,162,168,178,203 Amnion membrane derived stem cells have yet 
to be investigated as an OA therapeutic. Additionally, no side-by-side comparisons have 
been conducted in order to determine the relative efficacy of amnion-based approaches 
with those currently under pre-clinical investigation (adipose derived stem cells and bone 
marrow derived stem cells). These authors also know of no (ex vivo or in vivo) studies 
comparing the differential therapeutic effects of stem cell administration location.  
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  Stem cells from the amniotic membrane (a tissue routinely discarded after the 
birth of term pregnancies) exhibit numerous characteristics of an ideal stem cell source, 
including, heightened differentiation potential, availability in high yields, heightened 
immunomodulatory properties, the ability to induce pro-regenerative (M2) phenotypes 
within macrophages.49,54,55,68,71,73,87,91,97,220,222–224 Additionally, perinatal stem cells may 
offer accelerated treatment time lines as they do not require pro-inflammatory priming 
prior to initiating therapeutic benefit.225 Thus, amnion membrane derived stem cells are 
likely an under investigated stem cell source for orthopedic tissue engineering and 
regenerative medicine strategies. 
 
2.2. Specific Aims 
  Our goal is to investigate the utility of amnion derived stem cells for orthopedic 
regenerative medicine. Through standardized ex vivo comparative analyses, we aim to 
compare the relative efficacy of amnion derived stem cell differentiation and therapeutic 
relevance with a commonly utilized stem cell source, adipose derived stem cells.  
2.2.1 Aim I: To directly compare the abilities of amnion and adipose derived stem 
cells to differentiate towards osteogenic and chondrogenic lineages 
  Our goal is to compare the efficacy of amnion and adipose stem cell 
differentiation towards osteogenic and chondrogenic lineages, offering initial insight into 
the utility of amnion derived stem cells in orthopedics. In order to accomplish this, an 
amnion stem cell harvest procedure and optimized differentiation protocols must be 
developed. Utilizing such methods a controlled ex vivo comparison of differentiation 
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should be conducted evaluating both genes and proteins characteristic of the respective 
lineages being examined.      
2.2.2 Aim II: To validate a human explant joint tissue co-culture model of OA 
  Our goal is to validate an ex vivo platform for testing potential future OA 
therapeutics, including amnion derived stem cells. Such a platform (i.e. a validated model 
of osteoarthritis) should demonstrate likeness to the human condition by demonstrating 
disease progression, pathophysiological levels of pro-inflammatory cytokines and 
synovial macrophage involvement. Macro and micro-architecture, inflammatory as well 
as biochemical assessments should be employed in order to verify such characteristics. 
Aim III: To evaluate the ability of MSCs to mitigate OA progression in this 
validated ex vivo model 
  Our goal is to investigate the utility of amnion derived stem cells as an OA 
therapeutic, ex vivo, and to compare their efficacy against a field standard stem cell, 
adipose derived stem cells. This controlled comparison (where all experimental variables 
excluding one (i.e. stem cell type or administration location) are held constant) should 
investigate differential therapeutic effects between routes of administration and allow for 
meaningful insights regarding the efficacy and mechanism of action of MSCs in OA. As 
before, macro and micro-architecture, inflammatory as well as biochemical assessments 
should be employed in order to examine these claims. 
 Aim IV: To compare the therapeutic effects of hAMSCs and hADSCs to attenuate 
OA progression in vivo 
  Our goal is to investigate the differential therapeutic effects of amnion and 
adipose derived stem cells in an established animal model of OA. This pilot study will 
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provide foundation in vivo evidence into the utility of amnion membrane derived stem 
cells as an efficacious therapeutic for OA. This approach involves demonstrating OA 
disease progression in non-treated control animals as well as showing mitigation of 
disease progression in treated animals. As before, macro and micro-architecture, 
inflammatory as well as biochemical assessments should be employed in order to 
examine these claims. 
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CHAPTER THREE 
AIM I: TO DIRECTLY COMPARE THE ABILITIES OF AMNION AND ADIPOSE 
STEM CELLS TO DIFFERENTIATE TOWARDS & CHONDROGENIC LINEAGES  
3.1 Introduction 
Cartilage defects represent debilitating lesions, which cause patients significant 
pain and oftentimes lead to patient immobility.226,227 A majority of these are classified as 
full thickness cartilage defects, which involve not only the articular cartilage but also the 
sub-chondral bone.227–229 Cartilage in particular lacks the intrinsic ability to repair and 
regenerate itself.226,229 This is in part due to the senescent phenotype of the host cells, 
chondrocytes, preventing the generation of healthy extracellular matrix (ECM) required 
to fill defect areas. Surgically, such defects are currently addressed by micro fracture or 
autologous chondrocyte transplantation.227–229 Both of these techniques function by 
introducing populations of healthy, reparative cells to the defect area in the hopes that the 
cartilage ECM will be regenerated and joint function will be improved.227–229 
Mesenchymal stem cells represent a recently investigated alternative approach to 
cartilage defect repair largely due to their ability to differentiate into both cartilage and 
bone phenotypes.226,227,229,230  
Adult mesenchymal stem cells are considered alternative cell sources for use in 
orthopaedic regenerative medicine. Typically derived from bone marrow (hBMSCs) or 
adipose tissue (hADSCs), these cells have the ability to self renew, exhibit 
immunomodulatory properties and differentiate towards numerous tissue lineages.63 Both 
cell types have been extensively investigated in preclinical osteochondral defect models 
as well as in human clinical trials, demonstrating significant clinical improvement (i.e. 
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reduced pain, decreased symptom intensity and/or radiographic evidence of cartilage 
damage) as well as various degrees of cartilage regeneration.226,227,229,230 Additionally, 
early results indicate greater therapeutic efficacy using such approaches as compared to 
autologous chondrocyte transplantation.22,229 
 Recently, researchers have begun investigating the potential efficacy of perinatal 
stem cell populations (isolated from the amnion harvested after the birth of term 
pregnancies) for orthopaedic applications.68 Based on the minimal criteria established by 
the International Society for Cellular Therapy; 1) the ability to differentiate into 
osteogenic, chondrogenic and adipogenic lineages, 2) >95% positive expression of CD73, 
CD90 and CD105, and 3) <2% positive staining for CD45, CD34, CD14 or CD11b, and 
CD79 or CD19)25, there exists two primary cell types within the amnion exhibiting stem 
cell characteristics: amniotic epithelial cells (hAECs) and amniotic mesenchymal stem 
cells (hAMSCs). Developmentally, these cells arise from the pluripotent epiblast.218,221 
This may imply that these cells retain embryonic stem cell-like characteristics, potentially 
offering more robust therapeutic advantages.  
 While some have attempted to validate the use of perinatal cells in orthopaedic 
applications, none have conducted side-by-side comparisons of human amnion derived 
cells with adult mesenchymal stem cells in regards to their capacity to differentiate 
towards musculoskeletal tissue cell types. Significantly, the osteogenic and chondrogenic 
differentiation capacities of hADSCs and hBMSCs have been well established to occur at 
approximately 21-28 days.231–234 However, there is evidence suggesting the 
differentiation of perinatal stem cells may occur earlier than this, indicating perinatal 
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stem cells may be an alternative therapeutic with an accelerated timeline to clinical 
benefit.  
 It has been widely established that numerous experimental conditions impact stem 
cell properties, including their differentiation capacity.54,89,92 Experimental variables 
including stem cell passage number, media type and growth factor supplementation, cell 
seeding method or densities and gas exchange (i.e. hypoxic conditions), are often held 
consistent within studies. However various researchers employ different experimental 
methods making it difficult to directly compare results across studies found throughout 
published literature. Herein, studies were undertaken to compare the osteogenic and 
chondrogenic differentiation potential of human amnion and adipose derived stem cells 
under identical, standardized culture conditions with the goal of providing meaningful 
insight into the potential clinical efficacy of these cell types for the management of 
osteochondral defect repair/regeneration.  
3.2 Materials & Methods 
 hADSCs were purchased from Invitrogen (R7788-110). Trypsin was purchased 
from Fisher scientific (MT-25-053CI). Collagenase was purchased from Worthington 
Biochemicals (LS004196). Ambion Trizol Reagent (15-596-026) and Turbo DNA Free 
Kit (AM10907) were purchased from Fisher Scientific. Ambion RETROscript Reverse 
Transcription Kit was purchased from Life Technologies (AM1710). Qiagen QuantiTect 
Primer Assays employed in this work included: runx-2 (QT00020517), osteocalcin 
(QT00232771), sox-9 (QT00001498), aggrecan (QT00001365), collagen-2 
(QT00049518) and GAPDH (QT00079247). QuantiTect SYBR Green PCR Kit was also 
purchased from Qiagen (204143). Alizarin Red (A5533-25G) and Alcian Blue (A3157-
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10G) stains were purchased from Sigma. Normal Horse Serum (S2000), VECTASTAIN 
Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100) were purchased 
from Vector Laboratories, Inc. Triton X-100 and other basic chemicals were purchased 
from Fisher Scientific. Antibodies employed in this work included: mouse anti CD105 
(BD Biosciences, 555690), mouse anti CD73 (BD Biosciences, 550256), mouse anti 
CD45 (BD Biosciences, 555480), mouse anti CD90 (BD Biosciences, 555593), mouse 
anti EpCAM (BD Biosciences, 347198), rabbit anti collagen-2 (Abcam, Ab85266), and 
goat anti-mouse FITC secondary antibody (abD Serotec STAR117F).  
3.2.1 Amniotic Membrane Harvest 
Human placentas were obtained from consenting patients immediately following 
delivery via elective cesarean sections of full-term babies (Pro00031185-Greenville 
Health System). Amniotic membrane derived cells were isolated within 4 hours of 
delivery.  
3.2.2 Isolation and Enrichment of hAEC and hAMSC Populations  
Placentas (n=3) were placed with the umbilical cord facing upward such that the 
fetal (amniotic) surface was accessible (Figure 23A). The amniotic and chorionic 
membranes were identified and mechanically peeled from each other (Figure 23B). 
Enriched hAEC and hAMSC cell isolation methods were adapted from Barbati et al.55 
Briefly, amnions were digested twice in 0.25% trypsin for 30 minutes at 37°C with 
agitation to completely liberate hAECs followed by complete digestion in two digestions 
of collagenase [2mg/mL collagenase (249 U/mg)] for 30 minutes at 37°C with agitation 
each to subsequently liberate hAMSCs.  
3.2.2.1 Histological Confirmation of Amnion Cell Isolation 
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Amnion sections were secured within a tissue processing cassette, fixed in 10% 
phosphate buffered formalin overnight at room temperature prior to undergoing standard 
tissue processing, paraffin embedding and sectioning to 5 µm thickness. Sections were 
stained with Hematoxylin and Eosin (H&E) for visualization of ECM and cell nuclei.   
3.2.2.2 Flow Cytometric Analysis for Stem Cell Markers 
Cells were incubated in primary antibody (either CD105, CD73, CD45, CD90, all 
at 5µg/mL dilution or EpCAM at 0.3µg/mL dilution) for 30 minutes at room temperature. 
After 30 minute room temperature incubation in goat anti-mouse FITC secondary 
antibody (at 5µg/mL dilution), samples were read on a Guava easyCyte™ Single Sample 
Flow Cytometer.  
3.2.3 Confirmation of a Mixed Amnion Cell Population 
 Briefly, the amnion (n=1) was digested twice in 0.125% trypsin for 30 minutes at 
37°C with agitation to incompletely liberate hAECs followed by complete digestion in 
collagenase (two 2mg/mL collagenase (249 U/mg) digestions for 30 minutes at 37°C 
with agitation) to liberate the remaining hAECs and hAMSCs, termed the “Mixed” cell 
population. Cells were analyzed histologically and via flow cytometry as previously 
described.  
3.2.4 hADSC and Amnion Derived Cell Osteogenic Differentiation Potential 
3.2.4.1 Culture Conditions for Stem Cell Differentiation  
In preparation for in vitro differentiation studies, all cell types were expanded in 
standard culture medium under standard culture conditions (37°C with 5% CO2) with 
media changes every 3 days. The standard culture expansion medium for hAECs 
consisted of DMEM supplemented with 10ng/mL epidermal growth factor, 10% fetal 
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bovine serum and 1% antibiotic/antimitotic. The standard medium for hAMSCs and 
Mixed cells consisted of DMEM supplemented with 10% fetal bovine serum and 1% 
antibiotic/antimitotic. The standard (manufacture recommended) culture medium, 
MesenPro, was used for expanding hADSCs following the manufacturer’s instructions. 
All cells were used at passage 2. To induce osteogenic differentiation, cells were seeded 
at a density of 2.1x104/cm2 into tissue treated 12-well plates and cultured in monolayer 
for up to 28 days in osteogenic differentiation media (DMEM, 10% FBS, 1%AB/AM, 
0.1uM dexamethasone, 50µM ascorbate-2-phosphate, 10mM β-glycerophosphate). 
Negative controls were maintained in standard culture media 
(DMEM+10%FBS+1%ABAM). Differentiation capacity was assessed via histological 
staining (n=2/condition, described below) and gene transcript expression (n=4/condition, 
described below).   
3.2.4.2 Gene Transcript Analysis 
Total RNA from all differentiated and control conditions were isolated using 
Trizol reagent according to the manufacture’s instructions. RNA integrity and 
quantification was assessed using a BioTek Epoch reader according to the manufacture’s 
instructions. A total of 600µg-1mg of RNA was reverse transcribed using the Ambion 
RETROscript kit. Resulting cDNA was amplified using a Rotogene 3000 thermocycler. 
Reaction products were detected using human QuantiTect primers in conjunction with a 
QuantiTect SYBRgreen polymerase chain reaction (PCR) kit. Gene expression ratios 
were calculated using the 2-Δct method with GAPDH serving as a housekeeping gene. 
Gene expression is reported as fold increase. For native (baseline) gene expression, fold 
increase was calculated by the following equation: 2-Δctamnion cell group / 2-ΔcthADSCs. For 
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induced gene expression, fold increase was calculated according to the following 
equation: 2-Δctinduced /2-Δctcontrol, where control gene expression values were derived from 
controls of the same cell type cultured to the same time-point in the absence of induction 
medium.   
3.2.4.3. Alizarin Red Histological Staining for ECM Calcification  
Well plates were fixed in 4% formaldehyde for 30 minutes at room temperature 
prior to 3-minute Alizarin Red staining (2% aqueous Alizarin Red, pH 4.2) for 
visualization of calcium deposition. The percentage of the total well-plate area stained 
positive was quantified via color threshold analysis using NIH Image-J software by two 
blinded observers. 
3.2.5 hADSC and Amnion Derived Cell Chondrogenic Differentiation Potential 
3.2.5.1 Culture Conditions for Stem Cell Differentiation  
To induce chondrogenic differentiation, cells were seeded in pellet culture (1x105 
cells per pellet) and cultured in chondrogenic differentiation media (DMEM, 1% FBS, 
1% ABAM, 6.25µg/mL Insulin Transferrin Selenium, 50nM Ascorbate-2-phosphate, 
10ng/mL human TGF-β). Controls were plated at a density of 2.1x104/cm2 into tissue 
treated 12-well plates (i.e. 1x105 cells per well) and cultured in monolayer with standard 
culture media (DMEM+10%FBS+1%ABAM). Differentiation capacity was assessed via 
histological staining (n=2/condition, described below) and gene transcript expression 
(n=4/condition, previously described). 
3.2.5.2 Alcian Blue Histological Staining for ECM Glycosaminoglycan Content 
Chondrogenic cell pellets  (n=3 pellets/condition) were fixed in 10% phosphate 
buffered formalin for 30 minutes at room temperature before undergoing manual tissue 
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processing (utilizing the standard protocol of serial ethanol washes followed by Xylene 
and paraffin washes), paraffin embedding and sectioning. Sections were mordant in 3% 
aqueous Acetic Acid solution for 3 minutes prior to 30-minute staining in Alcian Blue 
(1% Alcian Blue in 3% aqueous Acetic acid, pH 2.5) for visualization of GAG 
deposition. Sections were counterstained with 0.1% aqueous Nuclear Fast Red for 5 
minutes for visualization of cell nuclei. The percentage of the total cell pellet area stained 
positive was quantified via color threshold analysis using NIH Image-J software by two 
blinded observers. 
3.2.5.3 Immunohistochemistry for Collagen Type 2 
Immunohistochemistry (IHC) on rehydrated paraffin sections was performed for 
detection of collagen type 2 in chondrogenic cell pellets (n=3 pellets/condition). Briefly, 
antigen retrieval was accomplished via 10mM Citric Acid incubation at 90°C for 20 
minutes. Sections were permeabilized with 0.025% Triton X-100 for 10 min and then 
incubated in normal blocking serum for 45 min at room temperature. Primary antibody 
(rabbit anti-collagen-2, 5µg/mL dilution) was applied for 1 h at room temperature. 
Negative staining controls did not receive primary antibody. Blocking of endogenous 
peroxidases was accomplished via incubation in 0.3% hydrogen peroxide in 0.3% horse 
normal serum for 30 min at room temperature. Visualization of antibody was 
accomplished via staining with the Vector ABC peroxidase substrate kit. Sections were 
counterstained with Hematoxylin prior to microscopic imaging.  
3.2.6 Microscopic Imaging 
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision 
software (Release 4.9.1 SP08-2013). 
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3.2.7 Statistical Analysis 
Results are represented as a mean ± standard error of the mean (SEM).  All 
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or 
analysis of variance (ANOVA) with a Tukey’s post-hoc analysis. Significance was 
defined in all cases as p<0.05. 
3.3 Results 
3.3.1 Amniotic Membrane Harvest 
 
Figure 23: Amniotic Stem Cell Harvest, Isolation and Characterization. A) Representative image of a human 
placenta with umbilical cord (black arrowhead) and epithelial layer of the amniotic membrane (white arrowhead) 
facing upwards.  B) Image depicting the separation of the amniotic membrane (white arrowhead) from the chorion 
(black arrowhead).  Representative H&E histological sections of C) fresh amniotic membrane exhibiting a continuous 
layer of hAECs (arrow heads) and intact stroma containing hAMSCs (box), D) amniotic membrane following 
incomplete removal of hAECs (arrowheads) with 0.125% trypsin and E) amniotic membrane after complete removal of 
hAECs with 0.25% trypsin.  Polarized light microscopy of monolayer culture expanded amnion derived cells; F) 
hAECs (cuboidal morphology - black arrowheads), G) a mixed population of hAECs (black arrowheads) and hAMSCs 
(white arrowheads) following incomplete dissociation of hAECs (0.125% trypsin) and H) hAMSCs (spindle 
morphology - white arrowheads).  I) Average viable cell yields from term human amniotic membrane.  J) Flow 
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cytometric analysis of cell surface mesenchymal stem cell, hematopoietic and epithelial markers expressed on passage 
2 hAECs, hAMSCs and a mixed population of both cell types (data represented as % positive staining ± SEM).   
 
Human placentas were successfully harvested (Figure 23A) and amniotic 
membranes were isolated (Figure 23B) within 3 hours of delivery of full-term babies. 
Histological analysis prior to membrane manipulation revealed a confluent layer of 
epithelial cells (Figure 23C – arrowheads) and an intact stromal layer (Figure 23C – box) 
containing mesenchymal cells.  
3.3.2 Confirmation of Enriched hAEC and hAMSC Populations from Amniotic 
Membrane 
Histological analysis of amniotic membranes following two serial digestions in 
0.25% Trypsin showed that the confluent epithelial layer was completely removed 
(Figure 23E). Subsequent collagenase digestion released the remaining cells from the 
stromal layer. Phase contrast microscopy of these plated cells revealed two distinct 
morphologies: cobblestone- and spindle-shaped (Figures 23F & H, respectively) 
indicative of epithelial and mesenchymal cells, respectively. Flow cytometric analysis of 
these cells at passage 2 illustrated that both cell types were positive for mesenchymal 
stem cell markers (CD73, CD90 and CD105) and negative for the lymphocyte common 
antigen, CD45 (Figure 3.1J). Cells isolated from the epithelial layer via trypsin digest 
(hAECs) were positive for epithelial marker, EpCAM, whereas cells isolated from the 
stroma via collagenase digestion (hAMSCs) were negative. Viable hAEC and hAMSC 
yields at harvest were determined to be 2.3x106 ± 3.7x105 and 1.6x106 ± 4.7x105 per 
milliliter of amnion, respectively.  Considering the average amniotic membrane size at 
harvest, approximately 4.2x107 ± 8.2x106 hAECs and 2.8x107 ± 7.2x106 hAMSC were 
obtained from each membrane.  
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3.3.3 Confirmation of a Mixed Amnion Cell Population 
Histological analysis of amniotic membrane following two serial digestions in 
0.125% Trypsin revealed a partially intact epithelial layer (Figure 23D). Subsequent 
collagenase digestion released the remaining cells from the epithelial and stromal layers. 
Phase contrast microscopy of these plated cells revealed a mixed morphology of 
cobblestone and spindle-shaped cells (Figure 23G). Flow cytometry further confirmed 
this mixed population of cells, as the surface profiles of these cells appeared to be a 
hybrid of the enriched hAEC and hAMSC populations with roughly 40% of the cell 
exhibiting positive staining for EpCAM (Figure 23J).    
3.3.4 hADSC and Amnion Derived Cell Osteogenic Differentiation Potential 
Gene transcript analysis of cells under normal culture conditions (in the absence 
of osteogenic differentiation media) indicated that hAECs demonstrated a significant 
increase in runx-2 expression at day 14 compared to their respective day 3 values (Figure 
24A).  Conversely, runx-2 expression was significantly decreased in hAMSCs compared 
to their day 3 values.  Furthermore, the amnion cell cultures trended towards having 
increased runx-2 expression compared to hADSCs (dotted line) at all time-points 
analyzed. With respect to osteocalcin, hAEC expression tended to be higher than 
hADSCs at all time-points investigated (Figure 24B).    
After osteogenic induction, runx-2 expression peaked at earlier time points in the 
hAECs and mixed cell groups compared to hADSCs (Figure 24C). Additionally, the fold 
increases in runx-2 expression was significantly greater in the mixed and hAMSC groups 
compared to hADSCs at day 3 and 7, respectively.  Interestingly, hAECs demonstrated a 
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significantly (p<0.05) lower fold change in runx-2 expression as compared to hADSCs at 
all time-points. The fold increases in osteocalcin observed in all amnion derived cell 
groups were significantly greater (p<0.05) than the changes observed in hADSCs at day 
14 (Figure 24D).   
 
Figure 24: Osteogenic Gene Transcript Expression of Human Amnion Derived Cells and hADSCs. Native 
(baseline) transcript expression levels of A) runx-2 and B) osteocalcin in hAECs, mixed (hAEC+hAMSC) and hAMSC 
groups relative to hADSCs (dotted line). C) runx-2 and D) osteocalcin expression of all osteogenically induced cell 
types as compared to control expression levels (i.e. cells of the same type cultured in non-induction media cultured to 
the same time-point; dotted line). * indicates statistical difference from hADSC group at same time point (p<0.05). # 
indicates statistical difference from day 3 time point (p<0.05). 
 
Semi-quantitative Alizarin Red staining indicated that the hAEC and mixed cell 
groups deposited significantly (p<0.05) more calcium at day 3 compared to hADSC 
(Figure 25A). Additionally, all amnion groups demonstrated significantly (p<0.05) 
increased presence of calcified matrix as compared to hADSCs at day 14 (Figure 25B). 
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Interestingly, hAECs cultured under normal conditions (in the absence of osteogenic 
media) demonstrated calcium deposition after 28 days (Figure 25C), whereas mixed 
amnion cell groups (Figure 25D) and hADSCs (data not shown) did not.  
 
Figure 25: Osteogenic Calcified Matrix Expression of Human Amnion Derived Cells and hADSCs. A) Alizarin 
red staining of monolayer cultures of osteogenically induced hAECs, mixed (hAEC+hAMSC), hAMSCs, and hADSCs 
(red=positive staining for calcium deposition) at day 7 and 14. B) Quantitative analysis of percent area of the well 
stained positive for calcium deposition.   Alizarin Red staining of C) hAECs and D) mixed cells cultured in the absence 
of osteogenic induction medium.  * indicates statistical difference (p<0.05) from hADSC group at same time point. # 
indicates statistical difference from day 3 time point (p<0.05). 
 
3.3.5 Comparison of hADSC and Amnion Derived Cell Chondrogenic 
Differentiation Potential 
Gene transcript analysis of cells under normal culture conditions (in the absence 
of chondrogenic differentiation media) showed that hADSCs (dotted line) had higher 
expression of the master chondro-regulatory transcription factor sox-9 as compared to the 
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hAMSC and mixed amnion cell groups at day 14 (Figure 26D).  Conversely, hAECs 
tended to express greater levels of sox-9 compared to hADSCs (dotted line) at all time-
points. Conversely, hAEC and hAMSC cell groups innately expressed higher levels of 
aggrecan gene transcript compared to hADSCs by day 14 (Figure 26E). The mixed 
amnion cell group demonstrated a significant increase in innate collagen type 2 gene 
expression as the culture period increased and both mixed and hAMSC groups tended to 
have increased collagen type II gene expression as compared to hADSCs (Figure 26B).  
Of note, collagen type 2 expression was highly variable in the hAEC study group (data 
not shown).  
 
Figure 26: Chondrogenic Gene Transcript Expression of Human Amnion Derived Cells and hADSCs. Native 
(baseline) transcript expression levels of D) sox-9 and E) aggrecan in hAECs, mixed (hAEC+hAMSC) and hAMSC 
groups relative to hADSCs (dotted line). A) sox-9, B) aggrecan and C) runx-2 expression of all chondrogenically 
induced cell types as compared to control expression levels (i.e. cells of the same type cultured in non-induction media 
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cultured to the same time-point; dotted line).  * indicates statistical difference from hADSC group at same time point 
(p<0.05). # indicates statistical difference from day 3 time point (p<0.05). 
 After chondrogenic induction, all amnion derived cells exhibited significantly 
(p<0.05) increased sox-9 gene transcript expression as early as day 3 (in Mixed and 
hAMSCs cell groups) and day 7 (in hAECs) as compared to hADSCs at the same time 
points (Figure 26A). As expected, peaks in sox-9 expression tended to precede peaks in 
aggrecan expression; however these peak values tended to appear earlier in hAMSC and 
Mixed cell groups as compared to hAEC and hADSCs. The fold change in aggrecan gene 
transcript expression peaked at day 7 in all amnion derived cell groups; these values were 
significantly greater than those of hADSCs at day 7 (Figure 26B). Notably, Mixed and 
hAMSC cell groups exhibited the largest fold change in aggrecan gene transcript 
expression of all differentiated cell types. The fold change in collagen type 2 gene 
transcript expression peaked in all differentiated cell types at day 7 (Figure 27C).  
Additionally, hAMSC and mixed amnion cell groups expressed greater levels of collagen 
type 2 compared to hADSCs at this time point (Figure 27C). Interestingly, runx-2 gene 
transcript expression in chondrogenically induced cells tended to be greater in hADSCs 
as compared to all amnion derived cell groups, though this difference was only 
significant at day 3 (Figure 26C).   
Immunohistochemical staining of cell pellets for collagen type 2 illustrated that 
Mixed and hAMSC cell groups produced collagen type 2 enriched matrix as early as 7 
days (Figure 27A). This continued through 14 days, at which time hADSC groups 
exhibited minimal collagen type 2 matrix production. 
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Figure 27: Chondrogenic gene transcript and cartilage matrix expression of collagen-2 in human amnion 
derived cells and hADSCs. A) Immunohistochemical staining (brown=positive staining for collagen-2 matrix) of 
chondrogenically induced hAMSC, Mixed (hAEC+hAMSC) and hADSC cell pellets. B) Native (baseline) transcript 
expression levels of collagen-2 in hAECs, mixed (hAEC+hAMSC) and hAMSC groups relative to hADSCs (dotted 
line). C) Collagen-2 expression of all chondrogenically induced cell types relative to native (baseline) expression levels 
(dotted line). * indicates statistical difference from hADSC group at same time point . # indicates statistical difference 
from day 3 time point (p<0.05). 
 
Histological analysis of chondrogenic cell pellets indicated a progressive increase 
in pellet diameter with time in culture (Figures 28A & C). At 7 days, the Mixed and 
hADSC cell groups exhibited the largest pellet diameter, whereas hAMSC pellets were 
the smallest. However, semi-quantitative Alcian Blue staining indicated that pellets 
formed by Mixed and hAMSC cell groups had significantly increased areal staining of 
GAG-enriched matrix at all time-points investigated as compared to the hADSC cell 
group (Figure 28B).  
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Figure 28 Chondrogenic matrix component expression of human amnion derived cells and hADSCs. A) Alcian 
Blue staining for glycosaminoglycan of chondrogenically induced hAEC, Mixed (hAEC+hAMSC), hAMSC and 
hADSC cell pellets (blue=positive staining for GAG) at day 7 and day 14. B) Quantitative analysis of percent area of 
the cell pellet stained positive for GAG C) Comparison of chondrogenically induced hAEC, Mixed (hAEC+hAMSC), 
hAMSC and hADSC cell pellet diameter at day 7 and 14. * indicates statistical difference from hADSC group at same 
time point (p<0.05). # indicates statistical difference from day 3 time point (p<0.05). 
3.4. Discussion  
Herein, we demonstrate the ability of amnion derived stem cells to differentiate 
earlier and more robustly into osteogenic and chondrogenic lineages compared to a 
commonly used stem cell source; hADSCs. Specifically, our results highlight the utility 
of hAECs and hAMSCs as well as hAMSCs and mixed (hAEC+hAMSC) cell 
populations for osteogenic and chondrogenic differentiation, respectively. Furthermore, 
we confirm the availability of amnion cells to be obtained in large quantitates. The 
prevalence of osteochondral defects coupled with the progression of such lesions to 
debilitating musculoskeletal tissue pathologies (i.e. osteoarthritis), highlight the need for 
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alternative therapeutic strategies, addressing both the bone and cartilage. Therefore, a 
stem cell source exhibiting enhanced osteogenic and chondrogenic differentiation could 
prove beneficial.   
Histological analysis prior to enzyme digest indicated that the mechanical 
separation of the amniotic membrane from the chorion during tissue harvest and 
subsequent transport did not detrimentally alter the native architecture of the amnion as 
evidenced histologically by an intact amniotic epithelium and underlying stroma. 
Histological and flow cytometric results demonstrated the ability to isolate both hAECs 
and hAMSCs via sequential enzymatic digestion with trypsin and collagenase, 
respectively and that they maintain stemness markers through passage two. These results 
are in alignment with previous reports which demonstrate that both cell populations 
exhibit stem cell characteristics.54,58,92,224,235 In addition to the minimal criteria established 
by the International Society for Cellular Therapy, hAECs have been shown to express 
pluripotent stem cell markers such as NANOG and SOX-2, only minimally express 
HLA-A/B/C, and do not express HLA-DP/DQ/DR surface antigens.58,236 However, there 
are mixed reports of hAEC surface expression (particularly CD105), especially with 
serial passaging.49,237,238 hAECs have been shown to express similar major 
histocompatibility complex surface profiles as hAMSCs.54,57,224,235 Flow cytometric 
analysis performed within the current study allowed for the confirmation of the isolation 
of these two distinct cell populations from one another, or in the case of the Mixed cell 
group, the hybrid isolation of these cell types. The Mixed group was included in this 
study for two primary purposes. First, it potentially represents a more clinically relevant 
amnion-based therapeutic approach, where the entire amnion (with its two comprising 
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stem cell like cell populations) would be utilized. Examples of such previously 
investigated approaches have been succinctly reviewed elsewhere.68 However our results 
appear to indicate lower levels of CD90 and CD73 from cells in this Mixed population 
state. Second, some isolation methods described throughout literature indicate that in 
many instances collagenase digestion is performed on the amniotic membrane without 
prior trypsinization thus yielding a mixed population of amniotic cells.  Thus it would be 
beneficial to determine if the presence of both stem cell types simultaneously have an 
effect on differentiation potential and so that comparisons to these studies could be 
drawn.   
 Isolated amniotic membranes varied in size (16.8mL±3.8mL), with cell yield 
directly relating to amnion weight [mg] and volume [mL]. Similar to previous reports, 
our results demonstrated higher numbers of hAECs than hAMSCs isolated from the 
amniotic membrane.10,49,54,55,71 We report an average of 2.3x106 hAEC and 1.6x106 
hAMSC per mL amniotic tissue, which is significantly greater than the reported 5.4x105 
hADSCs isolated per mL from adipose tissue.61  
hADSCs were chosen as a representative mesenchymal stem cell for comparative 
analysis due to their proven osteogenic and chondrogenic differentiation potential, the 
numerous studies confirming their stem cell criteria, and their clinical relevance (relative 
abundance with minimally invasive harvest procedures).63 The osteogenic and 
chondrogenic differentiation capacities of hADSCs and hBMSCs have been well 
established to occur after 21 days in their respective induction media.231–234 Considering 
this, the current study was designed to analyze initial time points at less than 21 days in 
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order to establish if amnion derived cells were capable of differentiation prior to this 
time.   
Innate gene transcript expression results for the current experiments were 
consistent with reports that amnion derived cells exist in a multi-differentiated state, 
meaning in their natural, undifferentiated state they can express genes of each germ layer 
(i.e. endodermal and mesodermal for hAECs and hAMSCs, respectively).89 Consistent 
with previous reports, our analysis also revealed all three cell types investigated could be 
successfully differentiated into osteogenic and chondrogenic lineages.42,63,89,93  
 With respect to osteogenic gene transcript expression, hAECs demonstrated a 
trend towards increased innate expression of runx-2 and osteocalcin compared to 
hADSCs.  Following induction, hAMSCs demonstrated the highest runx-2 expression at 
day 7.  Additionally, all amnion derived cell groups demonstrated significantly higher 
osteocalcin expression at day 14 compared to hADSCs with hAECs demonstrating the 
highest fold change in expression.  
Furthermore, differentiation of amnion derived cells appeared to precede hADSCs 
and resulted in more robust matrix production. More specifically at nearly every time-
point investigated, significantly more calcified matrix was found in the presence of 
amnion derived cells as compared to hADSCs, especially in cultures with hAMSCs and 
hAECs suggesting enhanced osteogenesis.  Of note, in the absence of osteogenic 
induction media, hAECs were able to produce calcified ECM by 28 days; a phenomenon 
that was not observed in hAMSC, mixed or the hADSC group. This is not the first report 
on the innate capacity of hAECs to differentiate into an osteogenic lineage.as other have 
also observed this innate capacity for osteogenic differentiation.239 Interestingly, mixed 
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cells did not display this innate capacity for osteogenic differentiation in the absence of 
induction media despite flow cytometric results which indicated that the mixed amnion 
cell group contained as much as 40% hAECs, yet the ability of the hAECs to 
spontaneously differentiate appears to be reduced in the presence of hAMSCs. 
Furthermore, these results indicate that osteogenic differentiation of hAECs can be 
obtained without the addition of exogenous chemicals, potentially minimizing lab costs 
and concerns of chemical manipulation and toxicity for clinical application.  Thus both 
hAMSCs and hAECs may be more optimal for bone repair/regeneration applications as 
compared to hADSCs.  
 With respect to induced chondrogenic differentiation, hAMSCs and amnion 
derived mixed cells consistently produced ECM containing more collagen type 2 and 
glycosaminoglycan as compared to hADSCs at the time-points investigated. Gene 
expression data demonstrating increased sox-9, aggrecan, and collagen type 2 expression 
corroborated these findings. Although the chondrogenic cell pellets containing hAMSCs 
only tended to be smaller and more compact as compared to all other groups by day 7, the 
percent areal staining for glycosaminoglycan-rich ECM was highest possibly indicating 
an enhanced recapitulation of condensation observed during chondrogenesis during 
embryological development. hAMSCs and mixed amnion cell groups also trended 
towards having innately higher collagen type 2 and aggrecan gene transcript expression 
in the absence of chondrogenic induction media suggesting that these cells may be more 
optimal for cartilage repair/regeneration applications as compared to hADSCs. These 
results also add to previous findings that indicate hAMSCs may be more efficient in 
chondrogenic differentiation than hAECs.239  
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The pre-mature ossification of mesenchymal stem cells is thought to be one of the 
greatest drawbacks to their clinical use.228 Considering this, it has been demonstrated 
herein that amniotic cell types undergoing chondrogenic differentiation express 
significantly less osteogenic markers than hADSCs, potentially indicative of a decreased 
potential for endochondral ossification. Thus, hAMSCs may prove more useful for 
regenerative therapies requiring continual chondrogenesis as opposed to the typical 
progression of chondrogenesis through endochondral ossification, however further 
studies illustrating this point are warranted.   
Although care was taken to standardize the experimental conditions during these 
in vitro investigations, so study limitations were noted. Unavoidably, amniotic 
membranes and hADSCs were obtained from different donors. It has been shown that 
donor health and age impact stem cell properties.5,10,11,98 The most accurate comparative 
analysis would have been to obtain stem cells from the same donor; however this was not 
possible in this case for patient safety. Additionally, some reports have concluded that 
bone marrow stem cells (hBMSCs) are potentially more robust at musculoskeletal tissue 
differentiation.233,240 Therefore, future studies will aim to perform similar analyses 
comparing amnion derived cells to hBMSCs as well. It may also be advantageous to 
complete chondrogenic differentiation comparative analyses under hypoxic conditions, as 
numerous reports indicate increased clinical relevance and enhanced differentiation 
utilizing such approaches.32,241  
Taken together, this data suggests amniotic cells are an ideal alternative cell 
source for orthopaedic regenerative medicine approaches. Amniotic stem cell yields are 
higher per tissue volume compared to hADSCs and they appear to more readily 
93 
differentiate into osteogenic and chondrogenic lineages. Moreover, these differentiation 
capacities make amnion stem cells a candidate stem cell for osteoarthritis therapies.  
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CHAPTER FOUR 
AIM II: TO VALIDATE A HUMAN EXPLANT JOINT TISSUE CO-CULTRE 
MODEL OF OA 
4.1 Introduction 
Osteoarthritis (OA) is the most common form of arthritis, affecting over 30% of 
the U.S. population over the age of 65.11,12,110,111,113–117 OA is the result of cartilage 
degradation, impaired joint mobility and severe pain - making it one of the leading causes 
of disability worldwide.12,110,111,113,119,120 Though commonly associated with the 
destruction of cartilage, OA is a disease of the entire joint space.12,85,108,113,117,126–128 
While OA is stereotypically described as a physical wear and tear disease242,243, 
mounting evidence suggests that synovial inflammation significantly contributes to its 
pathogenesis.243 In OA, macrophages infiltrate the synovium and secrete supra-
physiological levels of pro-inflammatory cytokines (including TNF- α and IL1-β), which 
create a caustic joint environment promoting articular cartilage degradation.127,243 
Degraded matrix fragments activate toll-like receptors (TLRs) within cells of the synovial 
membrane, activating nuclear-factor κB (NF-κB), a potent pro-inflammatory 
transcription factor.108,113,135 TLR activation is also responsible for the downstream up-
regulation of MMPs and aggrecanses.113,128,135,140 In addition to synovial TLR activation, 
chondrocytes have exhibited TLR activation in response to degraded matrix 
fragements.12,113 Ultimately, this TLR cascade results in the recruitment of increased 
numbers of macrophages and pro-inflammatory cytokine secretion, creating a state of 
chronic, low-grade inflammation.113,135,244 Thus, OA is most accurately described as a 
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feed-forward pathology where the cartilage and synovium exhibit reciprocal pathologic 
effects on one another.    
Investigators have studied this pathogenesis and efficacy of potential future OA 
therapies via the use of in vitro culture models of human cartilage explants exposed to 
supra-physiological levels of exogenous inflammatory cytokines (i.e. IL-1 and TNF-α) 
commonly observed in OA in order to accelerate cartilage destruction.140,245 More 
recently, researchers have begun co-culturing human joint tissue explants (cartilage 
together with synovium) in an attempt to more accurately reflect the complexity of the 
joint space environment as well as the many known mediators of OA resulting from the 
natural progression of the disease.128,140 Although such co-culture models have 
demonstrated likeness to the natural disease state246, to our knowledge these systems have 
not been extensively validated in order to determine the degree to which they model: 
cartilage destruction in the presence of both synovial macrophages and pathophysiologic 
levels of pro-inflammatory cytokines, gradual progression with time and, significantly, a 
feed-forward progression.  
In an attempt to confirm that such co-culture models reflect human OA pathology 
and progression, herein an investigation into human joint tissue explant co-culture has 
been undertaken.  This was accomplished by comparing human joint explant co-cultures 
of cartilage and synovium together with cultures of isolated human cartilage (in order to 
determine the effects of the synovium on the cartilage) and isolated human synovium (in 
order to determine the effect of the cartilage on the synovium), ultimately to demonstrate 
the ability of OA explant co-culture to effectively model the feed-forward nature of OA 
as well as gradual disease progression with time.  Furthermore, the impact/role of 
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synovial macrophage’s contribution to the OA model was investigated by selective 
depletion via clodronate. Taken together, validation of such a model may highlight its 
utility in OA research, as it may prove to be an effective system for investigating OA 
pathology and evaluating potential future therapies.  
4.2 Materials & Methods 
 
  Insulin Transferrin Selenium was purchased from Life Technologies (41400045). 
Ascorbate-2-phosphate (59-990-141) and trans-well culture plates (07-200-157) were 
purchased from Fisher Scientific. Clophosome A was purchased from FormuMax 
Scientific Inc (F70101C-A-2). Live/Dead Animal Cell Kit was purchased from VWR 
(89260-208). 1,9 Dimethyl-Methylene Blue (341088-1G), Chondroitin Sulfate (C4384-
5G), Hydroxyproline Assay Kit (MAK008-1KT), Safranin-O Stain (S2255-25G) and Fast 
Green Stain (F7258-25G) were purchased from Sigma. Normal Horse Serum (S2000), 
VECTASTAIN Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100) 
were purchased from Vector Laboratories, Inc. Triton X-100 and other basic chemicals 
were purchased from Fisher Scientific. Antibodies employed in this work included: anti-
mannose receptor (ab32527) and anto-CCR7 (ab64693). All ELISAs employed in this 
work were purchased from RayBiotech: Human TNF-alpha (LH-TNFa-1), Human MMP-
13 (ELH-MMP13-1) and Human IL-1 beta (ELH-IL1b-1).  
4.2.1 Joint Tissue Harvest and Culture Initiation 
 
Human cartilage and synovium were obtained from consenting patients immediately 
following total knee arthroplasty for OA (IRB# PRO00031185 Greenville Health System). All 
patients were classified as having Kellgran-Lawrence grade 4 OA. Using aseptic technique, 
cartilage and synovium tissues were biopsied into 6mm diameter samples in preparation for in 
vitro culture. Tissue biopsies were placed in 12-well plates (1 cartilage and 1 synovium biopsy / 
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well) and maintained in 2mL DMEM supplemented with 1% Insulin Transferrin Selenium (ITS), 
1% antibiotic/antimitotic (ABAM) and 50nM Ascorbate-2-phosphate for 3 days in standard 
culture conditions (5% CO2; 20% O2; 37° C). Henceforth, this media formulation will be referred 
to as “explant medium.” Care was taken to ensure the cartilage and synovium were not in direct 
contact. After 3 days, the media was removed and labeled “day 0” media.   
 
 
Figure 29: Methods Schematic demonstrating the described comparative analysis between control OA explant co-
culture (“OA”), OA tissue cultured in isolation (“cartilage only” and “synovium only”) and macrophage depleted OA 
cultures, after 15 days.  
 
 
4.2.1.1 In Vitro Co-Culture  
Cartilage biopsies (n=15) were placed in the bottom of a 12-well trans-well plate (1 
cartilage biopsy/well) and submerged in 1.5mL explant medium. The well insert was returned to 
the well and patient- matched synovial biopsies were placed within inserts (1 synovium 
n=14 
n=15
 
n=15
 
n=7
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biopsy/well) with 500µL explant medium. Media was changed every 3 days until the termination 
of culture at 15 days. This is depicted in figure 29. 
4.2.1.2 In Vitro Cartilage Only Culture 
Cartilage biopsies (n=14) were placed in the bottom of a 12-well trans-well plate (1 
cartilage biopsy/well) and submerged in 1.5mL explant medium. Media was changed every 3 
days until the termination of culture at 15 days. This is depicted in figure 29. 
4.2.1.3 In Vitro Synovium Only Culture 
Synovial biopsies (n=15) were placed within well inserts (1 synovium biopsy/well) and 
treated as previously described until the termination of culture at 15 days. This is depicted in 
figure 29. 
4.2.1.4 In Vitro Macrophage Depleted Co-culture Culture 
  Synovial biopsies (n=7) were placed in the wells of a 12 well plate and submerged 
in 1.5mL explant medium. To deplete synovial macrophage populations, 24 hours prior 
to the initiation of co-culture each synovial biopsy was treated with 0.2mL 
Clophosome®-A (liposome encapsulated clodronate). After 24 hours, each synovial 
biopsy was washed 3x in explant medium prior to co-culture initiation with patient-
matched OA cartilage as previously described. This is depicted in figure 29. 
 
4.2.2 Synovial Macrophage Phenotype 
 
Immunohistochemistry (IHC) on rehydrated paraffin synovium sections was performed 
for detection of synovial macrophages. Briefly, antigen retrieval was accomplished via 10mM 
Citric Acid incubation at 90°C for 20 minutes. Slides were rinsed twice in TBS for 5 minutes, 
permeabilized in 0.025% Triton X-100, non-specific binding and endogenous peroxidases were 
blocked with normal serum and a solution of 0.3% hydrogen peroxide in 0.3% normal serum, 
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respectively.  A rabbit polyclonal antibody towards human CCR7 (0.5µg/mL dilution) or human 
mannose receptor (1µg/mL dilution) was incubated for 1 hour at room temperature prior to 
thorough rinsing and incubation at room temperature for 30 minutes with a secondary 
biotinylated antibody and avidin biotin complex according to manufacturer’s instructions 
(Vectastain®ABC Elite Kit Rabbit IgG - Vector Labs).  A DAB substrate kit (Vector Labs: 
SK4100) was used to visualize positive staining prior to counterstaining with a dilute 
hematoxylin solution for 30 seconds.  Negative controls did not receive primary antibody.  
4.2.3 Live/Dead Staining 
 Live/Dead staining was completed on cartilage and synovium according to 
manufacture instructions. Briefly, cartilage and synovium were incubated in a Live/Dead 
working solution (2µM calcein AM and 4µM Ethd-1) and at room temperature for 45 
minutes. Tissues were placed on a microscope slide prior to fluorescent imaging.  
4.2.4 Histopathological Assessment of Explant Tissue 
 
Cartilage sections were secured within a tissue processing cassette, fixed in 10% 
phosphate buffered formalin overnight at room temperature prior to undergoing standard 
tissue processing, decalcification, paraffin embedding and sectioning at 5 µm thickness. 
Sections were stained with Safranin-O counterstained with Fast Green for visualization of 
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1% 
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for 
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with 
1% Safranin-O for 15 minutes. Three images were taken spanning the surface length of 
the sample. An observer blinded to the condition of the cartilage completed the OARSI 
histopathological assessment on each image according to the direction of Pritzker et al.247 
These results were averaged to obtain the final sample OARSI score.  
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4.2.5 Assessment of Cartilage Degradation 
 
4.2.5.1 Cartilage Glycosaminoglycan (GAG) Content  
  Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer, 
pH 7.5 overnight at 65°C. Tissue digests were assessed for GAG content via 
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg 
DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards 
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample 
absorbance was read at 525nm.   
4.2.5.2 Collagen Leaching to Culture Media 
  Culture media was assessed for hydroxyproline collagen content via 
Hydroxyproline Assay Kit according to manufacture instructions. Briefly, samples were 
hydrolyzed with hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells 
were evaporated to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer 
Mixture and Diluted DMAB Reagent followed by 5-minute room temperature and 90-
minute 60°C incubations, respectively. Standards were created using a 1mg/mL stock 
solution of Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.  
 
4.2.6 Co-culture Media Pro-Inflammatory Profile  
 
 ELISA was performed according to manufacture instructions. Briefly, 96-well plates 
were incubated overnight at 4°C with standards and explant co-culture media samples 
(n=3 per condition). After several washes, wells were incubated with biotinylated 
antibodies (either TNF-α, IL-1β or MMP-13) for 1&h, followed by incubation in HRP-
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conjugated streptavidin for 45&min. Enzymatic reactions were allowed to develop, and the 
absorbance of each plate was read at 450&nm. 
4.2.7 Microscopic Imaging 
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision 
software (Release 4.9.1 SP08-2013). For all semi-quantitative histological data, three 
images were taken of each sample. An observer blinded to the condition of the sample 
manually counted each of these three images in order to determine the relative number of 
positive cells (i.e. brown cells (IHC), live cells or dead cells (Live/Dead), etc.) per 
sample. These three results were averaged in order to obtain the final percentage of 
positive cells for each sample.  
4.2.8 Statistical Analysis Results% are% represented% as% a% mean% ±% standard% error% of% the% mean% (SEM).% % All%statistical% analyses% were% performed% by% twoPtailed% Student’s% tPtest% of% unequal% variance% or%onePway%analysis%of%variance%(ANOVA).%Significance%was%defined%in%all%cases%as%p<0.05.% 
 
4.3 Results 
 
4.3.1 Joint Tissue Harvest and Culture Initiation 
  Human joint tissues were successfully harvested and 6mm biopsies of patient- 
matched cartilage and synovium were obtained. Tissues were maintained in in vitro 
culture for 15 days without any macroscopic signs of tissue deterioration or bacterial 
infection.  
4.3.2 Synovial Macrophage Phenotype 
 
  IHC staining of CCR7 (figure 30) showed a relatively constant percentage (84.5% 
to 76.8%) of M1 polarized macrophages over 15 days in OA co-culture. Over 15 days, 
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the synovium only culture group exhibited a statistical decrease in the percentage of cells 
staining positive for macrophage markers (84.6% to 58.6%). IHC staining confirmed the 
targeted depletion of macrophages in the macrophage depleted group (17.2% positive 
staining at day 0). This depletion effect remained throughout the culture period (14.8% at 
day 15). After 15 days in culture, synovium from OA co-culture contained a statistically 
higher percentage of macrophages compared to the other conditions tested.   
 
 
Figure 30: Confirmation of Macrophage Depletion. Semi-quantitative analysis of immunohistochemical stain for 
synovial M1 macrophages in all study groups over 15 days. At right, corresponding representative images of M1 
macrophage staining (brown = positive) across study groups. Image inserts are negative controls. # indicates statistical 
difference (P<0.05) from day 0 to day 15. * indicates statistical difference (p<0.05) between study groups within time 
point. 
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4.3.3 Live/Dead Staining 
 
  Live/Dead staining of cartilage biopsies (figure 31A) revealed a statistical 
decrease (85.3% to 56.8%) in chondrocyte viability over 15 days in OA co-culture. 
Conversely, cartilage from the cartilage only culture exhibited relatively constant (85.3% 
to 74.9%) chondrocyte viability. Over 15 days, the macrophage depleted culture group 
demonstrated a statistical increase in chondrocyte viability (to 97.7%). By day 15, 
chondrocyte viability was significantly different (p<0.05) between all groups, with 
macrophage depleted cultures demonstrating the highest viability followed by cartilage 
only and OA co-culture.  
  Live/Dead staining of synovium biopsies (figure 31B) revealed a statistical 
decrease in synovial cell viability over 15 days in both the OA co-culture (72.1% to 
44.6%) and the synovium only culture (72.1% to 54.1%). Conversely, the synovium from 
the macrophage depleted co-culture exhibited a statistical increase in synovial cell 
viability (to 98.7%). Therefore after 15 days in culture, synovium from the macrophage 
depleted co-culture contained a statistically greater percentage of viable cells compared 
to synovium cultured alone or with OA cartilage.  
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Figure 31: Cell Viability Assessment. A) Semi-quantitative analysis of Live/Dead chondrocyte staining from each 
group over 15 days with corresponding representative day 15 Live/Dead images of the cartilage. B) Semi-quantitative 
analysis of Live/Dead synovial cell staining (Red = dead cell; Green = viable cell) from each study group over 15 days 
with corresponding representative day 15 Live/Dead images of the synovium. White scale bar is equal to 100µm. # 
indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference (P<0.05) between study 
groups within time point. 
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4.3.4 Histopathological Assessment of Explant Tissue 
 
 
Figure 32: OARSI Histopathological Evaluation of Cartilage Microarchitecture. Graph of average OARSI scores 
(stage OA x grade OA) for each study group, with greater scores indicating greater cartilage deterioration.  Graph insert 
is a Safranin-O stained cartilage section (Red= Proteoglycan-rich Cartilage; Green= Background) depicting cartilage 
surface microarchitecture after 15 days in macrophage depleted culture. At right, a patient matched set of Safranin-O 
stained cartilage sections, showing relative progression of OA in OA co-culture and cartilage only culture groups over 
15 days. # indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference (P<0.05) 
between study groups within time point. 
 
  Safranin-O stained cartilage evaluated via the OARSI histopathological 
assessment is represented in figure 3. The cartilage exhibited increased surface 
fibrillation across greater portions of the cartilage surface, manifesting in a statistically 
increased (worse) OARSI score when OA joint explants were co-cultured together 
(p<0.05). Conversely, cartilage from the cartilage only culture and macrophage depleted 
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co-culture trended towards decreased (better) scores. After 15 days, the OA co-culture 
OARSI score was statistically higher (worse) than the cartilage only culture.  
 
4.3.5 Assessment of Cartilage Degradation 
   
  As seen in figure 33, cartilage GAG content evaluated via DMMB assay revealed 
that OA co-culture resulted in a significant and progressive loss of GAG content (from 
141.9µg/mg to 65.7µg/mg). Conversely, over 15 days the cartilage only culture and 
macrophage depleted co-culture showed no statistical progression. Therefore after 15 
days in culture, cartilage from the OA co-culture contained a statistically lower 
percentage of GAG compared to other tested groups.  
  Culture media evaluated via hydroxyproline assay revealed that OA co-cultures 
trended toward an increase in the amount of collagen leached from OA cartilage into the 
culture media. Conversely, cartilage only culture and macrophage depleted co-culture 
appeared to remain constant throughout the culture period. After 15 days, OA co-culture 
resulted in significantly more collagen leached into the media as compared to cartilage 
only culture.   
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Figure 33: Biochemical Evaluation of Cartilage. A) DMMB glycosaminoglycan (GAG) assay depicting average 
cartilage GAG content from each study group after 15 days. The range of D0 values is depicted as a shaded box from 
140-210ug GAG/mg Tissue. B) Hydroxyproline assay depicting average amount of collagen leached from the cartilage 
into the culture media from each study group after 15 days. The range of D0 values is depicted as a shaded box from 
0.007-0.009µg/uL. # indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference 
(P<0.05) between study groups within time point.  
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4.3.6 Co-culture Media Pro-Inflammatory Profile 
 
   
Figure 34: Cytokine Analysis over 15 Days in Culture. A) Average IL1-#concentration in cell culture media from 
each study group. B) Average TNF-%concentration in cell culture media from each study group. C) Average MMP13 
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concentration in cell culture media from each study group. “Not detected” indicates no sample from the study group 
contained sufficient cytokine concentrations for detection (Minimum detection limit of IL1-β, TNF-α and MMP13 
ELISA kits: 0.3 pg/mL, 30 pg/mL and 6 pg/mL, respectively). * indicates statistical difference (P<0.05) between study 
groups within time point. 
 
  Figure 34A illustrates day 0 IL-1β media content tended to be lower in 
macrophage depleted groups; however this was not found to be statistically significant. 
By day 15, IL-1β was only detected in media from the OA co-culture group.  
  TNF-α ELISA performed on cell culture media revealed that macrophage 
depletion did not significantly influence day 0 TNF-α concentrations. However, figure 
34B demonstrates by day 15 TNF-α was no longer detected in macrophage depleted co-
cultures. While TNF-α concentrations remained constant in OA co-cultures, cartilage 
only culture and synovium only culture trended towards reduced concentrations.  
  MMP-13 ELISA performed on cell culture media revealed that over 15 days in 
culture, OA co-cultures significantly increased in MMP-13 content (p<0.05). MMP-13 
was only minimally detected at day 0 and not detected at day 15 in macrophage depleted 
co-cultures.  
  A thorough cytokine profile via RayBiotech QAH-CYT-SW-1 cytokine array can 
be found in appendix a.  
 
4.4 Discussion 
We successfully demonstrate human joint tissue explant co-culture mimics OA 
pathogenesis by modeling: 1) cartilage destruction in the presence of synovial 
macrophages and pathophysiologic levels of inflammatory cytokines, 2) gradual 
progression with time and 3) a feed-forward progression, where the cartilage and 
synovium each contribute to the other’s disease progression. 
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OA is a multifactorial disease affecting the major components of the human joint 
space: the cartilage, the synovium and the synovial fluid.242,243,248,249 In OA, the cartilage 
matrix degrades.113,135 The synovial fluid provides not only nutrients to joint tissues but 
also a potent cocktail of pro-inflammatory cytokines (ex. IL-1β and TNF-α), as 
well.113,135 The synovial fluid becomes filled with degradation products, primarily 
cleaved collagen, from the cartilage.11 The synovium becomes inflamed, a condition 
known as synovitis in which this traditionally 2-3 cell layer membrane undergoes 
hypertrophy as macrophages infiltrate the fibrous matrix.113,135,242  
An ideal in vitro model would mimic the aforementioned characteristics of OA 
through evidence of cartilage matrix degradation (i.e. loss of proteoglycan and collagen 
content), maintenance of the pro-inflammatory milieu within the culture (media) 
environment and maintenance of inflammatory cell populations within the synovium. A 
model exhibiting progression of the disease would display worsening matrix degradation 
with time and increasing concentrations of pro-inflammatory cytokines and downstream 
matrix degrading enzymes.   
  The OA co-culture system described herein effectively models gradual OA 
progression with evidence of statistically increased cartilage fibrillation and decreased 
cartilage GAG content, as well as trends towards increased pro-inflammatory cytokines 
and collagen concentrations within the culture media. Given the short-term nature of the 
study, it was unlikely to observe statistical differences in collagen leaching into the 
culture media due to previous reports that collagenolytic activity in OA tissues peaks at 4 
weeks.250 
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  Significantly, the control groups in this study allowed us to confirm OA explant 
co-culture’s ability to model the feed-forward pathogenesis of the disease, where the 
cartilage and synovium appear to feed off each other, working in tandem to further 
disease progression. Decreases in cartilage GAG and leached collagen contents as well as 
microscopic surface fibrillation were observed to a lesser extent when OA cartilage was 
cultured alone, without synovial contributions. The relatively constant percentage of 
macrophages observed in the OA co-culture group seems to indicate that the 
macrophages receive continued stimulation within the explant co-culture model; whereas 
synovium only cultures exhibited a statistical decrease in the percentage of macrophages 
potentially due to the removal of such stimulatory cues (likely from the cartilage, as OA 
chondrocyte TLR activation has been extensively described by others12,113). This 
activation pathway results in the up-regulation of MMPs and ADAMTS. Specifically, 
TLR-2 and TLR-4 are up-regulated in regions of cartilage erosion.113,135 Up-regulation of 
these specific TLRs has been linked to downstream increases in master MMP regulator, 
MMP-3.113,135 This could be one pathway accounting for the increases in MMP-13 
observed in our OA co-culture and cartilage only groups.  
  Interestingly, though there is a constant presence of macrophages observed during 
OA co-culture, the percentage of viable cells within OA co-cultured synovium 
statistically decreases with time. This may indicate that the viability of host synovial 
(fibroblastic) cells, not macrophages, was compromised. This could be a further 
indication of the worsening health of the synovial tissue as OA progresses. Though 
general tissue manipulation and in vitro culture can account for some loss in viability, our 
viability results generally support a feed-forward inducing effect of cell death when 
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cartilage and synovium are cultured together. In order to ensure these effects were not the 
result of culture system overload (i.e. depriving the cells of appropriate levels of 
nutrients), we seeded an additional 1.5x105 human stem cells onto the surface of the 
cartilage and monitored viability effects. This data (not shown) demonstrated that cell 
viability was maintained, and in some cases increased OA chondrocyte viability. 
Corroborating viability results in joint explant co-culture models used by others were not 
found in current literature. However, these results could indicate a currently overlooked 
mechanism whereby OA progression is driven by a loss in specialized tissue cell types in 
favor of inflammatory cell populations.   
  In order to specifically assess the impact of synovial macrophages on OA 
progression in the model, select synovium samples were pre-treated with Clodronate 
(“macrophage depleted co-culture”), a bisphosphonate known to induce apoptosis in 
phagocytic cells without affecting non-phagocytic cell viability, prior to the initiation of 
co-culture.185,186,188,193,251 Previously it has been shown that such depletion results in 
downstream reductions in IL-1β and TNF-α concentrations as well as reduced cartilage 
destruction in experimental models of arthritis.189,191,193 Results from the current study 
confirmed similar outcomes in this joint tissue explant co-culture model. 
  Though macrophages were successfully depleted in our in vitro model, it is worth 
noting that such sustained macrophage depletion may not likely be an advantageous 
therapeutic avenue in vivo due to macrophage recruitment/replenishment though the 
native synovial blood supply.185 However, macrophage depletion more likely represents a 
mechanistic tool for researchers as opposed to a potential future therapeutic. 
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Interestingly, clodronate is currently being investigated as an OA therapeutic both in 
animals and in human clinical trials, albeit with mixed results.122,198–200  
  OA explant co-culture also more effectively models pro-inflammatory cytokine 
involvement in the human pathology. IL-1β is a macrophage secretion product 
suppressing aggrecan and collagen synthesis, which is heavily implicated in OA disease 
pathology and progression.104,110,113,135 Physiological levels of IL-1β in osteoarthritic 
synovial fluid have been reported at <4.8pg/mL.136,147,149 At all culture time-points in this 
study, values for this cytokine fell within reported in vivo ranges, which is significantly 
lower than the reported 5mg/mL of IL-1β used in studies which chemically induce OA 
through the addition of supraphysiological levels of cytokines to cartilage explant only 
culture models.245,252 This seems to indicate that cartilage-synovial co-culture provides a 
more natural model of the cytokine profile of OA, though further comparative analyses 
would need to be completed to corroborate this claim. Others have noted extremely low 
concentrations of IL-1β in ex vivo cultures.252–254 This has been attributed to the extreme 
lability associated with this cytokine, and researchers have cautioned conclusions based 
solely on IL-1β biochemical analysis.173,255 Both IL-1β and TNF-α induce signaling 
pathways resulting in pro-inflammatory stimulation and decreased collagen expression.104 
As TNF-α is a macrophage-secreted product, the dramatic concentration reduction 
observed in the macrophage depleted groups was expected. In a similar manner, the 
removal of the synovium (“cartilage only”) represents the removal of synovial 
macrophages and would thus also be expected to lower TNF-α concentrations. It is 
interesting that the removal of the cartilage (“synovium only”) yields a similar effect, 
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again potentially supporting the concept that OA progresses via a feed-forward, cell 
mediated destructive mechanism.  
  In conclusion, we were able to successfully demonstrate human joint tissue 
explant co-culture mimics OA pathogenesis by modeling: 1) cartilage destruction in the 
presence of inflammatory cytokines and synovial macrophages, 2) gradual progression 
with time and 3) a feed-forward progression, where the cartilage and synovium exhibit 
reciprocal pathologic effects on one another. Additionally, our mechanistic evaluations 
utilizing macrophage depletion studies indicate synovial macrophages and/or their 
secretions are likely primary effectors driving disease progression in the model. This 
work highlights the utility of joint tissue explant co-culture in OA research, as it is an 
effective system for investigating OA pathology and evaluating potential future therapies. 
  Though this ex vivo model mimics key aspects of human OA, any in vitro model 
is subjected to limitations. Specifically, this experimental design requires tissue biopsies 
that demonstrate relatively equal disease status at the time of culture initiation. While 
care was taken to ensure only the use of cartilage immediately surrounding areas of OA-
induced cartilage erosion, there is inherent variability associated with each biopsy. In 
future studies, we suggest minimizing this variability through halving each sample, using 
one half as a biopsy-matched day 0 control. An additional limitation is inherent inter-
patient variability. We attempted to overcome such variability through increased sample 
sizes (n=15). Normalization of data to each patient’s matched day 0 values is also 
suggested thus eliminating result biases from inter-patient variability. Lastly, there is 
extremely limited data describing the use of human joint tissue explant co-culture making 
it difficult to validate results across different investigators via comparisons with peer-
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reviewed literature sources. As more studies are published using such models, 
comparative data should become available to allow for cross comparisons. However, as 
of now we caution cross comparisons of this work with those employing smaller sample 
sizes and tissue samples from different species. As previously indicated, a sample size of 
at least 14 was required in order to obtain the statistical differences and trends described 
herein. Additionally, the known differences in inflammatory-driven cartilage matrix 
degradation between species limit the utility of cross-species comparisons.108,110,151,152   
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CHAPTER FIVE 
 
AIM III: TO EVALUATE THE ABILITY OF MSCs TO MITIGATE OA 
PROGRESSION IN THIS VALIDATED EX VIVO MODEL 
 
5.1 Introduction 
 
While osteoarthritis (OA) is traditionally viewed as a physical wear and tear 
disease, mounting evidence suggests that M1 macrophage-driven synovial inflammation 
significantly contributes to its pathogenesis.243 Pro-inflammatory, M1, macrophage 
secretions create a degenerative joint environment, ultimately resulting in the up-
regulation of effectors promoting cartilage degradation and causing patients immense 
pain. Current OA treatments are palliative, failing to halt the progression of the disease. 
Stem cells offer a potential therapeutic alternative due to their anti-inflammatory and 
immunomodulatory properties.54,218 Current stem cell-based therapies focus on the intra-
articular injection of adult stem cells including those derived from adipose tissue 
(hADSCs).120,207 However, perinatal stem cells, specifically those derived from the 
amniotic membrane (a tissue routinely discarded as medical waste following the birth of 
full-term babies), have illustrated promise as an alternative stem cell source for 
regenerative medicine.68,218 Though perinatal stem cells have yet to be tested as a 
therapeutic strategy combatting OA, recent evidence suggests perinatal stem cells exhibit 
superior chondro-protective effects, exhibiting the ability to induce a pro-regenerative 
(M2) phenotype within synovial macrophages.73,87  
  Herein, we describe efforts undertaken to establish the ability of stem cells to 
mitigate OA progression in an established ex vivo co-culture model of naturally 
progressing OA. We employed standardized comparative analyses utilizing two stem cell 
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sources, hADSCs and human amniotic mesenchymal stem cells (hAMSCs), in order to 
determine the relative efficacies of a newly investigated (perinatal) and a clinically 
established (hADSC) stem cell source as potential OA therapeutics. Furthermore, 
following the current paradigm of intra-articular administration, it is likely that injected 
stem cells would be found in a mixed contact scenario with OA cartilage where only 
some stem cells remain in direct contact with the cartilage (see appendix A). In an effort 
to better understand the potential efficacy of intra-articular administration of perinatal 
stem cells as a future OA treatment paradigm, we evaluated and compared the potential 
differential effects of administering hAMSCs in two different co-culture models (i.e. 
direct and indirect contact co-culture with OA cartilage in the presence of synovium). 
Taken together, such results would highlight the utility of a currently under investigated 
stem cell source (hAMSCs) for OA regenerative medicine approaches and provide 
significant mechanistic into their clinical use.  
 
5.2 Materials & Methods 
 
  Insulin Transferrin Selenium was purchased from Life Technologies (41400045). 
Ascorbate-2-phosphate (59-990-141) and trans-well culture plates (07-200-157) were 
purchased from Fisher Scientific. Clophosome A was purchased from FormuMax 
Scientific Inc (F70101C-A-2). Live/Dead Animal Cell Kit was purchased from VWR 
(89260-208). 1,9 Dimethyl-Methylene Blue (341088-1G), Chondroitin Sulfate (C4384-
5G), Hydroxyproline Assay Kit (MAK008-1KT), Safranin-O Stain (S2255-25G) and Fast 
Green Stain (F7258-25G) were purchased from Sigma. Normal Horse Serum (S2000), 
VECTASTAIN Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100) 
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were purchased from Vector Laboratories, Inc. Triton X-100 and other basic chemicals 
were purchased from Fisher Scientific. Antibodies employed in this work included: anti-
mannose receptor (ab32527) and anto-CCR7 (ab64693). All ELISAs employed in this 
work were purchased from RayBiotech: Human TNF-alpha (LH-TNFa-1), Human MMP-
13 (ELH-MMP13-1) and Human IL-1 beta (ELH-IL1b-1).  
 
5.2.1 Joint Tissue Harvest and Culture Initiation 
 
Human cartilage and synovium were obtained from consenting patients immediately 
following total knee arthroplasty for OA (IRB# PRO00031185 Greenville Health System). All 
patients were classified as having Kellgran-Lawrence grade 4 OA. Using aseptic technique, 
cartilage and synovium tissues were biopsied into 6mm diameter samples in preparation for in 
vitro culture. Tissue biopsies were placed in 12-well plates (1 cartilage and 1 synovium biopsy / 
well) and maintained in 2mL DMEM supplemented with 1% Insulin Transferrin Selenium (ITS), 
1% antibiotic/antimitotic (ABAM) and 50nM Ascorbate-2-phosphate for 3 days in standard 
culture conditions (5% CO2; 20% O2; 37° C). Henceforth, this media formulation will be referred 
to as “explant medium.” Care was taken to ensure the cartilage and synovium were not in direct 
contact. After 3 days, the media was removed and labeled “day 0” media.  
5.2.1.1 hAMSC Culture  
 
Figure 35: Methods Schematic Demonstrating the Described Comparative Analysis between Control OA 
Explant Co-culture (“OA”) and OA Co-cultures Treated with Stem Cells Applied Directly or Indirectly to the 
Cartilage Surface after 15 days. This comparative analysis will determine the relative efficacies of two potential 
clinically relevant routes of administration. 
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Joint co-culture was initiated as previously described. hAMSCs were isolated 
from term amniotic membrane as previously described (Aim I). Each stem cell treated co-
culture was simultaneously cultured with a patient matched “OA” control. 
5.2.1.1.1 OA+hAMSC (Direct Culture)  
At day 0, 1x105 hAMSCs were seeded directly on top of cartilage biopsies.  
5.2.1.1.1 OA+hAMSC (Indirect Culture)  
At day 0, 1x105 hAMSCs were seeded indirectly onto the bottom on a porous 
trans-well insert.  
5.2.1.2 OA+hADSC Culture 
Joint co-culture (n=5) was initiated as previously described. hADSCs were 
purchased from a commercial vendor for comparative analysis. At day 0, 1x105 hADSCs 
were seeded directly on top of cartilage biopsies. Each stem cell treated co-culture was 
simultaneously cultured with a patient matched “OA” control. 
 
Figure 36: Methods Schematic Demonstrating the Described Comparative Analysis between Control OA 
Explant Co-culture (“OA”) and OA Co-cultures Treated with either hAMSCs or hADSCs after 15 days. This 
comparison will determine the relative efficacies of a commonly utilized (hADSC) with a newly investigated (hAMSC) 
stem cell therapy for OA mitigation. 
 
5.2.2 Synovial Macrophage Phenotype 
 
Immunohistochemistry (IHC) on rehydrated paraffin synovium sections was performed 
for detection of synovial macrophages. Briefly, antigen retrieval was accomplished via 10mM 
Citric Acid incubation at 90°C for 20 minutes. Slides were rinsed twice in TBS for 5 minutes, 
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permeabilized in 0.025% Triton X-100, non-specific binding and endogenous peroxidases were 
blocked with normal serum and a solution of 0.3% hydrogen peroxide in 0.3% normal serum, 
respectively.  A rabbit polyclonal antibody towards human CCR7 (0.5µg/mL dilution) or human 
mannose receptor (1µg/mL dilution) was incubated for 1 hour at room temperature prior to 
thorough rinsing and incubation at room temperature for 30 minutes with a secondary 
biotinylated antibody and avidin biotin complex according to manufacturer’s instructions 
(Vectastain®ABC Elite Kit Rabbit IgG - Vector Labs).  A DAB substrate kit (Vector Labs: 
SK4100) was used to visualize positive staining prior to counterstaining with a dilute 
hematoxylin solution for 30 seconds.  Negative controls did not receive primary antibody.  
5.2.3 Live/Dead Staining 
Live/Dead staining was completed on cartilage and synovium according to 
manufacture instructions. Briefly, cartilage and synovium were incubated in a Live/Dead 
working solution (2µM calcein AM and 4µM Ethd-1) and at room temperature for 45 
minutes. Tissues were placed on a microscope slide prior to fluorescent imaging.  
5.2.4 Histopathological Assessment of Explant Tissue 
Cartilage sections were secured within a tissue processing cassette, fixed in 10% 
phosphate buffered formalin overnight at room temperature prior to undergoing standard 
tissue processing, decalcification, paraffin embedding and sectioning at 5 µm thickness. 
Sections were stained with Safranin-O counterstained with Fast Green for visualization of 
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1% 
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for 
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with 
1% Safranin-O for 15 minutes. Three images were taken spanning the surface length of 
the sample. An observer blinded to the condition of the cartilage completed the OARSI 
121 
histopathological assessment on each image according to the direction of Pritzker et al.247 
These results were averaged to obtain the final sample OARSI score.  
5.2.5 Assessment of Cartilage Degradation 
 
5.2.5.1 Cartilage Glycosaminoglycan (GAG) Content  
 Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer, pH 
7.5 overnight at 65°C. Tissue digests were assessed for GAG content via 
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg 
DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards 
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample 
absorbance was read at 525nm.   
5.2.5.2 Collagen Leaching to Culture Media 
 Culture media was assessed for hydroxyproline collagen content via Hydroxyproline 
Assay Kit according to manufacture instructions. Briefly, samples were hydrolyzed with 
hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells were evaporated 
to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer Mixture and 
Diluted DMAB Reagent followed by 5-minute room temperature and 90-minute 60°C 
incubations, respectively. Standards were created using a 1mg/mL stock solution of 
Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.  
5.2.6 Co-culture Media Pro-Inflammatory Profile  
 
 ELISA was performed according to manufacture instructions. Briefly, 96-well plates 
were incubated overnight at 4°C with standards and explant co-culture media samples 
(n=3 per condition). After several washes, wells were incubated with biotinylated 
antibodies (either TNF-α, IL-1β or MMP-13) for 1&h, followed by incubation in HRP-
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conjugated streptavidin for 45&min. Enzymatic reactions were allowed to develop, and the 
absorbance of each plate was read at 450&nm. 
5.2.7 Microscopic Imaging 
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision 
software (Release 4.9.1 SP08-2013). For all semi-quantitative histological data, three 
images were taken of each sample. An observer blinded to the condition of the sample 
manually counted each of these three images in order to determine the relative number of 
positive cells (i.e. brown cells (IHC), live cells or dead cells (Live/Dead), etc.) per 
sample. These three results were averaged in order to obtain the final percentage of 
positive cells for each sample.  
5.2.8 Statistical Analysis 
Results are represented as a mean ± standard error of the mean (SEM).  All 
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or 
one-way analysis of variance (ANOVA). Significance was defined in all cases as p<0.05.  
 
5.3 Results 
 
5.3.1 Joint Tissue Harvest and Culture Initiation 
  Human joint tissues were successfully harvested, 6mm biopsies of patient- 
matched cartilage and synovium were obtained, and the tissues were maintained in ex 
vivo culture for 15 days without any macroscopic signs of bacterial infection.  
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5.3.2 Synovial Macrophage Phenotype 
 
Figure 37: Semi-Quantitative Analysis of M1 Polarized Macrophages in hAMSC and hADSC-Treated Cultures 
demonstrating stem cell treatment results in a statistical reduction in M1 macrophages within the synovium. 
Corresponding representative images of macrophage staining (brown = positive) are located to the right of each graph. 
Photo inserts represent negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates 
statistical difference (P<0.05) between study groups within time point. 
   
  IHC staining of CCR7 (Figure 37) showed a relatively constant percentage 
(84.1% to 79.9%) of M1 polarized macrophages over 15 days in OA co-culture. Over 15 
days, both the OA+hAMSC and the OA+hADSC groups exhibited a statistical decrease 
in the percentage of cells staining positive for macrophage markers (88.7% to 48.6% and 
79.5% to 57.2%, respectively).  
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Figure 38: Semi-Quantitative Analysis of M1 Polarized Macrophages in Direct and Indirect-Treated Cultures 
demonstrating stem cell treatment results in a statistical reduction in M1 macrophages within the synovium regardless 
of the route of administration. Corresponding representative images of macrophage staining (brown = positive) are 
located to the right of each graph. Photo inserts represent negative controls. # indicates statistical difference (P<0.05) 
from day 0 to day 15 * indicates statistical difference (P<0.05) between study groups within time point. 
 
 
Similarly, figure 38 shows both the direct and the indirect hAMSC groups exhibited a 
statistical decrease in the percentage of cells staining positive for macrophage markers 
over 15 days (88.7% to 48.6% and 79.9% to 36.5%, respectively). 
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Figure 39: Semi-Quantitative Analysis of M2 Polarized Macrophages in hAMSC and hADSC-Treated Cultures 
demonstrating hAMSC treatment results in a statistical increase in M2 macrophages. Corresponding representative 
images of macrophage staining (brown = positive) are located to the right of each graph. Photo inserts represent 
negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates statistical difference 
(P<0.05) between study groups within time point. 
 
  As illustrated in figure 39, in OA+hAMSC cultures, this decrease in M1 polarized 
macrophages was concomitant with a statistical increase in M2 polarized macrophages. 
However, OA and OA+hADSC cultures exhibited almost no change in the percentage of 
M2 polarized macrophages within the synovium over 15 days. In figure 40, both direct 
and indirect hAMSC culture produced this statistical increase in M2 macrophages 
(Interestingly, direct and indirect culture accomplished this equally effectively). 
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Figure 40: Semi-Quantitative Analysis of M2 Polarized Macrophages in Direct and Indirect-Treated Cultures 
demonstrating both routes of administration result in a statistical increase in M2 macrophages. Corresponding 
representative images of macrophage staining (brown = positive) are located to the right of each graph. Photo inserts 
represent negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates statistical 
difference (P<0.05) between study groups within time point. 
 
5.3.3 Live/Dead Staining 
 
  Live/Dead staining of cartilage biopsies (figure 41) revealed a statistical decrease 
(87.8% to 59.1%) in chondrocyte viability over 15 days in OA co-culture as well as 
OA+hADSC culture (87.1% to 49.9%). Conversely, cartilage treated with hAMSCs 
exhibited relatively constant (88.5% to 89.8%) chondrocyte viability.  
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Figure 41: Semi-Quantitative Analysis of Chondrocyte Viability in hAMSC and hADSC-Treated Cultures with 
representative day 15 Live/Dead images, demonstrating OA+hAMSC ability to most effectively maintain chondrocyte 
viability. White scale bar is equal to 100µm. # indicates statistical difference (p<0.05) from day 0 to day 15. * indicates 
statistical difference (p<0.05) between study groups within time point. 
 
  
However, figure 42 illustrates that this observed increase in chondrocyte viability is 
dependent on the route of administration of the hAMSCs.  
 
128 
Figure 42: Semi-Quantitative Analysis of Chondrocyte Viability in Direct and Indirect-Treated Cultures with 
representative day 15 Live/Dead images, demonstrating OA+hAMSC ability to most effectively maintain chondrocyte 
viability. White scale bar is equal to 100µm. # indicates statistical difference (p<0.05) from day 0 to day 15. * indicates 
statistical difference (p<0.05) between study groups within time point. 
 
 
5.3.4 Histopathological Assessment of Explant Tissue 
 
  Safranin-O stained cartilage evaluated via the OARSI histopathological 
assessment is represented in figures 43 and 44. The cartilage exhibited increased surface 
fibrillation across greater portions of the cartilage surface, manifesting in a statistically 
increased (worse) OARSI score when OA joint explants were co-cultured together 
(p<0.05). Conversely, figure 43 demonstrates OA+hAMSC cartilage exhibited less 
surface fibrillation, manifesting in a statistically decreased OARSI score. While 
OA+hADSC cultures trended towards a similar decrease.  
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Figure 43: Average OARSI Scores in hAMSC and hADSC-Treated Cultures with corresponding safranin-o stained 
cartilage sections depicting worsening microarchitecture in un-treated groups as well as the ability of stem cells to deter 
surface fibrillation. 
 
 
Interestingly, figure 44 depicts that this chondroprotective effect of the hAMSCs appears 
to be dependent on the route of administration, as Indirect cultures still exhibited a trend 
towards worse cartilage surface fibrillation (worsening OARSI score), though this trend 
was not as dramatic as OA control cultures. Interestingly indirect cultures exhibited 
statistically decreased number of chondrocyte clusters, another metric employed by 
researchers to gauge OA progression, compared to OA+hADSC cultures (see appendix 
A).    
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Figure 44: Average OARSI Scores in Direct and Indirect-Treated Cultures with corresponding safranin-o stained 
cartilage sections depicting worsening microarchitecture in un-treated groups as well as the ability of stem cells in 
direct contact with cartilage to deter surface fibrillation. 
 
 
5.3.5 Assessment of Cartilage Degradation 
 
  As seen in figure 45, cartilage GAG content evaluated via DMMB assay revealed 
that OA co-culture resulted in a progressive loss of GAG content (from 181.9µg/mg to 
141.7µg/mg). Conversely, over 15 days the OA+hADSC culture showed no progression, 
and the OA+hAMSC groups exhibited a trend towards increased cartilage GAG content 
(156.4µg/mg to 247.0µg/mg). 
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Figure 45: Average Cartilage GAG Content in hAMSC and hADSC-Treated Cultures demonstrating the ability of 
hAMSCs to mitigate cartilage GAG deterioration. The range of D0 values is depicted as a shaded box from 148-200µg 
GAG/mg dry weight tissue. 
 
Similar to previous assessment measures, indirect culture of hAMSCs resulted in a trend 
toward less change in cartilage GAG content (-12.2 ± 21.0% Indirect vs. -40.2 ± 8.9% 
OA). However, figure 46 illustrates direct contact culture of hAMSCs resulted in a 
significant positive change in GAG content (30.7% ± 17.1%).  
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Figure 46: Average Cartilage GAG Content in Direct and Indirect-Treated Cultures demonstrating the ability of 
hAMSC seeded directly onto the cartilage surface to mitigate cartilage GAG deterioration.  
 
  Culture media evaluated via hydroxyproline assay revealed that OA co-cultures 
trended toward an increase in the amount of collagen leached from OA cartilage into the 
culture media (Figure 47). OA+hADSC cultures exhibited similar trends. Conversely, 
OA+hAMSC cultures maintained the amount of collagen leached into culture media.  
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Figure 47: Average Change in Media Hydroxyproline Content in hAMSC and hADSC-Treated Cultures 
depicting the relative increase in collagen leached from OA cartilage into the culture media in OA control and 
OA+hADSC groups, while hAMSC treated groups remained constant.  
 
 
Culture media evaluated via hydroxyproline assay revealed that the ability of hAMSCs to 
halt the progression of collagen leaching from cartilage appears to be dependent on the 
route of administration (Figure 48). While indirect cultures exhibited no change in the 
amount of collagen released into culture media, direct cultures demonstrated a trend 
towards decreased collagen released into culture media. 
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Figure 48: Average Change in Media Hydroxyproline Content in Direct and Indirect-Treated Cultures depicting 
the relative increase in collagen leached from OA cartilage into the culture media in OA control and OA+hADSC 
groups, while hAMSC treated groups remained constant.   
 
 
5.3.6. Pro-Inflammatory Profile Assessment 
 
Figure 49: IL-1β Analysis in hAMSC and hADSC-Treated Cultures depicting the average IL-1β concentrations in 
cell culture media from each study group. (Minimum detection limit: 0.3 pg/mL).  
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  Figure 49 illustrates a trending decrease in IL-1β concentrations in OA+hAMSC 
treated cultures, while all other cultures remained constant. Figure 50 depicts the 
relationship between IL-1β concentration and route of administration. The ability of 
hAMSCs to quell IL-1β secretion appeared to be dependent on the route of 
administration. 
Figure 50: IL-1β Analysis in Direct and Indirect-Treated Cultures depicting the average IL-1β concentrations in 
cell culture media from each study group. (Minimum detection limit: 0.3 pg/mL).   
 
  While TNF-α concentrations remained constant in OA co-cultures, OA+hAMSC 
and OA+hADSC cultures trended towards reduced concentrations (figure 51).  
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Figure 51: TNF-α Analysis in hAMSC and hADSC-Treated Cultures depicting the average TNF-α concentrations 
in cell culture media from each study group. (Minimum detection limit: 6pg/mL). 
 
Direct and indirect administration of hAMSCs accomplished this equally effectively. 
Figure 52: TNF-α Analysis in Direct and Indirect-Treated Cultures depicting the average TNF-α concentrations in 
cell culture media from each study group. (Minimum detection limit: 6pg/mL). 
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  MMP-13 ELISA performed on cell culture media revealed that over 15 days in 
culture, there were no significant changes in MMP-13 media concentration. However, the 
stem cell treated groups exhibited trends towards decreased MMP-13 concentrations 
(Figure 53).   
 
Figure 53: MMP-13 Analysis in hAMSC and hADSC-Treated Cultures depicting the average MMP-13 
concentrations in cell culture media from each study group. (Minimum detection limit: 30pg/mL).  
 
 
Analysis of direct and indirect hAMSC cultures showed no significant changes in MMP-
13 concentrations. However, the direct group did exhibit a trend towards decreased 
MMP-13 while the indirect group exhibited no change compared to OA controls (Figure 
54). 
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Figure 54: MMP-13 Analysis in hAMSC and hADSC-Treated Cultures depicting the average MMP-13 
concentrations in cell culture media from each study group. (Minimum detection limit: 30pg/mL).  
 
In addition to these ELISA data, a comprehensive cytokine array was completed (see 
appendix B for complete results). Most notably, this showed statistical increases in anti-
inflammatory marker IL-13 in OA+hADSCs cultures and anti-inflammatory marker IL-4 
in OA+hAMSC cultures.    
5.4 Discussion 
  With the evolving view of OA as an inflammatory condition driven by 
macrophages and their pro-inflammatory secretions, immunomodulatory therapies have 
come to the forefront of investigation. Due to their trophic, anti-inflammatory and 
immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA 
therapies.11,12,84,134 In fact pre-clinical animal studies and human trial results support OA 
mitigation through the intra-articular injection of stem cells.12,120 
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  Though two specific stem cell sources have been widely investigated as a 
potential OA therapeutic, there are drawbacks associated ADSCs and bone marrow 
derived stem cells (BMSCs) that are less attributable to alternative stem cell sources 
(such as perinatal stem cells), including 1) the inability of BMSCs isolated from OA 
patients to proliferate and differentiate as effectively as BMSCs from healthy donors, 2) 
low cell yields and 3) painful harvest procedures.11,12,84 
  Conversely, perinatal stem cells exhibit significant advantageous qualities 
including, 1) high cell yields, 2) ontogenetically youthful status limiting their exposure to 
detrimental age-related changes and 3) superior chondro-protective effects in an 
inflammatory environment, exhibiting the ability to induce a pro-regenerative (M2) 
phenotype within synovial macrophages.68,73,87,221 Significantly, our data further supports 
this ability of hAMSCs (but not hADSCs).  
  It has been demonstrated that stem cells must be “primed” in order to exhibit anti-
inflammatory and immunomodulatory characteristics.134,214 Typically this involves the 
stimulation of stem cells through potent pro-inflammatory cytokines such as INF-γ.84,214 
Though the exact timeline has not been established, the need for priming does represent 
an inherent delay in the efficacy of OA stem cell therapies. This could be one explanation 
for delays in patient progress post initiation of stem cell therapy. Interestingly, it has been 
demonstrated that perinatal stem cells do not require priming prior to initiating 
therapeutic benefit; this could explain why hAMSCs appear to more effectively mitigate 
OA progression in our investigation. Additionally, it has been demonstrated that 
reductions in both IL-1β and TNF-α are necessary to mitigate OA disease progression.225 
Only hAMSCs are able to elicit reduction in both cytokines. IL-13, IL-10 and IL-4 induce 
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an M2 phenotype within macrophages.256,257 IL-13 and IL-4 have demonstrated the 
ability to mitigate cartilage degradation in vitro.258 While IL-4 and IL-10 have direct 
effects on chondroprotection through the down regulation of ADAMTSs and MMPs, 
respectively, IL-13 produces an indirect anti-inflammatory effect through the regulation 
of PGE2.259 There is limited data providing insight into the relative efficacy of IL-4 and 
IL-13 therapeutic strategies. However, this mechanistic insight seems to offer a potential 
explanation for the heightened and more rapid mitigation of OA observed in hAMSC-
treated cultures. Please see appendix B for more detailed mechanistic insight into stem 
cell mode of action (accomplished via a comprehensive cytokine analysis).  
  The intra-articular administration of stem cell therapies delivers stem cells into 
the joint space, likely resulting in a mixed contact scenario where only some stem cells 
remain in direct contact with the cartilage. Interestingly there is evidence suggesting stem 
cells do not tend to stay in direct contact with the cartilage; they home to the 
synovium140, furthering the need for researchers to understand the potential mechanistic 
differences and differential therapeutic effects of both treatment modalities. While stem 
cells likely generate therapeutic benefit via the secretion of immunomodulatory mediators 
(thus not requiring direct contact with cartilage)11,120, potential advantages of direct 
contact with the damaged cartilage have yet to be established. Interestingly, indirect 
contact co-culture of hAMSCs (which as figure 54 illustrates may actually be in direct 
contact with synovium via porosity in the trans-well insert) seem to exhibit similar 
mitigation of synovial pro-inflammatory M1 macrophages, though this does not translate 
into an increased chondro-protective effect in the timeframe studied. OA has increasingly 
become understood as a multi-focal disease, where both the cartilage and the synovium 
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Figure 54: Indirect Contact hAMSCs May be in Direct Contact with Synovium due to the porosity of the insert 
being large enough to allow passage of extension but not entire cells.  
 
 
exhibit key surface receptors (toll-like receptors) fueling the pro-inflammatory activation 
pathways characteristic of OA progression.12,125,135,260 While the exact etiology of OA is 
still largely unknown, it is generally assumed that cartilage injury (as opposed to synovial 
inflammation) initiates the propagation of OA.125,135 If true, it could be argued that 
therapies targeting the source of OA pathogenesis, the cartilage, would be most 
efficacious. Our results seem to indicate that such a targeted approach would be 
therapeutically beneficial. 
  In conclusion, we were able to successfully demonstrate that perinatal stem cells 
are capable of mitigating disease progression in an explant co-culture model of OA. 
Moreover, perinatal stem cells appear to more effectively mitigate OA disease 
progression compared to a commonly employed stem cell, hADSCs. The observed 
reduction in M1 macrophage populations could be a primary mechanism explaining the 
halt of OA progression observed in stem cell treated groups. Likewise, the increase in M2 
macrophage populations observed in hAMSC treated groups could be a primary 
mechanism explaining the enhanced ability of hAMSCs to mitigate OA progression. 
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Significantly, both direct and indirect contact co-culture of hAMSCs with human OA 
cartilage seem to result in the mitigation of OA progression. However, direct contact co-
culture with human OA cartilage seems to result in enhanced chondro-protective effects, 
exhibited by enhanced chondrocyte viability, maintenance of cartilage GAG content and 
trending reductions in the concentrations of cartilage matrix degrading enzymes and 
collagen leaching. Taken together, these results (and those highlighted in Appendix B) 
highlight the utility of hAMSCs for OA regenerative medicine approaches and provide 
significant mechanistic into their clinical use.  
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CHAPTER SIX 
 
TO COMPARE THE THERAPEUTIC EFFECTS OF hAMSCs AND hADSCs TO 
ATTENUATE OA PROGRESSION IN VIVO 
 
6.1 Introduction 
 
With the evolving view of OA as an inflammatory condition driven by macrophages and 
their pro-inflammatory secretions, immunomodulatory therapies have come to the 
forefront of investigation. Due to their trophic, anti-inflammatory and 
immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA 
therapies.11,12,84,87,134,202    
Numerous stem cell therapies have been described in animal models of OA. The 
stem cells are typically delivered via intra-articular injection into the knee joint. In 
comparison studies, stem cell therapies have been shown to yield better outcomes than 
autologous chondrocyte transplantation.12 There is also evidence that the stem cells are 
still located within guinea pig joint tissues after 1 week120,170 and up to 8 weeks post-
implantation in rats.120 There are also reports of the stem cells exhibiting signs of 
proliferation and differentiation. 120,170  
  Preliminary results from our group support the enhanced mitigation of OA by 
amnion compared to adipose stem cell treated groups, ex vivo (chapter V). However, to 
date amniotic stem cells have yet to be tested in vivo as an OA therapeutic. Additionally, 
no direct comparative analyses have been conducted investigating the relative therapeutic 
potential of amniotic stem cells with current clinically investigated stem cell sources (i.e. 
bone marrow and adipose tissue). 
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  Herein, we describe efforts undertaken in order to determine: 1) if amniotic 
mesenchymal stem cells are capable of mitigating OA progression in vivo and 2) if this 
therapeutic approach is at least as beneficial as those utilizing adipose derived stem cells.  
 
6.2 Materials & Methods 
hADSCs were purchased from Invitrogen (R7788-110). Trypsin was purchased 
from Fisher scientific (MT-25-053CI). Collagenase was purchased from Worthington 
Biochemicals (LS004196). Guinea pigs were purchased from Charles River RMS. 
Pharmaceutical grade HA was purchased from Lifecore Biomedical (HA700K-1). Indian 
Ink was purchased from Dr. Martin’s Bombay.  
6.2.1 Stem Cell Preparation 
Human placentas were obtained from consenting patients immediately following 
delivery via elective cesarean sections of full-term babies (Pro00031185-Greenville 
Health System). Amniotic membrane derived cells were isolated within 4 hours of 
delivery. hAMSCs were isolated as previously described (chapter III). Briefly, placentas 
were placed with the umbilical cord facing upward such that the fetal (amniotic) surface 
was accessible. The amniotic and chorionic membranes were identified and mechanically 
peeled from each other. Amnions were digested twice in 0.25% trypsin for 30 minutes at 
37°C with agitation to completely liberate the epithelial layer followed by complete 
digestion in two digestions of collagenase [2mg/mL collagenase (249 U/mg)] for 30 
minutes at 37°C with agitation each to subsequently liberate hAMSCs. hAMSCs were 
expanded until p2 in standard culture medium (DMEM+10%FBS+1%AB/AM), with the 
media changed every 3 days.  
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hADSCs were purchased from a commercial vendor and expanded until p2 
according to manufacturer’s instructions, with the media changed every 3 days.   
At p2, all cell types were suspended in sterile HA in order to obtain 1x106 viable 
stem cells/100µL HA aliquot. HA suspensions were loaded into 21g syringes in 
preparation for injection. 
6.2.2 Stem Cell Intra-Articular Injections 
 As illustrated in figure 55, n=24 guinea pigs were allowed 14 days upon arrival to 
our facilities for acclimation. According to approved animal used protocols, at day 0 n=6 
guinea pigs were used to practice injections. Briefly, a HA+hAMSCs suspension was 
injected into the left stifle and a saline injection was administered into the right stifle of 
these guinea pigs. Ultrasound guidance was utilized similar to methods described by 
Vazquez et al.1 Briefly, stifles were placed in flexion, the ultrasound probe was covered 
with gel and applied to the leg surface near the patella. A 21-gague syringe (loaded 
HA+hAMSCs) was inserted posterior to the medial edge of the patellar ligament. After 
initial insertion, the leg was placed in extension to facilitate visualization of the intra-
articular space. The needle was inserted until it was in direct contact with the femur, and 
the contents of the syringe were injected. 
Additionally, at day 0 our experimental group underwent their first round of 
injections. The left stifle received an injection of either an HA+hAMSC suspension, an 
HA+hADSC suspension or HA alone (the HA group was included to ensure the HA itself 
did not offer significant therapeutic benefit, confounding our results). Notably, the 
passage (2), number of stem cells (1x106/injection) and injection volume (100µL) 
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remained constant between groups. The right stifle received a saline injection; these 
limbs served as terminal time point OA controls.   
After 7 days, the set of 6 practice guinea pigs were euthanized and their saline 
injected limbs served as day 0 degenerative controls. After 1.5 months, the remaining 
guinea pigs (n=18) were administered a second injection according to the methods 
previously described. Finally after 3 months, the guinea pigs were euthanized. Outcome 
measures for this study included macro and micro surface architecture and biochemical 
assessments of the cartilage; as well as synovial inflammation. 
6.2.3 Cartilage Surface Macro Architecture  
 Formalin fixation (48 hours) was followed by 7 days in decalcification solution. 
After 3x washing in PBS, joints were dissected until the femoral condyles and tibial 
plateaus were easily accessible. Approximately 100µL of 20% vol/vol solution of Indian 
Ink in PBS was applied to the exposed cartilage surfaces, excess liquid was blotted away 
and macroscopic images were taken.  
6.2.4 Cartilage Surface Micro Architecture 
Guinea pig stifles were secured within a tissue processing cassette, fixed in 10% 
phosphate buffered formalin overnight at room temperature prior to undergoing standard 
tissue processing, decalcification, paraffin embedding and sectioning at 8 µm thickness. 
Sections were stained with Safranin-O counterstained with Fast Green for visualization of 
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1% 
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for 
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with 
1% Safranin-O for 15 minutes. 
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6.2.5 Assessment of Cartilage Degradation 
As depicted in figure 56, stifles for biochemical analysis were removed from the 
guinea pig. The femur and tibial surfaces were identified, and these surfaces were divided 
into their medial and lateral components. The cartilage was then removed using a curette. 
As guinea pigs primarily load the medial compartment of their joint; this area is most 
susceptible to OA. To ensure results were not skewed by the tibial portions, assessments 
were completed in quartered sections. The results from the medial tibial surface, which is 
the surface most prone to OA in this model, are described herein.  
Figure 56: Methods Schematic of Cartilage Harvest for biochemical evaluation. Stifles were dissected to expose the 
femoral and tibial surfaces. These surfaces were further divided into medial and lateral components. Only results from 
the medial tibial surfaces are reported, as this is the area most prone to OA development in this animal model. 
 
 
6.2.5.1 Cartilage Glycosaminoglycan (GAG) Content  
  Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer, 
pH 7.5 overnight at 65°C. Tissue digests were assessed for GAG content via 
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg 
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DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards 
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample 
absorbance was read at 525nm.   
6.2.5.2 Collagen Leaching to Culture Media 
  Cartilage was assessed for hydroxyproline collagen content via Hydroxyproline 
Assay Kit according to manufacture instructions. Briefly, samples were hydrolyzed with 
hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells were evaporated 
to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer Mixture and 
Diluted DMAB Reagent followed by 5-minute room temperature and 90-minute 60°C 
incubations, respectively. Standards were created using a 1mg/mL stock solution of 
Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.  
6.2.6 Histological Confirmation of Synovitis 
Synovial sections were secured within a tissue processing cassette, fixed in 10% 
phosphate buffered formalin overnight at room temperature prior to undergoing standard 
tissue processing, paraffin embedding and sectioning to 8 µm thickness. Sections were 
stained with Hematoxylin and Eosin (H&E) for visualization of cellularity and membrane 
hypertrophy. 
6.2.7 Microscopic Imaging 
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision 
software (Release 4.9.1 SP08-2013). 
3.2.8 Statistical Analysis 
Results are represented as a mean ± standard error of the mean (SEM).  All 
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or 
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analysis of variance (ANOVA) with a Tukey’s post-hoc analysis. Significance was 
defined in all cases as p<0.05.  
6.3 Results   
6.3.1 Stem Cell Preparation 
 Stem cell populations were successfully expanded and prepared for intra-articular 
injection.
6.3.2 Stem Cell Intra-Articular Injections 
 Stem cell suspensions were successfully injected into the intra-articular space of 
guinea pig stifles. See appendix A for more detailed information on these confirmation 
assessments.  
6.3.3 Cartilage Surface Macro Architecture  
Figure 57: Cartilage Surface Macro-Architecture demonstrating medial tibial surface erosion in 3-month saline and 
HA injected groups. Varying amounts of surface fibrillation/erosion is noted within stem cell treated groups.
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Figure 57 illustrates cartilage surface macro architecture assessments. A 
macroscopic image of a stifle with the femoral condyles exposed on the top and the tibial 
surface exposed on the bottom is presented in the top left of figure 57. The creamy and 
shiny quality of the cartilage is easily noticeable; it is present everywhere except over the 
medial tibial surface, which is highlighted by the black circle.  
Indian ink stains bone as well as fibrillation of the cartilage surface. After 3 
months, the medial tibial surface of saline injected stifles, which macroscopically looked 
quite eroded, stains deep blue (figure 57). The HA group exhibited similar intense blue 
staining on the medial tibial surface (figure 57). However, the stem cell treated groups 
showed varying evidence of surface fibrillation and/or erosion (figure 57). 
6.3.4 Cartilage Surface Micro Architecture 
Figure 58: Cartilage Surface Micro Architecture of Controls, indicating high cartilage proteoglycan content at day 
0. However by 3 months, the proteoglycan content has been largely degraded.  
 
At day 0, there was a large volume of proteoglycan rich matrix (figure 58). 
However, after 3 months this rich proteoglycan matrix appeared to have degraded away 
(figure 58). Comparatively the HA group showed similar if not lower proteoglycan 
content (compared to 3-month saline injected controls). While stem cell treated groups 
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showed at least comparable if not more proteoglycan rich matrix (figure 59). 
Figure 59: Cartilage Surface Micro Architecture of Experimental Groups, indicating low proteoglycan content in 
HA-treated groups. However, stem cell treated groups show at least equivalent levels of proteoglycans compare to 
controls. 
 
6.3.5 Assessment of Cartilage Degradation 
hAMSC treatment resulted in significantly greater (p<0.05) cartilage GAG 
content compared to our untreated and HA controls (figure 60).  
 
Figure 60: Cartilage GAG Content in all guinea pig groups. hAMSC-treated groups exhibit the highest cartilage 
GAG content after 3 months. 
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Additionally, hAMSC treatment resulted in significantly greater (p<0.05) 
cartilage collagen content compared to HA controls (figure 61).  
 
 
Figure 61: Cartilage Collagen Content in all guinea pig groups. hAMSC-treated groups exhibit the highest cartilage 
collagen content after 3 months.  
 
6.3.6 Histological Confirmation of Synovitis 
Figure 62 shows H&E staining of synovium sections for assessment of synovitis. 
Beginning with day 0 controls, there is intense cellularity near the lining; therefore the 
lining does exhibit hyperplasia, with an addition 4+ layers of cells than what would 
typically be expected in the synovial lining (this is highlighted by the black boxes). After 
3 months, the non-treated group (this was the group which received saline injections) 
showed similar cellularity and membrane hypertrophy; indicating at least equivalent 
levels of synovitis over this 3-month period. After 3 months, the HA group also showed 
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high cellularity and extensive membrane hypertrophy, likely indicating the HA treatment 
had no therapeutic, immunomodulatory effect. Conversely, after 3 months the hAMSC 
treated group showed moderate cellularity with less hypertrophy. Like the hAMSC 
group, the hADSC group appeared to contain less cells along the synovial lining. 
 
Figure 62: Histological Assessment of Synovitis demonstrating trends between control (untreated) stifles and treated 
stifles with time. Black boxes highlight the synovial lining. 
3-month saline injected right stifles (pictured along the top in figure 63) were then 
compared with their subject matched 3-month treatment injected left stifles (pictured 
along the bottom of figure 63). Synovitis appeared to progress in the HA-treated group. 
The hAMSC treated group appeared to show improvement in both cellularity and 
membrane hyperlasia.  Lastly, the synovitis in hADSC treated guinea pigs appeared to be 
the same.  
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Figure 63: Subject-Matched Histological Assessment of Synovitis demonstrating trends between subject-matched 
left (treatment) and right (control) stifles.  
 
6.4 Discussion 
 We were able to confirm and employ our approach of intrtopa-articular injection 
of stem cells in a pilot guinea pig study (see appendix A). We also demonstrated 
preliminary trends supporting the therapeutic efficacy of hAMSC and hADSC therapies 
mitigating OA progression in vivo. While we are continuing to analyze this data, the 
biochemical data specifically seems to indicate hAMSCs, in particular, are having a 
beneficial effect.   
The Dunkin Hartley guinea pig animal model was employed in this study, 
because anatomically, the guinea pig knee is very similar to the human knee, though it is 
much smaller.160 Additionally, guinea pigs exhibit the multi-factorial nature of bone 
growth and growth plate fashion observed in humans.160 Notably, guinea pigs primarily 
load the medial stifle, making the medial compartment most prone to OA development 
(similar to humans).160 The histopathology of the guinea pig has been extensively 
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evaluated and deemed similar to human OA.160 
All guinea pigs showed no signs of immunologic rejection throughout the study. 
There were no abnormal behavioral changes (aggressiveness or lethargy) typically 
associated with bio-incompatability. However, IHC detection of lymphocytes should be 
employed in order to confirm this.  
 Both macro- and microscopically, it appeared the guinea pigs did reliably develop 
OA of the medial tibial plateau at 6-months of age (animals were 6-months old upon 
study termination at 3-months). Though the Dunkin Hartley guinea pig model does 
reliably develop OA in the entire medial compartment by 1-year of age.2,3 Our results 
indicate OA was limited to the medial tibial compartment. An extended treatment 
timeline as well as the use of older animals would likely yield more advanced disease 
progression. 
 Synovial inflammation also confirmed OA progression in the guinea pigs with 
time. The grouping, size and shape of the cells observed in synovial inflammatory 
assessments appear to be some sort of inflammatory cell, potentially a macrophage, but 
macrophage-specific staining via IHC would be necessary to confirm this. These 
assessments proved particularly useful as they also led to the determination that due to 
small sample sizes, increased control (n=6) vs. experimental (n=2) subject numbers and 
moreover, large inter-subject variability, the most appropriate reporting of the in vivo 
data involved comparing the subject-matched treatment and saline injected limbs. Such 
comparisons appeared to offer more accurate depictions of disease 
progression/mitigation.  
156 
   We noted the hAMSC-treated group appears to more successfully mitigate 
synovial inflammation. Not surprisingly, this group also preliminarily exhibited superior 
chondro-protection compared to hADSC and HA treated groups. As previously 
discussed, OA is an inflammatory condition driven by a feed-forward, macrophage-based 
mechanism. Based on previous results and the preliminary results of this study, hAMSCs 
me in fact be lowering the number of M1 macrophages or facilitating some sort of 
macrophage polarization shift. Whether this results or is a result of chondro-protective 
effects remains to be seen.  
 There are many more analyses that can be conducted on these samples, including 
tracking of the stem cells and macrophage/lymphocyte detection. Tracking of stem cells 
could be accomplished utilizing IHC detection of human mitochondria. In future 
iterations of such studies, the stem cells could be fluorescently tagged prior to injection as 
another metric of stem cell tracking. Similar to those results reported in chapter V, it 
would be interesting to track macrophage phenotype over time. Ex vivo we have 
demonstrated hAMSC treatment seems to shift macrophage polarization to an M2 
phenotype. However, it remains to be seen if similar phenomena occur in vivo. 
Unfortunately, this will require anti-body development, as the necessary antibodies are 
not currently available in the guinea pig. IHC detection of lymphocytes will help further 
claims of biocompatibility of the injected stem cell therapeutics. Though such methods 
utilizing human cells in this guinea pig model have been previously described with no 
immune rejection,4 this should be confirmed in our investigation. In future guinea pig 
studies, it would be ideal to obtain synovial fluid samples. Cytokine profiling would be a 
potential alternative method of gaining insight into macrophage polarization. 
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Additionally, it would be interesting to confirm the IL-4 and IL-13-dependent therapeutic 
mechanisms proposed in aim III, in vivo.  
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CHAPTER SEVEN 
 
CONCLUSIONS 
 
 
  In conclusion, we were able to successfully demonstrate stem cells from the 
amniotic membrane exhibit heightened differentiation potential, availability in high 
yields, heightened immunomodulatory properties, and the ability to induce pro-
regenerative (M2) phenotypes within macrophages, in musculoskeletal tissue-related 
experiments. Additionally, perinatal stem cells appeared to offer accelerated treatment 
time lines compared to a field standard stem cell, adipose derived stem cells.  
In aim I, we were able to successfully isolate amniotic stem cells in high yields 
and differentiate them into osteogenic and chondrogenic lineages more readily than 
hADSCs. These differentiation capacities verified that amnion stem cells a candidate 
stem cell for osteoarthritis therapies. We therefore, continued to examine the utility of 
amnion stem cells through investigations into their OA therapeutic efficacy.  
  In aim II, we were able to successfully demonstrate human joint tissue explant co-
culture mimics OA pathogenesis by modeling: 1) cartilage destruction in the presence of 
inflammatory cytokines and synovial macrophages, 2) gradual progression with time and 
3) a feed-forward progression, where the cartilage and synovium exhibit reciprocal 
pathologic effects on one another. Additionally, our mechanistic evaluations utilizing 
macrophage depletion studies indicate synovial macrophages and/or their secretions are 
likely primary effectors driving disease progression in the model. This work highlights 
the utility of joint tissue explant co-culture in OA research, as it is an effective system for 
investigating OA pathology and evaluating potential future therapies. 
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  In aim III, we were able to successfully demonstrate that perinatal stem cells are 
capable of mitigating disease progression in an explant co-culture model of OA. 
Moreover, perinatal stem cells appear to more effectively mitigate OA disease 
progression compared to a commonly employed stem cell, hADSCs. Significantly, both 
direct and indirect contact co-culture of hAMSCs with human OA cartilage seem to result 
in the mitigation of OA progression. However, direct contact co-culture with human OA 
cartilage seems to result in enhanced chondro-protective effects. Lastly, we were able to 
propose a mechanism for the observed mitigation via M2 macrophage anti-inflammatory 
secreted products.  
 In aim IV, we were able to successfully complete pilot animal study comparing the 
relative therapeutic efficacy of hAMSC and hADSC therapies for the mitigation of OA. 
Evidence, specifically biochemical analyses, appears to suggest hAMSCs offer superior 
therapeutic benefit. 
  For these reasons, we believe amnion membrane derived stem cells are an 
efficacious stem cell source for orthopedic tissue engineering and regenerative medicine 
strategies. 
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CHAPTER EIGHT 
 
RECOMMENDATIONS 
 
8.1 What Worked Well 
Many of the methodologies employed in this research proved extremely efficacious 
and/or added validity to the work. I suggest the following methods continue to be 
implemented in future iterations of this work: 1. Conducting%standardized%experiments%comparing%the%investigated%amnion%stem%cells%against%commonly%employed%stem%cells%allowed%for%conclusions%regarding%the% validation% of% amnion% as% a% stem% cell% source% for% orthopedic% regenerative%medicine%(validation%requires%comparison%to%established%standards;%in%this%case%hADSCs).%I%encourage%similar%comparative%analysis%to%be%conducted%with%another%commonly% employed% stem% cell,% hBMSCs,% as% well% as% some% more% widely%researched%perinatal%stem%cells,%CMSCs%and%chord%blood%stem%cells.%Comparisons%between% human% joint% tissue% explant% coPculture% and% chemical% doping% models%would%also%prove%beneficial.%%%%2. All%histological%assessments%were%conducted%by%at%least%one%blinded%researcher.%This/these% researcher(s)% remained% blinded% to% the% condition/treatment% of% the%sample%being%analyzed.%This%added%significant%validity%to%the%obtained%results,%as%it%limits%peerPreview%rejection%of%the%results%due%to%researcher%bias.%3. Large%sample%sizes%were%required%in%order%to%overcome%interPpatient%variability%of%OA%disease% characteristics.%Based%on% this%work,%utilizing% sample% sizes%below%10% is% highly% discouraged,% as% it% does% not% seem% to% accurately% reflect% the% trends%and/or%statistical%differences%observed%with%n=15+%samples.%
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8.2 Future Suggestions for Aim I 
  Chondrocytes above the non-calcified zone in cartilage live under hypoxic 
conditions. While researchers are unsure of the exact mechanism(s), it appears that 
obtaining the appropriate ratios of aggrecan and collagen-II described in articular 
cartilage requires hypoxic conditions. Our experiments were conducted under normoxic 
conditions. Thus, chondrogenic differentiation characteristics could have been altered or 
more likely, will be enhanced and/or accelerated if completed under hypoxic conditions. 
 Mechanical stimulation is necessary in order to maintain cartilage homeostasis. 
This stimulation provides many functions, including facilitating synovial fluid movement 
and preventing the secretion of pro-inflammatory cytokines. The development of a 
bioreactor system that could apply appropriate mechanical loading to the cell system may 
enhance and/or accelerate chondrogenic differentiation of amnion stem cells.  
 Many musculoskeletal tissue pathologies, including OA, involve the creation and 
maintenance of a pro-inflammatory milieu within the pathologic tissue. Differentiation of 
most stem cells, including hADSCs, has been shown to be less effective under such 
inflammatory conditions. However, there is evidence that perinatal stem cells are able to 
differentiate under inflammatory conditions. Therefore, the results of our differentiation 
study (which favor amnion stem cells) could become even more skewed if the experiment 
were conducted with media supplemented with pro-inflammatory cytokines (ex. INF-γ, 
TNF-α, IL-1β).  
 Lastly, there are minor adjustments to the method that could be employed to 
increase the clinical relevance of the study. Firstly, the amino stem cells could be isolated 
using the explant culture technique (i.e. without enzymatic digestion). Secondly, the 
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amnion cells should undergo at least one freeze-thaw cycle prior to use in the 
differentiation study, as this will more closely mimic the tissue-banking processes that 
would be necessary with the clinical use of amnion. Finally, during stem cell expansion 
and differentiation, animal-serum media should be employed.   
 
8.3 Future Suggestions for Aim II 
 As previously indicated, cartilage homeostasis requires hypoxia and mechanical 
stimulation. The development of a bioreactor system that could apply appropriate 
mechanical loading to the co-culture systems would more closely mimic the native 
anatomy and physiology being modeled.  
For similar reasons, the meniscus, a highly inflammatory tissue of the OA joint 
space, could be added to the co-culture system. As OA progression seems to be 
inflammatory based, this may further enhance the OA progression observed. Extending 
the length of the study to at least 28 days would also likely show greater disease 
progression. However, our low synovium viability results seem to indicate that culture 
past this time period may not be possible. 
While literature-based comparisons are possible based on these results, 
standardized comparative analyses employing this OA co-culture model and those 
employing chemical doping of the co-culture media are strongly encouraged. Such results 
would bolster claims of this model more accurately reflecting the natural and progressive 
nature of human OA. 
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8.4 Future Suggestions for Aim III 
Significant variability was observed both within and between samples in the OA 
co-culture studies. In order to be sure such variability does not significantly alter the 
observed data trends, the 6mm biopsy tissue samples could be cut in half prior to 
initiating culture. One half of the sample could receive hADSC treatment while the other 
half of the sample could receive hAMSC treatment. Additionally, a dosing study to 
determine a the stem cells required to effectively mitigate disease progression would 
offer significant, clinically relevant, insight.  
The model could also be employed in further mechanistic studies in order to 
further confirm and/or advance studies of OA. For example, M2 macrophage specific 
clodronate could be introduced into the culture system in order to systematically deplete 
M2 macrophages. Disease progression similar (if not worsened compared) to OA co-
culture controls would be anticipated. Additional biochemical screening could include 
PGE2 (to further investigate hADSC mitigation via auxiliary pathways), IL-1Ra (a known 
competitor of IL-1 binding which could be up-regulated by stem cells) and ADAMTS-5 
(the primary ADAMTS involved in OA which could be differentially down-regulated). 
Additionally, this experimental design could be modified in order to test the regenerative 
(vs. mitigation) capacity of the stem cells. Creating a reproducible defect within the 
cartilage biopsies and monitoring the condition of the defect with time/treatment could 
accomplish this.    
In an attempt to make these studies more clinically relevant, minced amnion could 
be employed as an alternative (therapeutic) study group. There is precedence for the use 
of amniotic membrane, as numerous amniotic membrane-based products are 
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commercially available. If minced amnion is an efficacious therapeutic alternative, it may 
prove easier to obtain FDA backing than stem cell therapies.  
 
8.5 Future Suggestions for Aim IV 
 Dunkin-Hartley guinea pigs reliably exhibit severe OA by one year of age. 
Therefore increasing the study duration and/or utilizing older animals would be 
encouraged in order to ensure each animal exhibited OA prior to stem cell injection.  
 A stem cell tracking study would provide information regarding the length of time 
the stem cells remain in the joint space as well as the location of the stem cells. This 
could provide mechanistic insight into the primary mode of action of the stem cells 
(differentiation into chondrocytes vs. immunomodulatory). Such a study may also help 
ease concerns regarding the short lifespan of HA within the joint, as stem cell migration 
from the HA carrier into the joint space could be monitored. While IHC or 
immunofluorescence for human mitochondria is one method for tracking stem cells, 
immunofluorescent tagging of the stem cells is another commonly employed alternative. 
Though such an approach would require the use of female guinea pigs, the use of male 
cells in a female animal model would allow the tracking of stem cells via Y-chromosome 
in situ hybridization.  
 The inabilities to test for M1/M2 macrophages and to obtain synovial lavages 
were severe limitations of our pilot guinea pig study described in aim IV. It is strongly 
recommended to obtain synovial fluid samples in order to obtain further mechanistic 
insight into the action of the stem cells. Particularly, it would be interesting to see if the 
up-regulation of IL-13 and IL-4 in hADSC and in hAMSCs, respectively, observed ex 
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vivo is also observed in vivo.  
Lastly, steps could be taken to increase clinical relevance. The addition of more 
clinically relevant outcome measures would also enhance the validity of further guinea 
pig investigations. Functional testing through the use of cage platforms (monitoring 
animal activity levels) or guinea pig pedometers could be employed. Radiographic-based 
assessments of the joint space would also more accurately reflect clinical grading and 
assessment of the joint. Additionally, synthetic HA could be investigated as a stem cell 
carrier due to its more prevalent use compared to natural HA.  Furthermore, there is 
precedence (from a regulatory standpoint) for the use of amniotic membrane as a wound 
covering. Therefore investigating the use of amniotic membrane as a “band aid” covering 
the synovial membrane (vs. a stem cell therapy) may be worthwhile. Results from our 
hAMSCs seeded in indirect contact with the cartilage surface (aim III) seem to support 
such an approach.   %%%%%%%%%
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APPENDIX A 
ADDITIONAL DATA/FIGURES 
Figure A.1: Detailed Methods Schematic describing the experimental design of the differentiation study described in 
aim I.  
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Figure A.2: Alternate depiction of TLR-activation highlighting the ability of chondrocytes (in additional to synovial 
cells) to contribute to TLR-activation.  
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Figure A.3: Pictorial Representation of the Multi-Focal Therapeutic Potential of Stem Cells highlighting two of 
the proposed mechanisms of action: differentiation and immune modulation. 
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Figure A.4: Detailed Methods Schematic Describing Joint Tissue Explant Tissue Harvest and the initiation of co-
culture. 
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Figure A.5: The Fate of Intra-Articularly Injected Stem Cells is Unknown. Stem cells are typically administered 
via intra-articular injection, and it is currently not known what tissue(s) the stem cells actually remain in contact with. It 
is possible the stem cells are directed to that surface via signaling cues and settle (due to gravity) on the surface of the 
cartilage. It is also possible that the movement of the joint would actually prevent the stem cells from settling and they 
could remain in indirect contact with the cartilage surface. Therefore we wanted to investigate the effects of varying 
stem cell administration location on therapeutic potential.  
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Alternative Method of Achieving Chondrogenic Differentiation: Micro Mass Culture 
 
 
Methods: hAESCs, hADSCs, and Mixed cell groups (n=4 per cell type per treatment) for 
use in chondrogenic differentiation were seeded in micro-culture at 8x104/10µL media. 
After 2 hours, the remaining media was added to the micro-culture. At select time points, 
cultures were stained with Alcian Blue and underwent semi-quantitative analysis as 
described previously in chapter IV.  
 
Results: All negative control cell groups exhibited GAG deposition by day 14, and figure 
A.6 confirms this deposition continued through day 28. Staining of the negative controls 
appeared to be less extensive than in the test groups (Figure A.7), and semi-quantitative 
analysis confirmed this in most cases. Additionally it was noted that, in comparison to the 
hAESCs and hADSCs, the hybrid cell population proliferated much more extensively, 
and yielded greater staining, by each time point (Figure A.7).    
 
Table&A.1:&Average&%&Area&Stained&by&Alcian&Blue&&
Day&28&
&&
hAEC& hAEC&Neg.& Mixed& Mixed&Neg.& hADSC& hADSC&Neg.&
43.02*+& 31.28*+& 86.70*+#& 97.13*+#& 26.20*#& 24.22*+&
Day&14&
&&
hAESC& hAESC&J& hAMSC& hAMSC&J& hADSC& hADSCJ&
28.41*+#& 26.15*+& 30.15*+#& 26.39*+#& 20.30*#& 25.88*+&
Day&7&
&&
hAESC& hAESC&J& hAMSC& hAMSC&J& hADSC& hADSC&J&
0.01& 0.00& 0.00& 0.00& 0.00& 0.00&
Day&3&
&&
hAESC& hAESC&J& hAMSC& hAMSC&J& hADSC& hADSC&J&
0.00& 0.00& 0.00& 0.00& 0.00& 0.00&
Table A.1: Semi-Quantitative Alcian Blue results demonstrating the increased chondrogenic differentiation of 
amnion groups compared to hADSCs. *Denotes statistical difference (P<0.05) between test group and respective 
control within time point +Denotes statistical difference (P<0.05) between cell group and hADSC test group within 
time point # Denotes statistical difference (P<0.05) between cell group and hADSC negative group within time point 
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Figure A.6: Micro Mass Chondrogenic Differentiation of Negative Controls with Alcian Blue staining. GAG 
deposition was apparent across all groups by 14 days. No significant morphological changes were noted. 
 
 
 
Figure A.7: Micro Mass Chondrogenic Differentiation of Experimental Group with Alcian Blue staining. GAG 
deposition was visible across all groups by day 14. Morphological changes were apparent in both amniotic membrane-
derived cell groups as early as day 3, whereas hADSCs maintained their spindle shape a through 28 days. 
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Chondrocyte Clustering in OA Co-culture 
 
 
 
As previously indicated, normal 
chondrocytes are held in place due 
to their senescent state. However, 
in OA chondrocytes activate: 
proliferating and secreting matrix. 
This results in the chondrocytes 
moving and forming cell clusters. 
An example of chondrocyte 
clustering observed in OA cartilage 
explants can be seen in figure A.8.
Counting the number of cell 
clusters is a method employed by 
researchers to convey the extent of 
OA progression. Clusters were 
only counted if they consisted of at least 3 chondrocytes. Figure A.9 demonstrates the 
limited differences between study groups. There appeared to be no difference in the 
number of chondrocyte clusters observed in OA, cartilage only or hADSC-treated groups 
after 15 days. However, hAMSCs in direct contact with cartilage demonstrated a trend 
towards reduced chondrocyte clustering and hAMSCs in indirect contact with cartilage 
demonstrated statistically reduced chondrocyte clustering compared to hADSC-treated 
groups.  
Figure A.8: Chondrocyte Clustering observed in a safranin-O 
stained cartilage explant. Prominent clusters are circled. 
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Figure A.9: Chondrocyte Clustering observed in OA explant co-culture over 15 days. 
 
Figure A.10 shows a patient-matched set of safranin-o stained cartilage explants, 
demonstrating the trending decrease in clusters observed in hAMSC-treated groups.  
 
Figure A.10: Chondrocyte Clustering in Patient-Matched Cartilage Explants observed after 15 days 
 
The depth of chondrocyte clustering is also considered to be reflective of the stage of 
OA; where clustering within the superficial-middle zones represents early stage OA and 
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clustering within the middle-deep zones represents late stage OA. Figure A.11 illustrates 
the relative depth of chondrocyte clusters observed within study groups. 
 
 
Figure A.11: Relative Depth of Chondrocyte Clustering observed after 15 days in explant co-culture. 
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Initial Feasibility Assessment for Guinea Pig Injection Study: Stem Cell Viability 
 
In an attempt to ensure stem cell viability post submersion in HA and injection through a 
syringe, the viability of hAMSCs and hADSCs was tracked through this process in an 
initial feasibility study (n=3 per stem cell type). In order to gain meaningful insight into 
the affect of HA suspension and syringe injection, all stem cell culturing conditions and 
materials employed in this study were identical to those previously described in chapter 
VI (i.e. this feasibility study employed identical methods to those utilized in the actual 
guinea pig injections). 
 
Methods: Passage 1 hAMSCs and hADSCs were plated under standard expansion culture 
conditions. At confluence, cells were passaged and initial viability of these passage 2 
cells was established via Trypan Blue counting in a BioRad TC-20 cell counter. 1x106 
cells were submerged in individual aliquots of 100µL HA, loaded into a 21-gauge syringe 
and the total volume of HA+SC suspension was ejected. The HA+SC suspension was 
then counted to determine the effect of the HA carrier and injection process on cell 
viability.  
 
Results: As illustrated in figure A.12, cell viability was not affected by submersion in HA 
followed by injection through the syringe. The average HA suspension and injection 
process lowered cell viability by <1.5%. No statistical differences were observed between 
initial and final viability counts or between stem cell types. 
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Figure A.12: Stem Cell Viability Assessment post submersion in the HA carrier, loading and injection through a 
syringe.  
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Initial Feasibility Assessment for Guinea Pig Injection Study: Stem Cell Injection 
 
In an attempt to ensure the joint space could be successfully located, and the injections 
could be delivered into the intra-articular joint space, n=3 rats and n=6 guinea pigs were 
used in ultra-sound guided practice injections.  
 
Methods: Ultrasound guidance was utilized similar to methods described by Vazquez et 
al.261 Briefly, rat stifles were placed in flexion, the ultrasound probe was covered with gel 
and applied to the leg surface near the patella. A 21-gague syringe was loaded with PBS, 
and the needle was inserted posterior to the medial edge of the patellar ligament. After 
initial insertion, the leg was placed in extension to facilitate visualization of the intra-
articular space. The needle was inserted until it was in direct contact with the femur, and 
the PBS was injected. 
 
Results: As illustrated in figure A.13A, the intra-articular space was correctly identified. 
The needle was inserted into the intra-articular space and identified via ultra-sound 
(figure A.13B). The PBS was not injected until the needle was successfully guided to the 
femur surface (figure A.13C).  
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Figure A.13: Ultrasound Confirmation of Practice Injection showed 
that the intra-articular space could be identified (A), the needle could be 
inserted (B) and the PBS injection could be ejected when the needle was at 
the surface of the femur. 
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APPENDIX B 
COMPREHENSIVE INFLAMATORY ASSESSMENT OF  
OA EXPLANT CULTURES 
 
Initial probes into the inflammatory profile of the described OA explant culture 
system included enzyme-linked immunosorbent assay (ELISA) for primary OA 
mediators: IL-1β, TNF-α and MMP-13, were described in chapters IV and V. In order for 
more thorough model validation efforts as well as further mechanistic confirmation of the 
therapeutic efficacy of the described stem cell therapies, a comprehensive inflammatory 
cytokine array was completed on media samples from OA explant co-cultures (OA day 0 
(n=13), OA day 15 (n=13), Macrophage depleted day 15 (n=5), OA+hADSC day 15 
(n=4), OA+hAMSC in direct contact with cartilage day 15 (n=5), OA+hAMSC in 
indirect contact with cartilage day 15 (n=3)). This array provided quantitative 
measurements of 20 human chemokines and cytokines. 13 of these provide pro-
inflammatory stimulation (IL-1α, IL-1β, TNF-α, RANTES, MCP-1, IL-8, IL-6, IL-2, IL-
5, IL-12, MIP-1a, MIP-1b and GM-CSF), while 3 are known anti-inflammatory 
mediators (IL-4, IL-10, IL-13). An additional marker, VEGF, has been used as a marker 
of synovitis (as synovitis is characterized by enhanced angiogenesis within the 
synovium). In this appendix we describe the results of this array and highlight the 
implications of these results. For clarification, please see the below list of formal and 
alternative names for each mediator investigated. 
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Table B.1 Clarification of Terminology & Cytokine Source 
Name on Cytokine 
Array 
Abbreviation Alternative Name(s) OA Tissue Source of Cytokine 
104,118,132,260,262,263 
Interleukin 1 alpha IL-1α 
Hematopoietin 1 Cartilage, 
Subchondral bone,  
Synovium 
Interleukin 1 beta IL-1β 
Leukocytic pyrogen, 
Eukocytic 
endogenous 
mediator, Ononuclear 
cell factor, 
Lymphocyte 
activating factor 
Cartilage, 
Subchondral bone,  
Synovium 
Tumor Necrosis 
Factor alpha TNF-α 
Cachexin, or 
Cachectin 
Cartilage, 
Subchondral bone,  
Synovium 
Interleukin 8 IL-8 CXCL8 Synovium 
Monocyte 
Chemoattractant 
Protein-1 
MCP-1 
Chemokine (C-C 
motif) ligand 2 
(CCL2) 
Synovium 
Regulated on 
Activation, Normal T 
cell Expressed and 
Secreted 
RANTES 
Chemokine (C-C 
motif) ligand 5 
(CCL5) 
Subchondral bone, 
Synovium 
Interleukin 6 IL-6 
Interferon Beta 2 Cartilage, 
Subchondral bone,  
Synovium 
Macrophage 
Inflammatory 
Protein-1a 
MIP-1a 
Chemokine (C-C 
motif) ligand 3 
(CCL3) 
Synovium 
Macrophage 
Inflammatory 
Protein-1b 
MIP-1b 
Chemokine (C-C 
motif) ligand 4 
(CCL4) 
Synovium 
Granulocyte-
Macrophage Colony-
Stimulating Factor 
GM-CSF 
Colony stimulating 
factor 2 (CSF2) Synovium 
Interleukin 10 IL-10 
human Cytokine 
Synthesis Inhibitory 
Factor (CSIF) 
NA 
Interleukin 13 IL-13 NA NA 
Interleukin 4 IL-4 NA NA 
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Figure B.2: Summary of IL-1#  concentrations from each OA explant group examined.  
 
IL-1# is typically secreted in early stage OA. IL-1a has been used as a prognostic 
indicator of early OA, as its serum detection successfully differentiated early stage OA 
patients from controls.262 Like IL-1", IL-1# is a potent pro-inflammatory mediator, 
which stimulates the secretion of numerous downstream pro-inflammatory mediators.252 
It would be expected that due to the removal of macrophages and increased anti-
inflammatory activity, IL-# would decrease in macrophage depleted and stem cell treated 
groups, respectively. However, no statistical differences are noted. 
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Figure B.3: Summary of IL-1"  concentrations from each OA explant group examined.  
 
IL-1" is typically secreted in late stage OA. IL-1" stimulates the production of 
cartilage degrading enzymes MMP-1, MMP-3 and MMP-13, cytokine IL-6 and 
chemokines IL-8, MCP-1 and RANTES.118 As this cytokine has been previously 
discussed in detail, this discussion will focus specifically on the reported results. 
Consistent with the ELISA data described in chapters IV and V, IL-1" decreased in 
macrophage depleted and stem cell treated cultures. Additionally, trends towards 
decreased Il-1" expression in amnion groups were observed (p<0.055 compared to OA 
day 0; p<0.061 compared to hADSC treated cultures).  At all points in culture, our results 
fell within physiological ranges, further demonstrating this OA co-culture system 
provides a more natural model of Il-1" involvement in OA pathogenesis.136,147,149 Others 
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have noted extremely low concentrations of IL-1β in ex vivo cultures.252–254 This has 
been attributed to the extreme lability associated with this cytokine, and researchers have 
cautioned conclusions based solely on IL-1β biochemical analysis.173,255 However, our 
other cytokine results coupled with our previous analyses described in chapters IV and V 
reinforce the validity of such conclusions.  
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Figure B.4: Summary of TNF-#  concentrations from each OA explant group examined. 
 
TNF-# stimulates the production of cartilage degrading enzymes MMP-1, MMP-
3 and MMP-13, cytokine IL-6 and chemokines IL-8, MCP-1 and RANTES.118 As this 
cytokine has been previously discussed in detail, this discussion will focus specifically on 
the reported results. No statistical differences are noted. Notably, the ELISA data 
described in chapter V showed a more distinctive trend of TNF-# reduction in amnion 
treated groups. This reduction concomitant with the observed reduction in IL-1" by was 
hypothesized to be a mechanism behind the enhanced mitigation observed in hAMSC 
treated groups, as it has been demonstrated that reductions in both are necessary for OA 
mitigation.150 This discrepancy in TNF-# results can likely be attributed to differences in 
sample sizes as well as in the detection method employed.  
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Figure B.5: Summary of IL-8 concentrations from each OA explant group examined. 
 
 IL-8 is a chemokine responsible for monocyte/macrophage recruitment. IL-8 
induces proteoglycan loss through the up regulation of MMPs as well as IL-6 
production.118 It would be hypothesized that macrophage depleted and stem cell treated 
cultures would express less IL-8 compared to other culture groups. However, no 
statistical differences are noted. 
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Figure B.6: Summary of MCP-1 concentrations from each OA explant group examined. 
 
MCP-1 plays a primary role in the recruitment and infiltration of 
monocytes/macrophages into target tissues.264 MCP-1 is specifically associated with 
chemotaxis of monocyte, memory T lymphocyte and natural killer cells.264 MCP-1 is 
secreted by a variety of cells, but it is largely associated as a macrophage secretion, and is 
thus used as a marker of pro-inflammatory activity. MCP-1 induces proteoglycan loss 
through the up regulation of MMPs as well as IL-6 production.118 It would be 
hypothesized that macrophage depleted and stem cell treated cultures would express less 
MCP-1 compared to other culture groups. However, no statistical differences are noted.  
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Figure B.7: Summary of RANTES concentrations from each OA explant group examined. 
 
RANTES is largely (but not exclusively) a macrophage secreted product that 
induces proteoglycan loss through the up regulation of MMPs as well as IL-6 
production.118 RANTES is up-regulated by other potent pro-inflammatory mediators, 
including IL-1" and TNF-#.265 RANTES is readily detected in normal adult joint tissues; 
however, it has been readily detected in OA patient joint tissues.265 MCP-1, RANTES 
and MIP-1b are all chemotactic for monocytes, but they bind with specific (different) 
receptors.264 This could be one explanation why the observed trends between these three 
cytokines are different. Notably, hAMSC-treated cultures in direct contact with cartilage 
exhibit statistically reduced RANTES expression compared to hADSC-treated cultures. 
Therefore, it could be hypothesized that hAMSC-treated cultures would also demonstrate 
the down-regulation of primary OA pro-inflammatory mediator IL-6.   
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Figure B.8: Summary of IL-6 concentrations from each OA explant group examined. 
 
 IL-6 is a prominent cytokine in the pathogenesis of osteoarthritis.118 IL-6 is 
known to be elevated within the synovial fluid of OA patients.118 IL-6 secretion results in 
the reduction in type II collagen from cartilage via the up regulation of MMP-1 and 
MMP-13.118 IL-6 secretion is dependent on IL-1, TNF-#, IL-8, MCP-1 and RANTES 
production (i.e. IL-6 is a downstream mediator). Since the previously described data 
demonstrates trending and/or statistical reductions in IL-1", TNF-# and RANETS 
expression in hAMSC-treated groups (compared to hADSC-treated groups), it was 
hypothesized that a reduction in IL-6 would also be observed. Our results confirm this 
hypothesis for hAMSCs in direct contact with the cartilage.  
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Figure B.8: Summary of MIP-1a concentrations from each OA explant group examined. 
 
 MIP-1a is a chemoattractant factor for monocytes/macrophages, and it has been 
implicated specifically in osteoarthritis pathology within human joints.266 MIP-1a has 
been used as a prognostic indicator of early OA, as its serum detection successfully 
differentiated early stage OA patients from controls.262 Additionally, MIP-1a has been 
correlated with IL-8 concentrations.262 Apart from the macrophage-depleted group, our 
MIP-1a results show similar trends to those of IL-8. As MIP-1a is a primarily 
macrophage secreted product, it is logical that its secretion would be reduced under 
conditions of macrophage depletion.  
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Figure B.9: Summary of MIP-1b concentrations from each OA explant group examined. 
 
 MIP-1b is a chemoattractant factor for monocytes/macrophages, and it has been 
implicated specifically in osteoarthritis pathology within human joints.266 In fact, MIP-1b 
is the only reported cytokine with elevated levels in OA patients compared to rheumatoid 
arthritis patients.266 Elevated MIP-1b expression has been correlated with worsened joints 
(as evaluated through clinical scoring systems) and local expression of pro-inflammatory 
mediators.262 The statistically reduced expression of MIP-1b in the macrophage-depleted 
group could explain and/or be explained by the reduction in other pro-inflammatory 
mediators observed (see figure B.17 for more information on the inter-relationships of 
this cytokine).    
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Figure B.10: Summary of INFg concentrations from each OA explant group examined. 
 
 INF-g promotes the differentiation of and is secreted by M1 macrophages.256 INF-
g, VEGF and/or GM-CSF stimulation results in the up-regulation of monokines, 
including, IL-1", IL6 and MCP-1.262 Interestingly, INFg expression appears to increase 
in stem cell treated cultures. This is counter to our hypotheses and the previously 
described IHC M1/M2 macrophage counts described in chapter V. However, as 
previously indicated, biochemical mediator quantification is extremely labile.118,255,265 
Many markers are involved in numerous complex biochemical cascades. Therefore, there 
may be an additional mechanism that is currently not accounted for in our discussions. 
Conclusions drawn from this cytokine data alone should be interpreted cautiously.    
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Figure B.10: Summary of VEGF concentrations from each OA explant group examined. 
 
 VEGF has a complicated and not clearly defined role in OA pathogenesis. 
Classically, VEGF is a fibroblastic secretion promoting angiongenesis.132,256 Thus, VEGF 
has been associated with blood vessel growth in wound healing as an M2 macrophage 
secreted product.256 However, as indicated previously, INF-g, VEGF and/or GM-CSF 
stimulation results in the up-regulation of monokines, including, IL-1", IL6 and MCP-
1.262,267 Our data does not seem to provide clarity into which mechanism is likely 
involved in our explant co-culture system.  
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Figure B.11: Summary of GM-CSF concentrations from each OA explant group examined. 
 
 GM-CSF is only involved in the development of macrophages under 
inflammatory conditions (i.e. diseases such as OA) as opposed to normal, homeostatic 
conditions.257 GM-CSF is associated with the differentiation and maintenance of M1 
macrophages.257 As indicated previously, INF-g, VEGF and/or GM-CSF stimulation 
results in the up-regulation of monokines, including, IL-1", IL6 and MCP-1.262,268 In light 
of the IHC results described in chapters IV and V, we would have expected levels of 
GM-CSF to be highest in OA and hADSC treated cultures. It is surprising to see these 
levels so low in OA cultures. However the relationship between high GM-CSF 
expression in hADSC treated cultures with low expression in hAMSC treated cultures 
seems to corroborate the previously described IHC data.   
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Figure B.12: Summary of IL-10 concentrations from each OA explant group examined. 
 
 IL-10 is the first of three anti-inflammatory mediators measured through our 
analyses (although some prefer to classify IL-10 as a regulatory, as opposed to anti-
inflammatory, cytokine269). IL-10, IL-13 and IL-4 induce an M2 phenotype within 
macrophages.256,257 IL-10 suppresses TNF-#, as it directly inhibits localization of nuclear 
NF-$B.267,270 However, IL-10 less reliably suppresses IL-1 synthesis. As previously 
indicated, the suppression of both IL-1" and TNF-# are necessary for inflammatory 
modulation.150 This could be one mechanistic explanation for the beneficial therapeutic 
effects observed with combination IL-4/IL-10 therapies270 as well as reports that IL-10 
alone is not an effective immunomodulator.268 IL-10 has also been shown to increase IL-
1Ra synthesis (IL-1Ra is a competitive inhibitor of IL-1").270  
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Figure B.13: Summary of IL-13 concentrations from each OA explant group examined. 
 
 IL-13, IL-10 and IL-4 induce an M2 phenotype within macrophages.256,257 IL-13 
and IL-4 have demonstrated the ability to mitigate cartilage degradation in vitro.258 While 
IL-4 and IL-10 have direct effects on chondroprotection through the down regulation of 
ADAMTSs and MMPs, respectively, IL-13 produces an indirect anti-inflammatory effect 
through the regulation of PGE2.259 There is limited data providing insight into the relative 
efficacy of IL-4 and IL-13 therapeutic strategies. However, this mechanistic insight 
seems to offer a potential explanation for the heightened and more rapid mitigation of OA 
observed in our data. This is described further in figure B.17.  
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Figure B.14: Summary of IL-4 concentrations from each OA explant group examined. 
 
 IL-4, IL-10 and IL-13 induce an M2 phenotype within macrophages.256,257 IL-4 
suppresses IL-1" and TNF-# expression.258,267,268 This suppression effect can be 
enhanced through concomitant expression of IL-10. IL-10 alone is not an effective 
suppressor of pro-inflammatory cytokines and does not result in significant 
chondroprotection.267 However, IL-4 alone offers both immunomodulatory and 
chondroprotective effects.267 hAMSC treatment significantly increases IL-4 expression 
(compared to OA cultures and hADSC-treated cultures). This provides mechanistic 
insight into a key up-stream anti-inflammatory mediator that could explain the previously 
results described results in chapter V. This is described further in figure B.17. 
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Figure B.15: Summary of IL-12 concentrations from each OA explant group examined. 
 
 IL-12 is classically considered to maintain and regulate inflammation within the 
synovium.271 IL-12 is a macrophage secretion associated with the recruitment of helper T 
cells (Th1).132 In this activation pathway, IL-12 functions to protect the body against 
intracellular pathogens through the up-regulation of INFg and IL-2.272 However, the 
trends in our INFg and IL-2 results do not seem to support this activation pathway of IL-
12. More recently, evidence supports a less significant role for IL-12 in pro-inflammatory 
responses, as IL-23 (not IL-12) is necessary for inflammatory reactions.272 For example, 
IL-23 and not IL-12 was required for the development of collagen-induced arthritis in 
mice.272 Though there is not a consensus within the scientific community, IL-12 is now 
hypothesized to play a protective role in immunity.272 IL-12 has also been shown to have 
an inhibitory effect on IL-17 (a marker of rejection and diseases characterized by chronic 
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inflammation).272 Therefore, the elevated levels of IL-12 observed in macrophage 
depleted and amnion stem cell treated groups may represent an under investigated 
mechanism of immune-regulation.  
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Figure B.16: Summary of IL-2 concentrations from each OA explant group examined. 
 
 
 IL-2 is associated with the recruitment of helper T cells (Th1) and promotion of 
inflammation via the stimulation of IL-17.132,272 Interestingly, our IL-2 results do not 
follow the stimulatory patterns expected with the classical activation of IL-12. The low 
levels of expression observed in most groups support the known auxiliary role of T-cells 
in OA. However, the heightened concentrations observed in the macrophage depleted and 
indirect hAMSC treated cultures are unexpected results.  
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Figure B.17: Simplified Summary of Examined Cytokine Relationships. Red text indicates pro-inflammatory (M1) 
macrophage pathway. Green text indicates anti-inflammatory (M2) macrophage pathway. Mixed colors indicate a 
multi-functional (pro and anti inflammatory) role in OA. Dashed lines indicate multi-step pathways that are not 
pictured for simplicity. Note: PGE2 does not directly stimulate IL-1 and TNF production; it increases expression of 
surface TLRs therefore increasing the binding activity of IL-1" and TNF#. PGE primarily acts via the COX-2 pathway. 
 
The observed heightened expression of IL-13 by hADSC treated cultures may 
imply an insufficient or delayed anti-inflammatory effect due to its indirect role in 
chondroprotection. Primary PGE2 stimulates ADAMTS and MMP production via the 
COX-2 pathway, an auxiliary pathway in OA progression.273,274 PGE2 has secondarily 
been described as up-regulating the production of TLRs on cell surfaces, ultimately 
increasing the production of IL-1" and TNF-#.273 IL-4 has a more direct inhibitory role, 
acting on the primary NF-$B, MAPK and JAK/STAT pathways of OA 
progression.258,267,268 The up-regulation of IL-4 by hAMSC-treated cultures may explain 
the rapid and more extensive mitigation of disease progression observed.  
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